etoposide has been researched along with carmustine in 601 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 83 (13.81) | 18.7374 |
| 1990's | 205 (34.11) | 18.2507 |
| 2000's | 175 (29.12) | 29.6817 |
| 2010's | 110 (18.30) | 24.3611 |
| 2020's | 28 (4.66) | 2.80 |
| Authors | Studies |
|---|---|
| Barrows, LR; Ireland, CM; Kokoshka, JM | 1 |
| Corbett, TH; Edelstein, M; Hazeldine, ST; Horwitz, JP; Kushner, J; Palomino, E; Paluch, J; Polin, L; White, K | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Benfenati, E; Raska, I; Toropov, AA; Toropova, AP | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Campbell, RJ; Laws, ER; Saez, RJ | 1 |
| Abeloff, MD; Ettinger, DS; Khouri, NF; Lenhard, RE | 1 |
| Dombernowsky, P; Nissen, NI | 1 |
| Adam, M; Baruchel, A; Brice, P; Dombret, H; Gisselbrecht, C; Lepage, E; Marolleau, JP; Miclea, JM; Sitthy, X | 1 |
| Egerer, G; Ehrhardt, R; Haas, R; Hohaus, S; Hunstein, W; Witt, B | 1 |
| Christensen, IJ; Demant, EJ; Hansen, HH; Jensen, PB; Roed, H; Sehested, M; Vindeløv, L | 1 |
| Arya, R; Brito-Babapulle, F; Griffiths, T; Mufti, GJ; Pagliuca, A | 1 |
| Bosly, A; Doyen, C; Ferrant, A; Machiels, JP; Martiat, P; Michaux, JL | 1 |
| Bulova, SI; Ciobanu, N; Cooper, BW; Creger, RJ; Crilley, P; Fox, RM; Gucalp, R; Lazarus, HM; Shina, DC; Topolsky, D | 1 |
| Boiardi, A; Botturi, M; Broggi, G; Milanesi, I; Silvani, A | 1 |
| Janmohammed, RM; Leyland, MJ; Long, SG; Macdonald, DF; Milligan, DW; Smith, AG | 1 |
| Andersson, BS; Brunner, LJ; Huan, SD; LeMaistre, CF; Spencer, V; Spinolo, JA; Spitzer, G; Wallerstein, RO; Woo, SY; Yau, JC | 1 |
| Gore, M; Harding, M; Mansi, J; Meldrum, M; Milan, S; Perren, T; Selby, P; Treleavan, J; Viner, C; Zulian, G | 1 |
| Fritsch, HW; Holz, J; Jungclas, H; Köhl, P; Köppler, H; Pflüger, KH; Schmidt, L | 1 |
| Armitage, JO; Bierman, PJ; Glenn, LD; Kessinger, A; Reed, EC; Vaughan, WP | 1 |
| Blair, S; Cervi, P; Chopra, R; Goldstone, AH; Kinsey, S; Linch, DC; McMillan, AK; Moir, D; Patterson, KG; Richards, JD | 1 |
| Grau, C; Overgaard, J | 1 |
| Armitage, JO; Bierman, PJ; Kessinger, A; Vose, JM | 1 |
| Deisseroth, AB; Dicke, K; Jagannath, S; Kantarjian, HM; LeMaistre, CF; Spinolo, J; Spitzer, G; Talpaz, M; Yau, J | 1 |
| Douay, L; Eugene-Jolchine, I; Fouillard, L; Gorin, NC; Isnard, F; Laporte, JP; Najman, A; Stachowiak, J | 1 |
| Deisseroth, A; Dicke, K; Dunphy, F; Fogel, B; Huan, S; Jagannath, S; Souza, L; Spitzer, G; Taylor, K; Ventura, G | 1 |
| Ehsan, MN; Lau, DH; Lewis, AD; Sikic, BI | 1 |
| Bastion, Y; Coiffier, B; Tigaud, JD | 1 |
| Mandelli, F; Meloni, G | 1 |
| Briere, J; Casassus, P; Desablens, B; Gandhour, B; Harousseau, JL; Ifrah, N; Leprise, PY; Milpied, N | 2 |
| Boiardi, A; Botturi, M; Milanesi, I; Munari, L; Silvani, A; Solero, CL | 1 |
| De Fabritiis, P; Mandelli, F; Meloni, G; Petti, MC; Pinto, MR; Testi, AM; Vegna, ML; Vignetti, M | 1 |
| Bron, D; Coiffier, B; Gisselbrecht, C; Guglielmi, C; Hagenbeek, A; Kluin Nelemans, JC; Misset, JL; Philip, T; Somers, R; Van der Lely, J | 1 |
| Havemann, K; Köppler, H; Pflüger, KH | 1 |
| Bernard, JL; Bouffet, E; Coze, C; Gentet, JC; Lopez, M; Michon, J; Philip, I; Philip, T; Zucker, JM | 1 |
| Biron, P; Bouffet, E; Brunat-Mentigny, M; Chauvin, F; Ladenstein, R; Lasset, C; Philip, I; Philip, T | 1 |
| Cheung, NK; Gulati, SC; Kushner, BH; LaQuaglia, M; Mandell, LR; O'Reilly, RJ | 1 |
| Chrétien, P; Huot, J; Lambert, H; Landry, J; Roy, G | 1 |
| Barnett, MJ; Connors, JM; Fairey, RN; Fay, JW; Greer, JP; Herzig, GP; Herzig, RH; Klingemann, HG; LeMaistre, CF; Reece, DE | 1 |
| Barlogie, B; Beckord, J; Crowley, J; Pugh, RP; Salmon, SE | 1 |
| Baruchel, A; Boiron, M; Brice, P; Ferme, C; Gerota, O; Gisselbrecht, C; Lepage, E; Marolleau, JP | 1 |
| August, C; Bayever, E; Finlay, JL; Freid, A; Kamani, N; Kramer, E; Packer, R; Rorke, L; Sutton, L; Zimmerman, R | 1 |
| Alexanian, R; Barlogie, B; Dicke, KA; Hester, JP; Horwitz, LH; LeMaistre, CF; Spinolo, JA; Ventura, GJ; Wallerstein, RO; Yau, JC | 1 |
| Bostrom, B; Christiansen, NP; Haake, RJ; Hurd, DD; Kim, TH; Lasky, LC; Levine, EG; McGlave, PB; Peterson, BA; Weisdorf, DJ | 1 |
| Goldstone, A; McMillan, A | 1 |
| Blume, KG; Chao, NJ; Hoppe, RT; Horning, SJ; Kwak, LW; Long, GD; Negrin, RS; O'Connor, P; Stallbaum, B | 1 |
| Bron, D; Chauvin, F; Coiffier, B; Gisselbrecht, C; Guglielmi, C; Hagenbeek, A; Kluin Nelemans, JC; Misset, JC; Philip, T; Somers, R | 1 |
| Dezube, B; Frei, E; Herman, TS; Holden, SA; Tanaka, J; Teicher, BA | 1 |
| Gulati, S; Yahalom, J | 1 |
| Bigler, RD; Brady, LW; Brodsky, I; Bulova, S; Crilley, P; Micaily, B; Topolsky, D; Vonderheid, EC | 1 |
| Biron, P; Cahn, JY; Colombat, P; Gorin, NC; Herve, P; Lamagnere, JP; Laporte, JP; Philip, T | 1 |
| Coltman, CA; Crowley, JJ; Epstein, RB; Kim, PN; Neilan, B; O'Bryan, RM; Pazdur, R; Stuckey, WJ | 1 |
| Barlogie, B; Dicke, K; Estey, EH; Huh, YO; Kantarjian, HM; Keating, MJ; O'Brien, S; Smith, TL; Spinolo, J; Walters, RS | 1 |
| Armitage, JO; Maragos, D; Schouten, HC; Vose, J | 1 |
| Alberts, DS; Asbury, RF; Boros, L; Goodman, TL; Hickox, DE; Peng, YM; Penn, TE | 1 |
| Brandwein, JM; Callum, J; Keating, A; Scott, JG; Sutcliffe, SB | 1 |
| Antin, JH; Ault, KA; Bubley, GJ; Churchill, WH; Come, SE; Rappaport, JM; Rosenthal, DS; Schnipper, LE; Smith, BR; Wheeler, C | 1 |
| Briere, J; Casassus, P; Desablens, B; Gandhour, C; Harousseau, JL; Ifrah, N; Le Prise, PY; Milpied, N | 1 |
| Burns, LJ; Fyfe, MA; Ginder, GD; Gingrich, RD; Wen, BC | 1 |
| De Fabritiis, P; Mandelli, F; Meloni, G; Petti, MC | 1 |
| Dicke, KA; Estey, E; Horwitz, LJ; Jagannath, S; Kantarjian, H; Keating, M; McCredie, K; Spinolo, JA; Spitzer, G; Zander, AR | 1 |
| Carrasco, CH; Charnsangavej, C; Feun, LG; Gianturco, C; Lee, YY; Savaraj, N; Wallace, S; Yung, WK | 1 |
| Bukowski, RM; Montie, JE; Smith, GW | 1 |
| Barnett, MJ; Connors, JM; Fay, JW; Herzig, GP; Herzig, RH; Klingemann, HG; Phillips, GL; Reece, DE; Shepherd, JD; Wolff, SN | 1 |
| Cabanillas, FF; Fogel, B; Hagemeister, FB; Jagannath, S; Souza, LM; Spinolo, JA; Spitzer, G; Taylor, KM; Tucker, SL | 1 |
| Bauer, H; Fehrentz, D; Hunstein, W; Keilholz, U; Körbling, M | 1 |
| Armitage, JO; Bierman, PJ; Kessinger, A; Landmark, JD; Smith, DM; Weisenburger, DD | 1 |
| Benbunan, M; Brouet, JC; Castaigne, S; Cosset, JM; Fermand, JP; Gerota, J; Lévy, Y; Seligmann, M | 1 |
| Cabanillas, F; Dicke, KA; Hagemeister, FB; Horwitz, LJ; Jagannath, S; McLaughlin, P; Smith, KE; Spinolo, JA; Spitzer, G; Swan, F | 1 |
| Ahmed, T; Arlin, ZA; Ascensao, J; Ciavarella, D; Coleman, M; Engelking, C; Feldman, E; Gingrich, S; Hussain, F; Mittelman, A | 1 |
| Armitage, JO; Dicke, KA; Hagemeister, FB; Horwitz, LJ; Jagannath, S; Kessinger, A; Smith, K; Tucker, SL; Vaughan, WP; Velasquez, WS | 1 |
| Devereaux, S; Goldstone, AH; Gribben, JG; Linch, DC; McMillan, A; Patterson, K | 1 |
| Forgeson, G; Gore, M; McElwain, TJ; Milan, S; Nandi, A; Perren, TJ; Selby, P; Zulian, GB | 1 |
| Amadori, S; De Fabritiis, P; Mandelli, F; Meloni, G; Petti, MC; Pulsoni, A; Sandrelli, A | 1 |
| Ishitani, KP; Kaiser, DL; Niskanen, E; Pirsch, GW; Stewart, FM | 1 |
| Arriagada, R; Baume, D; Beaujean, F; Gouyette, A; Hayat, M; Le Chevalier, T; Ostronoff, M; Pico, JL; Rebattu, P | 1 |
| Peters, W; Souhami, R | 1 |
| Cabanillas, F; Hagemeister, FB; Jagannath, S; McLaughlin, P; Redman, JR; Rodriguez, MA; Swan, F; Velasquez, WS | 1 |
| Bouffet, E; Brunat-Mentigny, M; Carrie, C; Farge, A; Gentet, JC; Kremens, B; Meziane, F; Philip, T; Zucker, JM | 1 |
| Blaise, D; Gaspard, MH; Gastaut, JA; Maraninchi, D; Michel, G; Novakovitch, G; Rossi, JF; Stoppa, AM; Tubiana, N; Weiller, PJ | 1 |
| Bernal, SD; Cathcart, KN; Holden, SA; Teicher, BA | 1 |
| Ben-Sira, I; Cohen, S; Nissenkorn, I; Stark, B; Wysenbeek, YS; Zaizov, R | 1 |
| Huijgens, PC; Ossenkoppele, GJ; Reijneke, RM; Thomas, LL; van der Lelie, J; Wijngaarden, MJ | 1 |
| Beaujean, F; Behard, C; Benhamou, E; Deville, A; Flamant, F; Hartmann, O; Kalifa, C; Lejars, O; Patte, C; Thyss, A | 1 |
| Amadori, S; Avvisati, G; Mandelli, F; Meloni, G; Petti, MC; Tafuri, A | 1 |
| Covelli, A; De Fabritiis, P; Mandelli, F; Meloni, G; Petti, MC; Pulsoni, A; Sandrelli, A; Simone, F | 1 |
| Armitage, JO; Cabanillas, FF; Dicke, KA; Horwitz, LJ; Jagannath, S; Spitzer, G; Vellekoop, L; Zander, AR | 1 |
| Appelbaum, FR; Buckner, CD | 1 |
| Phillips, GL; Reece, DE | 2 |
| Boll, J; Deicher, H; Essers, U; Gamm, H; Glück, S; Görg, K; Gramatzki, M; Peest, D; Schedel, I; Schmoll, HJ | 1 |
| Dicke, KA; Horwitz, LJ; Jagannath, S; Keating, M; McCredie, KB; Spitzer, G; Vellekoop, L; Zander, AR | 1 |
| Baccarani, M; Bandini, G; Gherlinzoni, F; Lauria, F; Mazza, P; Ricci, P; Rosti, G; Tura, S; Visani, G; Zaccaria, A | 1 |
| Bresson, ML; Cattan, A | 1 |
| Wolff, SN | 1 |
| Carella, AM; Cerri, R; Congiu, A; Coser, P; Frassoni, F; Giordano, D; Martinengo, M; Nati, S; Santini, G; Santoro, A | 1 |
| Kessinger, A | 1 |
| Dicke, KA; Hagemeister, FJ; Jagannath, S; Kanojia, M; McLaughlin, P; Spitzer, G; Tannir, NM; Vellekoop, L; Zander, AR | 1 |
| Dicke, KA; Keating, MM; McCredie, KB; Spitzer, G; Vellekoop, L; Verma, DS; Zander, AR | 1 |
| Cattaneo, MT; Piazza, E; Varini, M | 1 |
| Klastersky, J; Sculier, JP | 1 |
| Kaye, SB | 1 |
| Dicke, KA; Lanzotti, V; Litam, J; McCredie, KB; Samuels, ML; Spitzer, G; Valdivieso, M; Verma, DS; Zander, A | 1 |
| Hilliard, S; Karas, JG; Peck, C; Roberts, D | 1 |
| Bron, D; Cahn, JY; Gisselbrecht, C; Guglielmi, C; Hagenbeek, A; Harousseau, JL; Philip, T; Somers, R; Sonneveld, P; Van der Lelie, H | 1 |
| Ciaccia, D; Corey, GR; Peters, W; Thel, MC; Vredenburgh, JJ | 1 |
| Mukaiyama, T; Ogawa, M | 1 |
| Cerny, T; Fey, M; Honegger, H; Jacky, E; Jost, LM; Pichert, G; Platzer, E; Stahel, RA; Tobler, A | 1 |
| Daguenel, A; Gorin, NC; Laporte, JP; Lesage, S; Najman, A; Parlier, Y; Woler, M | 1 |
| Dagis, AC; Molina, A; Nademanee, A; O'Donnell, MR; Parker, PM; Schmidt, GM; Smith, EP; Sniecinski, I; Snyder, DS; Stein, AS | 1 |
| Bosly, A; Coiffier, B; D'Agay, MF; Gisselbrecht, C; Haioun, C; Herbrecht, R; Lepage, E; Morel, P; Nouvel, C; Tilly, H | 1 |
| Bassan, R; Bellavita, P; Borleri, GM; Buelli, M; Comotti, B; Cortelazzo, S; Marziali, S; Rambaldi, A; Rossi, A; Viero, P | 1 |
| Chapman, CS; Ghosh, K; Murphy, P; Sivakumaran, M; Wood, JK | 1 |
| Dercksen, MW; Dirkson, MK; Gerritsen, WR; Pinedo, HM; Rodenhuis, S; Schaasberg, WP; Slaper-Cortenbach, IC; van der Schoot, CE; von dem Borne, AE | 1 |
| Brown, BW; Chao, NJ; Horning, SJ; Hoyle, C; Hu, WW; Kusnierz-Glaz, CR; Long, GD; Negrin, RS; Schriber, JR; Still, BJ | 1 |
| Dranitsaris, G; Sutcliffe, SB | 1 |
| Fuchsberger, P; Lakota, J | 1 |
| Barnett, MJ; Fairey, RN; Hogge, DE; Klasa, RJ; Klingemann, HG; Nantel, SH; Reece, DE; Shepherd, JD; Sutherland, HJ; Voss, NJ | 1 |
| Dommann-Scherrer, C; Honegger, HP; Jacky, E; Jost, LM; Maurer, R; Sauter, C; Stahel, RA | 1 |
| Arneson, M; Blumenschein, G; Dicke, JA; Dicke, KA; Fulbright, L; Hanks, S; Hood, DL; Vaughan, M | 1 |
| Dreger, P; Haferlach, T; Klöss, M; Loeffler, M; Löffler, H; Petersen, B; Schmitz, N | 1 |
| Crowther, D; Ghielmini, M; Morgenstern, GR; Pettengell, R; Radford, JA; Scheid, C; Stern, PL | 1 |
| Burns, LJ; Daniels, KA; Kersey, JH; McGlave, PB; Miller, WJ; Ramsay, NK; Weisdorf, DJ | 1 |
| Alonso, E; Berlanga, JJ; Ferrà, C; Gallardo, D; Grañena, A; Ponce, C; Riu, C; Salar, A | 1 |
| Andersson, B; Dimopoulos, M; Giralt, S; Khouri, I; Mehra, R; Przepiorka, D; Rodriguez, M; Suki, S; Tabocoff, J; van Besien, K | 1 |
| Dreger, P; Eckstein, V; Haferlach, T; Jacobs, S; Löffler, H; Marquardt, P; Müller-Ruchholtz, W; Mülverstedt, T; Schmitz, N; Suttorp, M | 1 |
| Bosly, A; Coiffier, B; Gisselbrecht, C; Haioun, C; Herbrecht, R; Lepage, E; Morel, P; Reyes, F; Sebban, C; Tilly, H | 1 |
| Armitage, JO; Bierman, PJ; Gwilt, P; Kris, E; Vaughan, WP; Vose, J | 1 |
| Bout, M; Brémond, JL; Dayan, A; Delain, M; Domenech, J; Gihana, E; Linassier, C; Petit, A; Petitdidier, C; Truglio, D | 1 |
| Goldstone, AH; Khwaja, A; Linch, DC | 1 |
| Fujimoto, Y; Ito, K; Itoyama, S; Onodera, M; Shimaoka, K; Sugawara, I; Watanabe, M; Yamashita, T | 1 |
| Daly, MB; Giguere, JK; Harden, EA; Harman, GH; Johnson, DB; Johnson, RA; Leff, RS; Mercier, RJ; Messerschmidt, GL; Snyder, MJ | 1 |
| Berger, NA; Chatterjee, S; Cheng, MF | 1 |
| Chopra, R; Goldstone, AH; Linch, DC; McMillan, A; Mills, W; Pearce, R | 1 |
| Anasetti, C; Bensinger, WI; Buckner, CD; Clift, RA; Demirer, T; Lilleby, K; Martin, P; Petersen, FB; Sanders, J; Weaver, CH | 1 |
| Duława, J; Franek, E; Hołowiecki, J; Kokot, F; Markiewicz, M; Wacławik, A; Wiecek, A; Wojnar, J | 1 |
| Bourdin, S; Harousseau, JL; Le Tortorec, S; Mahe, B; Mahe, JM; Mechinaud-Lacroix, F; Milpied, N; Moreau, P; Rapp, MJ; Wu, DP | 1 |
| Bourdin, S; Bulabois, CE; Bureau, B; Harousseau, JL; LeTortorec, S; Mahé, B; Mahé, MA; Milpied, N; Moreau, A; Moreau, P | 1 |
| Brice, P; Castaigne, S; Gisselbrecht, C; Marolleau, JP; Pautier, P | 1 |
| Adkins, DR; Boldt, D; Freytes, CO; Irvin, R; Kuhn, J; LeMaistre, CF; Lyons, R; Roodman, GD; Salzman, D; Smith, L | 1 |
| Bender-Götze, C; Burdach, S; Ebell, W; Friedrich, W; Herrmann, F; Klingebiel, T; Koscielniak, E; Kremens, B; Schmid, H; Siegert, W | 1 |
| Barbot, C; Jazwiec, B; Mahon, FX; Reiffers, J; Rice, A; Vanès, I | 1 |
| Asko-Seljavaara, S; Franssila, K; Kangas, L; Laasonen, A; Muhonen, T; Pyrhönen, S; Wasenius, VM | 1 |
| Chatterjee, R; Goldstone, AH; Katz, M; McGarrigle, HH; Mills, W | 1 |
| Attal, M; Canal, P; Huguet, F; Laurent, G; Pris, J; Schlaifer, D | 1 |
| Chopra, R; Goldstone, AH; Hancock, B; Hudson, GV; Linch, DC; McMillan, A; Milligan, D; Moir, D; Winfield, D | 1 |
| Antman, K; Ayash, L; Bierer, BE; Churchill, WH; Eder, JP; Elias, A; Gilliland, DG; Guinan, EC; Strawderman, M; Wheeler, C | 1 |
| Dreger, P; Gassmann, W; Glass, B; Haferlach, T; Horst, HA; Löffler, H; Ollech-Chwoyka, J; Schmitz, N; Suttorp, M | 1 |
| Fujioka, K; Funabiki, T; Ikuta, K; Kai, S; Kajigaya, Y; Matsuyama, S; Sakai, H; Sekiguchi, H; Sumita, H; Takahashi, H | 1 |
| Barnett, MJ; Connors, JM; Fairey, RN; Klingemann, HG; Nantel, SH; O'Reilly, S; Reece, DE; Shepherd, JD; Spinelli, JJ; Sutherland, HJ | 1 |
| Brosteanu, O; Haas, R; Hasenclever, D; Kirchner, H; Koch, P; Kuse, R; Lathan, B; Pfreundschuh, MG; Rueffer, U; Schmitz, N | 1 |
| Schmoor, C; Schumacher, M; Ulm, K | 1 |
| Bonilla, MA; Canete, A; Cheung, IY; Cheung, NK; Heller, G; Kushner, B; Larson, SM; Yeh, SJ | 1 |
| Bapat, A; Goldberg, J; Goldman, N; Gordon, R; Gryn, J | 1 |
| Attal, M; Canal, P; Chatelut, E; Dezeuze, A; Huguet, F; Laurent, G; Payen, C; Pris, J; Schlaifer, D | 1 |
| Armitage, JO; Bagin, RG; Bierman, PJ; Dicke, KA; Jagannath, S; Kessinger, A; Spitzer, G; Vose, JM | 1 |
| Anasetti, C; Appelbaum, FR; Bensinger, W; Bianco, J; Clift, R; Martin, P; Petersen, FB; Press, O; Singer, J; Weaver, CH | 1 |
| Bulova, SI; Ciobanu, N; Cooper, BW; Creger, RJ; Crilley, P; Fox, RM; Gucalp, R; Lazarus, H; Shina, DC; Topolsky, D | 1 |
| Bennett, C; Gopal, A; Gopal, R; Gulati, S; Toia, M | 1 |
| Caronia, F; Gentile, S; Indovina, A; Liberti, G; Majolino, I; Patti, C; Pisa, R; Santoro, A; Scimè, R; Vasta, S | 1 |
| Chopra, R; Goldstone, AH; Linch, DC; McMillan, AK; Patterson, KG; Pearce, R; Taghipour, G; Yuklea, S | 1 |
| Carlson, K; Hagberg, H; Oberg, G; Simonsson, B; Smedmyr, B | 1 |
| Cabanillas, F; Dicke, KA; Hagemeister, F; Horwitz, LJ; Jagannath, S; Spinolo, JA; Spitzer, G; Velásquez, W | 1 |
| Abrams, RA; Armitage, JO; Bierman, PJ; Dicke, KA; Klein, JL; Leichner, PK; Quadri, SM; Vose, JM; Vriesendorp, HM | 1 |
| Grosh, WW; Lowry, P; Quesenberry, PJ; Stewart, FM; Temeles, D; Thraves, T | 1 |
| Smith, RJ; Sweetenham, JW | 1 |
| Goldstone, AH; Linch, DC; Mills, W; Strang, J | 1 |
| Ahmed, T; Akhtar, T; Chun, H; Feldman, E; Grima, K; Helson, L; Lake, D; Mittelman, A; Puccio, C; Seiter, K | 1 |
| Elonen, E; Jokipii, A; Lautenschlager, I; Lyytikäinen, O; Ruutu, P; Tiittanen, L | 1 |
| Baars, JW; de Glas-Vos, CW; Rodenhuis, S; Thomas, BL; van der Lelie, H; van Dijk, MA; van Oers, RH; von dem Borne, AE | 1 |
| Calabresi, F; De Sanctis, V; Fiacchini, M; Gherlinzoni, F; Mandelli, F; Martelli, M; Martelli, MF; Meloni, G; Papa, G; Tura, S; Vignetti, M; Zinzani, PL | 1 |
| Döhner, H; Flentje, M; Goldschmidt, H; Haas, R; Hunstein, W; Möhle, R; Moos, M; Murea, S; Wannenmacher, M; Witt, B | 1 |
| Andrews, F; Bolwell, B; Collins, R; Fay, J; LeFever, A; Levitt, D; List, A; Nemunaitis, J; Pallansch, P; Resta, D; Rosenfeld, CS; Schuster, MW; Taylor, R | 1 |
| Curcio, C; D'Aprile, M; Gridelli, C; Ianniello, G; Lorusso, V; Palmeri, S; Palmieri, G; Perrone, F; Rossi, A; Veltri, E | 1 |
| Ager, S; Baglin, TP; Bass, G; Mahendra, P; Marcus, RE; Richards, EM | 1 |
| Ager, S; Baglin, TP; Barker, P; Bass, G; Bloxham, DM; Boraks, PA; Hood, IM; Jestice, HK; Johnson, D; Mahendra, P; Marcus, RE; Scott, MA | 1 |
| Hazelton, B; Li, W; Schwartzberg, L; Weaver, CH; West, W | 1 |
| Halvorson, RD; Raybon, KB; Snyder, MJ | 1 |
| Barbui, T; Bassan, R; Bellavita, P; Buelli, M; Comotti, B; Cortelazzo, S; Fracassetti, D; Marchioli, R; Marfisi, RM; Rambaldi, A; Rossi, A; Viero, P | 1 |
| Anderson, JR; Armitage, JO; Bierman, PJ; Bishop, MR; Freeman, MB; Kessinger, A; Vose, JM | 1 |
| Gazdar, AF; Ghosh, BC; Ihde, DC; Johnson, BE; Linnoila, RI; Minna, JD; Mulshine, JL; Oie, HK; Pass, HI; Phelps, R; Russell, EK; Shaw, GL; Steinberg, SM | 1 |
| Bernardi, R; Donzelli, M; Negri, C; Scovassi, AI | 1 |
| Bonini, A; Carotenuto, M; Cascavilla, N; D'Arena, G; Di Mauro, L; Greco, MM; Melillo, L; Minervini, MM; Musto, P; Sajeva, MR; Scalzulli, P | 1 |
| Haynes, AP; Iqbal, A; McQuaker, IG; Russell, NH | 1 |
| Allen, JC; Siffert, J | 1 |
| Mahendra, P; Marcus, RE; Nacheva, E; Richards, EM; Sinclair, P | 1 |
| Gaarsdal, E; Jensen, L; Johnsen, HE; Knudsen, LM; Nielsen, KJ; Nikolaisen, K | 1 |
| Fielding, AK; Goldstone, AH; Jamieson, E; Linch, DC; Sullivan, AM; Watts, MJ | 1 |
| Avvisati, G; Capria, S; Giona, F; Mandelli, F; Meloni, G; Micozzi, A; Vignetti, M | 1 |
| Crilly, R; Fromm, D; Kessel, D; Luo, Y; Webber, J | 1 |
| Bonanad, S; Carral, A; de la Rubia, J; Jarque, I; Larrea, L; López, F; Martín, G; Martínez, J; Picón, I; Sanz, GF; Sanz, MA; Sempere, A; Soler, MA | 1 |
| Berdel, WE; Hoppe, B; Knauf, WU; Koenigsmann, MP; Notter, M; Oberberg, D; Reufi, B; Thiel, E | 1 |
| Behringer, D; Fetscher, S; Finke, J; Kanz, L; Lange, W; Lübbert, M; Mertelsmann, R | 1 |
| Barbui, T; Bertini, M; Botto, B; Cinieri, S; Cortellazzo, S; Falda, M; Freilone, R; Grignani, F; Levis, A; Liberati, AM; Locatelli, F; Lovisone, E; Marmont, F; Pizzuti, M; Resegotti, L; Rossi, A; Viero, P; Vitolo, U | 1 |
| Barbui, T; Bassan, R; Bellavita, P; Comotti, B; Cortelazzo, S; Marchioli, R; Marfisi, RM; Rambaldi, A; Rossi, A; Viero, P | 1 |
| Amigo, ML; Caballero, MD; del Cañizo, C; García, R; Gonzalez, M; Hernández, JM; San Miguel, JF; Vazquez, L | 1 |
| Bayer, RA; Broun, ER; Brown, SL; Costa, JJ; Gabrilove, J; Gordon, MS; Hill, J; Ho, AD; Jelaca-Maxwell, K; McNiece, I; Moskowitz, CH; Nichols, CR; Nimer, SD; Stiff, P; Wyres, M | 1 |
| Cohen, IJ; Horev, G; Kornreich, L; Michowiz, S; Shuper, A; Weitz, R; Zaizov, R | 1 |
| Baccarani, M; Barillari, G; Cerno, M; Damiani, D; Fanin, R; Geromin, A; Infanti, L; Rinaldi, C; Savignano, C; Silvestri, F; Zaja, F | 1 |
| Betts, E; Goebel, ME; Honegger, H; Jost, LM; Nagler, A; Stahel, RA | 1 |
| Capria, S; Mandelli, F; Meloni, G; Modena, V; Vignetti, M | 1 |
| Bartels, H; Dreger, P; Glass, B; Kuse, R; Löffler, H; Schmitz, N; Sonnen, R; Uharek, L; von Neuhoff, N | 1 |
| Antin, J; Antman, K; Ault, K; Ayash, L; Bierer, B; Churchill, WH; Eder, JP; Eickhoff, C; Elias, A; Ferrara, J; Frei, E; Gaynes, L; Gilliland, G; Guinan, E; Ibrahim, J; Kadin, M; Mauch, P; Mazanet, R; McCauley, M; Parsons, S; Rimm, IJ; Schnipper, L; Schwartz, G; Tepler, I; Wheeler, C | 1 |
| Bible, KC; Kaufmann, SH | 1 |
| Brandwein, J; Crump, M; Dufresne, J; Girouard, C; Imrie, K; Keating, A; Pantolony, D; Prince, HM; Stewart, AK | 1 |
| Abella, E; Adams, PT; al-Katib, A; Dragovic, J; Du, W; Janakiraman, N; Karanes, C; Raman, SB; Ratanatharathorn, V; Sensenbrenner, L; Silver, SM; Uberti, J; Varterasian, M | 1 |
| Barbui, T; Bellavita, P; Cortelazzo, S; Marchioli, R; Marfisi, RM; Rambaldi, A; Rossi, A; Viero, P | 1 |
| Andresen, SW; Bolwell, BJ; Dannley, R; Goormastic, M; Kalaycio, M; Lichtin, A; Overmoyer, B; Pohlman, B | 1 |
| Brunet, S; Cancelas, JA; García, J; Madoz, P; Martínez, C; Martino, R; Sureda, A | 1 |
| de Crevoisier, R; le Cesne, A; le Chevalier, T | 1 |
| Blume, KG; Dahlberg, S; Fisher, RI; Forman, SJ; Horning, SJ; LeBlanc, M; McCall, AR; Nademanee, AP; Stiff, PJ | 1 |
| Amin, K; Anderlini, P; Andersson, B; Cabanillas, F; Champlin, R; Claxton, D; de Lima, M; Donato, M; Gajewski, J; Giralt, S; Khouri, I; Mehra, R; Popat, U; Preti, A; Przepiork, D; Pugh, W; Rodriguez, A; Rodriguez, J; Romaguera, J; van Besien, K | 1 |
| Andreeva, LA; Batan, ZE; Chervonobab, IuV; Chimishkian, KL; Demina, EA; Kondrat'eva, NE; Larionova, VB; Milanovich, NF; Mkheidze, DM; Ptuskin, VV; Snegir', VM; Tupitsyn, NN; Uss, AL; Zmachinskiĭ, VA | 1 |
| Bauer, PI; Kopper, L; Mihalik, R; Peták, I; Sebestyén, A; Süli-Vargha, H | 1 |
| Alexander, MA; Alvord, WG; Arguello, F; Greene, JF; Jorden, JL; Kalavar, NT; Klabansky, RL; Sausville, EA; Smith, EM; Stinson, SF | 1 |
| Buckner, CD; Rhinehart, S; Schwartzberg, L; Weaver, CH; West, J; West, WH; Zhen, B | 1 |
| Boyett, JM; Cairo, M; Dunkel, IJ; Ettinger, LJ; Finlay, JL; Garvin, JH; Goldman, S; Kaplan, AM; Li, H | 1 |
| Confer, DL; Epstein, RB; Mandanas, RA; Saez, RA; Selby, GB | 1 |
| Cheng, AL; Hung, RL; Liu, MY; Uen, WC; Wang, CH; Yeh, KH | 1 |
| Buckner, JC; Lewis, JE; McElroy, EA | 1 |
| Diehl, V; Engert, A; Josting, A; Kàtay, I; Rueffer, U; Tesch, H; Wickramanayake, PD; Winter, S | 1 |
| Alegre, A; Arranz, R; Cámara, R; Fernández-Rañada, JM; Figuera, A; Gil-Fernández, JJ; Granados, E; Martínez-Chamorro, C; Tomás, JF; Vázquez, L | 1 |
| Aurlien, E; Holte, H; Jakobsen, E; Kvalheim, G; Kvaløy, S; Pharo, A; Smeland, EB | 1 |
| Buckner, CD; Weaver, CH; Zhen, B | 1 |
| Dreger, P; Glass, B; Kuse, R; Löffler, H; Schmitz, N; Schoch, R; Sonnen, R; Uharek, L; von Neuhoff, N | 1 |
| Boyett, JM; Dunkel, IJ; Finlay, JL; Gardner, S; Garvin, JH; Goldman, S; Gollamudi, S; Guruangan, S; Merchant, TE; Rosenblum, M | 1 |
| Bulabois, CE; Colombat, P; Dupas, B; Harousseau, JL; Juge-Morineau, N; Mahé, B; Milpied, N; Moreau, A; Moreau, P; Rapp, MJ; Voillat, L | 1 |
| Cunningham, D; Popescu, RA; Wotherspoon, AC | 1 |
| Blumenstengel, K; Fricke, HJ; Höffken, K; Kath, R; Kunert, C; Sayer, HG; Vogel, W | 1 |
| Andreu, G; Aoudjhane, M; Bauters, F; Belkacemi, Y; Cheron, N; Douay, L; Fenaux, P; Fouillard, L; Gorin, NC; Isnard, F; Jouet, JP; Labopin, M; Laporte, JP; Lemonnier, MP; Lesage, S; Lopez, M; Morel, P; Najman, A; Noël-Walter, MP; Stachowiak, J; Zunic, P | 1 |
| Abboud, CN; Brasacchio, R; Constine, LS; DiPersio, JF; Duerst, RE; Eberly, S; Lancet, JE; Liesveld, JL; Linder, T; Muhs, A; Packman, CH; Rapoport, AP; Raubertas, RF; Rowe, JM | 1 |
| Fehse, N; Gutensohn, K; Hassan, HT; Kröger, N; Krüger, W; Lölliger, C; Zander, AR; Zeller, W | 1 |
| Bachelot, T; Biron, P; Blay, J; Chauvin, F; Gomez, F; Guglielmi, C; Hagenbeek, A; Philip, T; Sebban, C; Somers, R | 1 |
| Avramis, VI; Chelstrom, LM; Ek, O; Evans, W; Gunther, R; Irvin, JD; Messinger, Y; Myers, DE; Uckun, FM; Yanishevski, Y | 1 |
| Ames, MM; Bagniewski, PJ; Buckner, JC; Cascino, TL; Marks, RS; Rajkumar, SV; Reid, JM; Schomberg, PJ | 1 |
| Bamborschke, S; Diehl, V; Feiden, W; Lehrke, R; Re, D; Schröder, R; Tesch, H | 1 |
| Dias Wickramanayake, P; Diehl, V; Draube, A; Engert, A; Josting, A; Reiser, M; Scheid, C; Tesch, H; Wolf, J | 1 |
| Boiardi, A; Broggi, G; Fariselli, L; Pozzi, A; Salmaggi, A; Silvani, A | 1 |
| Barnett, MJ; Brockington, DA; Connors, JM; Fairey, RN; Klingemann, HG; Nantel, SH; Nevill, TJ; O'Reilly, SE; Phillips, GL; Reece, DE; Sayegh, A; Shepherd, JD; Spinelli, JJ; Sutherland, HJ; Voss, NJ | 1 |
| Boyett, JM; Finlay, JL; Grovas, AC; Lindsley, K; Rosenblum, M; Yates, AJ | 1 |
| Kiss, I; Tomasek, J | 1 |
| Fleming, DR; Goldsmith, GC; Herzig, RH; Stevens, DA | 1 |
| Belt, R; Coon, J; Cord, M; Dix, S; Geller, R; Howard, S | 1 |
| Brunet, S; Martino, R; Muñoz, L; Sierra, J; Subirà, M; Sureda, A | 1 |
| Bernard, EA; da Rocha, AB; Leyva, A; Logullo, AF; Mans, DR; Ruschel, C; Schwartsmann, G; Wetmore, LA | 1 |
| Devereux, S; Goldstone, AH; Gregory, W; Hancock, B; Harrison, CN; Hoskin, P; Hudson, GV; Linch, DC; MacMillan, AK; Milligan, D; Newland, AC; Winfield, D | 1 |
| Brunet, S; Domingo-Albós, A; López, R; Martino, R; Sierra, J; Sureda, A | 1 |
| Bolwell, BJ; Brown, RA; Collins, RH; Fay, JW; Fleming, DR; Goldsmith, LJ; Goodman, SA; Greer, JP; Herzig, GP; Herzig, RH; Lynch, JP; Pineiro, LA; Stein, RS; Stevens, DA; Wolff, SN | 1 |
| Baccarani, M; Cerno, M; Damiani, D; Fanin, R; Geromin, A; Grimaz, S; Infanti, L; Michieli, M; Savignano, C; Silvestri, F; Skert, C; Sperotto, A | 1 |
| Kosteljanetz, M; Kristjansen, PE; Lassen, U; Poulsen, HS; Wagner, A | 1 |
| Foss, HD; Keilholz, U; Knauf, W; Siehl, J; Szelényi, H; Thiel, E | 1 |
| Antman, KH; Balmaceda, C; Bruce, J; De LaPaz, R; Fetell, M; Hesdorffer, CS; Isaacson, S; Kaufman, E; Papadopoulos, KP; Savage, DG; Sisti, M; Troxel, A; Vahdat, LT | 1 |
| Bogart, JA; Chung, CT; Ryu, S; Ungureanu, C; Zamkoff, KW | 1 |
| Bourhis, JH; Brice, P; Brousse, N; Decaudin, D; Gisselbrecht, C; Haioun, C; Morel, P; Quesnel, B; Souleau, B; Van Hoof, A | 1 |
| Brandt, SJ; Goodman, S; Greer, JP; Macon, WR; McCurley, TL; Morgan, DS; Stein, RS; Wolff, SN | 1 |
| Alessandrino, EP; Bernasconi, C; Bernasconi, P; Caldera, D; Colombo, A; Klersy, C; Malcovati, L; Martinelli, G; Nascimbene, C; Varettoni, M; Vitulo, P; Volpini, E | 1 |
| Gregora, E; Havrdová, E; Kobylka, P; Kozák, T; Maaloufová, J; Marecková, H; Pit'ha, J; Pytlík, R; Vodvárková, S | 1 |
| Diehl, V; Draube, A; Engert, A; Josting, A; Reiser, M; Rueffer, U; Söhngen, D; Tesch, H; Wickramanayake, PD; Wolf, J | 2 |
| Abdallah, A; Haas, R; Ho, AD; Hohaus, S; Martin, S; Schlenk, RF; Voso, MT | 1 |
| Buthmann, U; Freund, M; Kleine, HD; Volk, J | 1 |
| Ayala-Sánchez, M; Esparza, MA; García-León, LD; González-Llaven, J; Guevara-Moreno, ME; Montiel-Cervantes, L; Rosas-Cabral, A; Sánchez-Cortés, E; Tripp-Villanueva, F; Vela-Ojeda, J | 1 |
| Alvarnas, JC; Blume, KG; Chao, NJ; Horning, SJ; Hu, WW; Long, GD; Negrin, RS; Schriber, JR; Stockerl-Goldstein, K; Tierney, K; Wong, R | 1 |
| Cherrington, JM; Kabbinavar, F; Mann, E; Schwartz, DP; Shawver, LK; Slamon, DJ; Strawn, LM | 1 |
| Berglund, A; Carlson, K; Enblad, G; Glimelius, B; Hagberg, H | 1 |
| Altés, A; Briones, J; Brunet, S; Cabezudo, E; López, R; Madoz, P; Martinez, C; Martino, R; Muñoz, L; Perea, G; Salar, A; Santamaría, A; Sierra, J; Sureda, A | 1 |
| Baker, D; Coccia, P; Cramer, LD; Dunkel, IJ; Finlay, JL; Garvin, J; Goldman, S; Kaplan, AM; Klemperer, M; Kramer, E; Packer, RJ; Papadakis, V; Papadopoulos, E; Strandjord, S; Willoughby, M | 1 |
| Argiris, A; Cooper, DL; Seropian, S | 1 |
| Bosly, A; Brice, P; Brière, J; Coiffier, B; Gaulard, P; Gisselbrecht, C; Haioun, C; Lederlin, P; Lepage, E; Morel, P; Nouvel, C; Reyes, F; Salles, G; Sebban, C; Tilly, H | 1 |
| Dzhumabaeva, BT; Efimov, IV; Kaplanskaia, IB; Margolin, OV; Moiseeva, TN; Pivnik, AV; Rasstrigin, NA; Roshchina, LS; Shavlokhov, VS; Sotnikov, VM; Stroiakovskiĭ, DL | 1 |
| Carreras, E; Esteve, J; Fernández, F; Martínez, C; Montserrat, E; Perales, M; Rovira, M; Urbano-Ispizua, A | 1 |
| Jantunen, E; Mahlamäki, E; Nousiainen, T | 1 |
| Blume, KG; Chao, NF; Feiner, RH; Horning, SF; Hu, WW; Johnston, LF; Kobler, S; Long, GD; Negrin, RS; Reddy, SA; Stockerl-Goldstein, KE; Strober, S; Wong, RM | 1 |
| Connor, TH; Singleton, LC | 1 |
| Blaise, D; Caraux, J; Chabannon, C; Faucher, C; Maraninchi, D; Vey, N | 1 |
| Carella, AM; Cavaliere, M; Corsetti, MT; De Stefano, F; Ferrara, R; Lambelet, P; Lerma, E; Loni, C; Pinotti, G; Romanelli, A; Tedeschi, L; Valbonesi, M; Verdiani, S; Vinci, M | 1 |
| Dobie, D; Hastings, M; Mahendra, P; Richardson, G; Tauro, S | 1 |
| Klener, P; Procházka, B; Slabý, J; Trnený, M | 1 |
| Cordone, I; De Cuia, R; Fenu, S; Guerrisi, V; Mandelli, F; Mauro, FR; Meloni, G; Pescarmona, E; Proia, A; Reato, G | 1 |
| Czorny, A; Godard, J; Jacquet, G; Miny, J; Plouvier, E; Raul, JS; Viennet, G | 1 |
| Bertino, JR; Coady-Lyons, N; Filippa, DA; Frank, R; Gonzales, M; Goy, A; Hedrick, EE; Louie, D; Moskowitz, CH; Nimer, SD; Noy, A; O'Brien, JP; Portlock, CS; Qin, J; Straus, D; Trippett, T; Walits, J; Yahalom, J; Zelenetz, AD | 1 |
| Bouafia, F; Coiffier, B; Dumontet, C; Espinouse, D; Hequet, O; Salles, G; Thieblemont, C | 1 |
| Beham-Schmid, C; Hoefler, G; Linkesch, W; Neumeister, P; Sill, H | 1 |
| Aleĭnikova, OV; Batan, ZE; Dziuba, EV; Milanovich, NF; Mitskevich, PB; Skriagin, AE; Solov'eva, NS; Uss, AL; Vlasenkova, SV; Zavgorodniaia, IL; Zhavrid, EA; Zmachinskiĭ, VA | 1 |
| Weiss, M | 1 |
| Gregora, E; Havrdová, E; Kobylka, P; Kozák, T; Maaloufová, J; Pit'ha, J; Pytlík, R; Vodvárková, S | 1 |
| Diehl, V; Ehninger, G; Franklin, J; Hasenclever, D; Kirchner, H; Koch, P; Lathan, B; Loeffler, M; Pfreundschuh, M; Rueffer, U; Schmitz, N; Sextro, M; Tesch, H | 1 |
| Blume, KG; Brown, BW; Cao, TM; Hoppe, RT; Horning, S; Hu, WW; Johnston, LJ; Negrin, RS; Shizuru, JA; Stockerl-Goldstein, KE; Taylor, TL | 1 |
| Bernard, M; Casassus, P; Delain, M; Desablens, B; Guilhot, F; Hunault-Berger, M; Ifrah, N; Jouet, JP; Milpied, N; Sadoun, A | 1 |
| Antin, J; Ault, K; Elias, A; Ibrahim, J; Khurshid, A; Mauch, P; Wheeler, C | 1 |
| Filippi, M; Gualandi, F; Inglese, M; Lugaresi, A; Mancardi, GL; Marmont, A; Marrosu, MG; Massacesi, L; Meucci, G; Murialdo, A; Pagliai, F; Saccardi, R; Sardanelli, F; Sormani, MP | 1 |
| Alfieri, E; Cirillo, S; D'Amore, R; Fiorillo, A; Greco, N; Maggi, G; Marano, I; Martone, A; Migliorati, R | 1 |
| Dreger, P; Glass, B; Kuse, R; Schmitz, N; Seyfarth, B; Sonnen, R | 1 |
| Cottler-Fox, M; Fassas, A; Gojo, I; Meisenberg, B; Papadimitriou, JC; Rapoport, A; Tricot, G | 1 |
| Alcaraz, L; Benboubker, L; Bergemer-Fouquet, AM; Calais, G; Colombat, P; Destrieux, C; Jan, M; Linassier, C | 1 |
| Benike, CJ; Caspar, CB; Czerwinsk, DK; Davis, TA; Engleman, EG; Hsu, FJ; Levy, R; Liles, TM; Taidi, B; van Beckhoven, A | 1 |
| Ansén, S; Bischoff, S; Bohlen, H; Diehl, V; Dietlein, M; Re, D; Scheidhauer, K; Schicha, H; Tesch, H; Weihrauch, MR; Wolf, J | 1 |
| Blume, KG; Chao, NS; Horning, SJ; Johnston, LJ; Long, GD; Negrin, RS; Shizuru, JA; Stockerl-Goldstein, KE; Stuart, MJ; Wong, RM | 1 |
| Blystad, AK; Delabie, J; Holte, H; Kvalheim, G; Kvaløy, S; Smeland, E | 1 |
| Bethe, U; Cornely, OA; Pels, H; Ritzkowsky, A; Seibold, M; Soehngen, D; Toepelt, K | 1 |
| Berger, F; Brice, P; Colin, P; Diviné, M; Fermé, C; Jaubert, J; Lederlin, P; Mounier, N; Reman, O; Salles, G; Stamatoullas, A; Voillat, L | 1 |
| Becherer, A; Dudczak, R; Greinix, HT; Jaeger, U; Kalhs, P; Karanikas, G; Kletter, K; Mitterbauer, M; Pötzi, C; Raderer, M | 1 |
| Ariatti, C; Bertini, M; Boccomini, C; Botto, B; Calvi, R; Capello, D; Carbone, A; Freilone, R; Gaidano, G; Gallo, E; Gloghini, A; Milan, I; Novero, D; Orsucci, L; Palestro, G; Parvis, G; Pregno, P; Saglio, G; Vitolo, U; Vivenza, D; Zagonel, V | 1 |
| Dreger, P; Glass, B; Haas, R; Kneba, M; Kröger, N; Kuse, R; Martin, S; Parwaresch, R; Schmitz, N; Sonnen, R | 1 |
| Barbui, T; Bassan, R; Carter, M; Casula, P; Di Bona, E; Fabris, P; Lambertenghi-Deliliers, G; Lerede, T; Lister, TA; Morandi, S; Pogliani, E; Rambaldi, A; Rohatiner, AZ; Rossi, G | 1 |
| Armitage, JO; Bierman, PJ; Chan, WC; Inwards, D; Kessinger, A; Loh, K; Lynch, JC; Nichols, C; Rifkin, R; Sharp, G; Vose, JM; Weisenburger, DD | 1 |
| Boissevain, F; Carella, AM; Decker, S; Diehl, V; Goldstone, AH; Haenel, M; Hasenclever, D; Kirchner, H; Koch, B; Lohri, A; Müller, P; Pfistner, B; Schmitz, N; Sextro, M; Sieber, M; Zschaber, R | 1 |
| Clemente González, C; García Parés, D; García-Bragado Dalmau, F; Guardia Sánchez, R; Pérez Ayuso, MJ; Porcar Ramells, C | 1 |
| Elonen, E; Franssila, K; Itälä, M; Jantunen, E; Kuittinen, O; Lehtinen, T; Oinonen, R; Wiklund, T | 1 |
| Byrne, J; Carter, GI; Craddock, CF; Cull, GM; Garg, M; Haynes, AP; Lui Yin, JA; Lush, RJ; Mahendra, P; Mufti, G; Pagliuca, A; Parker, JE; Potter, MN; Prentice, HG; Russell, NH | 1 |
| Bahng, HS; Jang, GD; Jeong, YH; Ji, HS; Kim, EK; Kim, SH; Kim, SW; Kim, WK; Lee, JS; Park, CJ; Park, IG; Suh, CW; Suh, EJ | 1 |
| Gallet, B; Genet, P; Jondeau, K; Laribi, K; Lionnet, F; Pulik, M; Touahri, T | 1 |
| Engert, A; Glossmann, JP; Josting, A; Paulus, U; Pfistner, B | 1 |
| Cavenagh, J; Chopra, R; Clark, FJ; Culligan, D; Davies, A; Fuller, S; Hunt, L; Hunter, A; Littlewood, T; Lush, R; Marks, DI; Marsh, J; Milligan, DW; Parker, A; Schey, S; Smith, GM; Towlson, K; Vandenberghe, E; Williams, CD; Yin, J | 1 |
| Castel, V; Dini, G; Fagioli, F; Ferrant, A; Frassoni, F; Labopin, M; Locatelli, F; Meloni, G; Messina, C; Ortega, J; Pession, A; Shaw, PJ; Sociè, G; Yaniv, I | 1 |
| Abel, U; Baudis, M; Birkmann, J; Bischoff, HG; Franke, A; Grundeis, M; Havemann, K; Hossfeld, DK; Kaiser, U; Karakas, T; Kneba, M; Köppler, H; Krahl, D; Mantovani, L; Mesters, RM; Metzner, B; Müller, P; Parwaresch, R; Pfab, R; Pfreundschuh, M; Reiser, M; Rothmann, F; Schmalenberg, H; Schmitz, N; Schumacher, K; Steinhauer, EU; Trümper, L; Uebelacker, I; von Seydewitz, CU | 1 |
| Albó, C; Arranz, R; Caballero, MD; Cabrera, R; Carreras, E; Conde, E; Fernández de Sevilla, A; Gandarillas, M; García Ruíz, JC; García-Conde, J; García-Laraña, J; Grande, C; Iriondo, A; Lahuerta, JJ; Marín, J; Moraleda, JM; Pérez-Equiza, C; Pérez-Simón, JA; Rifón, J; Rubio, V; San Miguel, JF; Sierra, J; Sureda, A; Varela, R; Vidal, MJ; Zuazu, J | 1 |
| Afanas'ev, BV; Alekseeva, IuA; Medvedeva, NV; Mikhaĭlova, NB; Zaritskiĭ, AIu; Zubarovskaia, LS | 3 |
| del Palacio, A; Garau, M; Molina, L; Relaño, MT | 1 |
| Beck, JD; Bornfeld, N; Havers, W; Klingebiel, T; Kremens, B; Neubert, D; Reinhard, H; Wieland, R | 1 |
| Cooney, JP; Parthasarathy, M; Stiff, PJ; Toor, AA | 1 |
| Arellano-Rodrigo, E; Bessell, EM; Graus, F; López-Guillermo, A; Montserrat, E; Nomdedeu, B | 1 |
| Ballen, K; Becker, PS; Clark, Y; Emmons, RV; Levy, W; Liu, Q; Rossi, HA; Westervelt, P | 1 |
| Bunin, N; Cotte, J; Gregson, B; Grupp, S; June, CH; Laport, GG; Levine, BL; Liebowitz, DN; Luger, SM; Porter, DL; Rivers, P; Schuster, SJ; Stadtmauer, EA; Strobl, FJ; Vonderheide, RH; Zheng, Z | 1 |
| Hara, N; Moritake, K; Osago, H; Shingu, T; Terashima, M; Tsuchiya, M; Uemura, T; Yamada, K; Yamasaki, T | 1 |
| Jantunen, E; Kuittinen, T; Nousiainen, T | 1 |
| Bolwell, BJ; Fisher, RI; Forman, SJ; LeBlanc, M; McCall, AR; Nademanee, AP; Stiff, PJ; Unger, JM | 1 |
| Mead, G; Woodcock, J; Young, C | 1 |
| NEU, JT | 1 |
| AMALRIC, R; CLEMENT, R | 1 |
| GIAUX, G; SWYNGEDAUW, J; TOISON, G | 1 |
| BOWMAN, DE | 1 |
| BACHMAN, CH; DAVIS, HW; GELORMINI, OJ | 1 |
| FRANKE, H | 1 |
| FETZER, H | 1 |
| BOONE, BR; GARRAHAN, NM; GORMAN, RE; NOBLE, FW | 1 |
| QUICK, D; RICHMOND, JD | 1 |
| ABBATE, MJ; BLOUT, ER | 1 |
| FLATBY, J; MAUDAL, S | 1 |
| RAMIOUL, H | 1 |
| GUALANDI, G; SERLUPI-CRESCENZI, G | 1 |
| SMITH, IH | 1 |
| ARDRAN, GM; CROOKS, HE | 1 |
| PROPST, A | 1 |
| MARX, P | 1 |
| DE VULPIAN, P | 1 |
| KOHN, HI | 1 |
| PIGNATARO, E | 1 |
| BERGSTROM, R | 1 |
| CHAUNDY, CJ | 1 |
| DENNIS, WL | 1 |
| EBERL, J | 1 |
| ECKER, A | 1 |
| HELD, F; SCHWARZ, R | 1 |
| HENCEK, M; ZACHAR, J | 1 |
| MAHFOUZ, MM | 1 |
| Au, WY; Chan, EC; Kwong, YL; Leung, AY; Liang, R; Lie, AK; Ooi, GC; Siu, LL | 1 |
| Abrey, LE; Anderson, ND; Caron, D; Correa, DD; Crump, M; DeAngelis, LM; Forsyth, P; Mason, WP; Moskowitz, CH; Nimer, SD; Paleologos, N; Stewart, D; Zelenetz, A | 1 |
| Arranz, R; Caballero, MD; Carreras, E; Conde, E; Fernández de Sevilla, A; Gandarillas, M; García-Laraña, J; Gutiérrez, A; Lahuerta, JJ; León, A; Marín, J; Rifon, J; Rodríguez, J; SanMiguel, J; Sureda, A; Varela, R; Zuazu, J | 1 |
| Abraham, J; Auber, M; Beall, CL; Bunner, P; Devetten, MP; Ericson, SG; Lynch, JP; Qazilbash, MH; Weisenborn, R | 1 |
| Ahn, HS; Choi, HS; Han, KS; Kang, HJ; Shin, HY | 1 |
| Fouillard, L; Frassoni, F; Gorin, NC; Labopin, M; Meloni, G; Polge, E | 1 |
| ROSWIT, B | 1 |
| LOW-BEER, BV | 1 |
| Amodeo, R; Anghel, G; De Rosa, L; Majolino, I; Pandolfi, A; Riccardi, M | 1 |
| Adams, PT; Ayash, LJ; Dawson, LA; Eisbruch, A; Lichter, AS; Ratanatharathorn, V; Reynolds, CM; Saito, NG; Schipper, MJ; Silver, SM; Uberti, JP | 1 |
| Blystad, AK; Delabie, J; Holte, H; Ikonomou, I; Kvalheim, G; Kvaløy, S; Vålerhaugen, H | 1 |
| Ball, ED; Bashey, A; Carrier, E; Chen, YA; Corringham, S; Holman, P; Wang, EH | 1 |
| Cailliot, C; Fouillard, L; Gorin, NC; Isnard, F; Labopin, M; Laporte, JP; Lesage, S; Najman, A; Yeshurun, M | 1 |
| Caballero, MD; Cañizo, MC; López-Holgado, N; Martín, A; Mateos, MV; Miguel, JF; Pérez-Simón, JA | 1 |
| Annaloro, C; Deliliers, GL; Ibatici, A; Nicolini, A; Pozzoli, E; Robbiolo, L; Salerno, F | 1 |
| Ardito, R; Cammarota, A; Di Renzo, N; Gallucci, G; Romano, G; Tartarone, A | 1 |
| Armitage, JO; Bierman, PJ; Bociek, G; Enke, C; Hankins, J; Lynch, JC; Vose, JM | 1 |
| Andresen, S; Ball, E; Bolwell, B; Cook, D; Kalaycio, M; Kuczkowski, E; Pohlman, B; Rybicki, L; Sobecks, R | 1 |
| Berdel, WE; Diehl, V; Dörken, B; Engert, A; Glossmann, JP; Hossfeld, DK; Josting, A; Kirchner, HH; Kisro, J; Mapara, M; Metzner, B; Rudolph, C; Sieber, M; Sienawski, M; Sieniawski, M | 1 |
| Bajor, DL; Bedi, T; Cooper, BW; Creger, RJ; Fox, RM; Fu, P; Gerson, SL; Koc, ON; Laughlin, MJ; Lazarus, HM; Payne, J; Wadhwa, PD | 1 |
| Caballero, MD; del Cañizo, MC; López-Holgado, N; Martín, A; Pérez-Simón, JA; San Miguel, JF; Vázquez, L | 1 |
| Alterini, R; Bernardi, F; Bosi, A; Carrai, V; Longo, G; Nassi, L; Rigacci, L | 1 |
| Buckner, JC; Dinapoli, RP; Fitch, TR; Krishnan, S; Maurer, MJ; Nordstrom, K; O'Fallon, JR; Rao, RD; Scheithauer, B; Schomberg, PJ | 1 |
| Barnes, C; Blanchette, V; Canning, P; Greenberg, M; Price, V | 1 |
| Abboud, CN; Bernstein, SH; Chapman, M; Friedberg, JW; Ifthikharuddin, JJ; Johnson, V; Lancet, JE; Liesveld, JL; Phillips, GL; Spreng, E; Vesole, DH | 1 |
| Bocková, J; Bystrická, E; Koza, V; Misaniová, L; Pavlicová, V; Scudlová, J; Valentová, D; Vokurka, S | 1 |
| Acholonu, S; Anderlini, P; Champlin, RE; Couriel, D; De Lima, M; Donato, ML; Fayad, L; Giralt, S; Hosing, C; Jones, R; Khouri, IF; Korbling, M; Maadani, F; Manning, JT; McLaughlin, P; Okoroji, GJ; Pro, B; Saliba, RM; Shpall, E; Younes, A | 1 |
| Rao, PS | 1 |
| Avvisati, G; Breccia, M; Capria, S; Cimino, G; Diverio, D; Latagliata, R; Meloni, G; Petti, MC | 1 |
| Alapetite, C; Anract, P; Babinet, A; Barthier, S; de Pinieux, G; Laurence, V; Palangié, T; Pierga, JY; Pouillart, P | 1 |
| Diehl, V; Dörken, B; Engert, A; Glossmann, JP; Josting, A; Kisro, J; Ko, Y; Mapara, M; Metzner, B; Nogova, L; Peters, N; Sieniawski, M; Staak, O | 1 |
| Abboud, CN; Felgar, R; Komrokji, RS; Oliva, JL; Zand, M | 1 |
| Arnaud, P; Bocaccio, C; Bourhis, JH; Carde, P; Ferme, C; Jabbour, E; Koscielny, S; Peslin, N; Ribrag, V; Vantelon, JM | 1 |
| Albarello, A; Ballerini, F; Balocco, M; Canepa, L; Canepa, P; Clavio, M; Garrone, A; Gobbi, M; Michelis, GL; Miglino, M; Pierri, I; Varaldo, R | 1 |
| Brevet, M; Damaj, G; Garidi, R; Gruson, B; Royer, B; Vaida, I | 1 |
| Abonour, R; Cornetta, K; Fineberg, NS; Hromas, R; Nelson, RP; Robertson, MJ | 1 |
| Ala-Kopsala, M; Hartikainen, J; Husso-Saastamoinen, M; Jantunen, E; Kuittinen, T; Nousiainen, T; Sipola, P; Vuolteenaho, O | 1 |
| Crump, M; Keating, A; Kuruvilla, J; Nagy, T; Pintilie, M; Tsang, R | 1 |
| Assouline, S; Carriere, P; Laneuville, P; Shustik, C; Sylvestre, MP | 1 |
| Bahlis, N; Balogh, A; Brown, C; Jones, A; Morris, DG; Russell, JA; Savoie, L; Stewart, DA; Valentine, K | 1 |
| Bystrická, E; Koza, V; Misaniová, L; Pavlicová, V; Scudlová, J; Valentová, D; Visokaiová, M; Vokurka, S | 1 |
| Gisselbrecht, C; Hagberg, H | 1 |
| Fairbairn, LJ; Garside, E; Margison, GP; Southgate, TD | 1 |
| Blume, KG; Horning, SJ; Johnston, LJ; Laport, GG; Law, LY; Lowsky, R; Negrin, RS; Shizuru, JA; Stockerl-Goldstein, KE; Wong, RM | 1 |
| Atkins, H; Bence-Bruckler, I; Bredeson, C; Huebsch, L; Leger, C; McDiarmid, S; Sabloff, M; Zhang, H | 1 |
| Ala-Kopsala, M; Hartikainen, J; Jantunen, E; Kuittinen, T; Mussalo, H; Nousiainen, T; Vanninen, E; Vuolteenaho, O | 1 |
| Caballero, D; Canales, MA; Hernandez-Navarro, F; Martin, A | 1 |
| Blechschmidt, M; Bornhäuser, M; Ehninger, G; Hänel, M; Hölig, K; Kroschinsky, F; Oelschlaegel, U; Ordemann, R; Platzbecker, U; Poppe-Thiede, K; Schaich, M | 1 |
| Bay, JO; Berthou, C; Bertrand, P; Brion, A; Camilleri-Broët, S; Colombat, P; Delepine, R; Delwail, V; Desablens, B; Lamy, T; Lemevel, A; Linassier, C; Rachieru, P | 1 |
| Cupelli, L; de la Rubia, J; Jarque, I; Jiménez, C; Lorenzo, I; Martín, G; Martínez, JA; Puig, N; Remigia, MJ; Sanz, GF; Sanz, J; Sanz, MA | 1 |
| Balzarotti, M; Bramanti, S; Castagna, L; Magagnoli, M; Mazza, R; Nozza, A; Russo, F; Santoro, A; Sarina, B; Siracusano, L; Timofeeva, I; Todisco, E | 1 |
| Dörken, B; Dreyling, M; Forstpointner, R; Freund, M; Ganser, A; Hiddemann, W; Hoster, E; Huber, C; Ludwig, WD; Nickenig, C; Trümper, L; Unterhalt, M | 1 |
| Bishton, MJ; Haynes, AP | 1 |
| Delgado-Lamas, JL; García-Ruiz-Esparza, MA; Gómez-Almaguer, D; Gómez-Rangel, D; Gutiérrez-Aguirre, CH; Morales-Toquero, A; Padilla-González, Y; Ruiz-Argüelles, GJ; Ruiz-Delgado, GJ; Vela-Ojeda, J | 1 |
| Arceci, RJ; Chen, AR; Colombani, P; Higman, MA; Schwartz, CL; Wharam, M; Williams, KM | 1 |
| Atta, J; Chow, KU; Hoelzer, D; Martin, H; Mitrou, PS; Weidmann, E | 1 |
| Amadori, S; Broccia, G; de Witte, T; Feremans, W; Fillet, G; Jehn, U; Leone, G; Meloni, G; Rio, B; Suciu, S; Thomas, X; Vignetti, M | 1 |
| Arber, C; Bucher, C; Buser, AS; Ghielmini, M; Gratwohl, A; Halter, J; Heim, D; Lohri, A; Meyer-Monard, S; Passweg, JR; Stern, M; Stussi, G; Tichelli, A | 1 |
| Chien, CY; Huang, HY; Hwang, CF; Lin, IH | 1 |
| Abdelkefi, A; Ben Abdeladhim, A; Ben Othman, T; Ladeb, S; Lakhal, A; Torjman, L | 1 |
| Benaroush, M; Blumenfeld, Z; Zuckerman, T | 1 |
| Ades, L; Attal, M; Bernard, M; Blaise, D; Bordigoni, P; Bourhis, JH; Cassuto, JP; Chevalier, P; Deconinck, E; Facon, T; Garban, F; Ifrah, N; Kuentz, M; Lioure, B; Michallet, M; Milpied, N; Porcher, R; Renaud, M; Socié, G; Tabrizi, R; Tilly, H; Vernant, JP; Vigouroux, S | 1 |
| Bajor, DJ; Cooper, BW; Creger, RJ; Fu, P; Gerson, SL; Koç, ON; Laughlin, MJ; Lazarus, HM; van Heeckeren, WJ; Wadhwa, PD; Xu, Z | 1 |
| Al-Ali, HK; Niederwieser, D; Wittekind, C | 1 |
| Brand, R; Dreger, P; Michallet, M | 1 |
| Bambach, B; Battiwalla, M; Benekli, M; Czuczman, MS; Hahn, T; Hernandez-Ilizaliturri, F; McCarthy, PL; Padmanabhan, S; Smiley, SL; Younis, T | 1 |
| Albo, C; Alonso, N; Arranz, R; Caballero, D; Conde, E; Fernández-Rañada, JM; Gandarillas, M; García Vela, JA; Garzón, S; Grande, C; Hernández, MT; Lahuerta, JJ; Mateos, MV; Rodríguez, J | 1 |
| Caballero, D; Canals, C; Finke, J; Goldstone, A; Hunter, A; Kienast, J; Kobbe, G; Kolb, HJ; Kyriakou, C; Metzner, B; Oberg, G; Reimer, P; Schmitz, N; Sureda, A; Theorin, N | 1 |
| Balzarotti, M; Boiardi, A; Calatozzolo, C; Ciusani, E; Croci, D; de Grazia, U; Salmaggi, A | 1 |
| Baker, N; Barker, P; Boogaerts, M; Canizo, CD; Johnsen, HE; Mesters, R; Russell, N; Schmitz, N; Schubert, J; Skacel, T | 1 |
| Bacon, P; Blijlevens, N; D'Addio, A; Einsele, H; Maertens, J; McCann, S; Niederwieser, D; Quinn, B; Rabitsch, W; Roosaar, A; Ruutu, T; Schouten, H; Schwenkglenks, M; Stone, R; Vokurka, S | 1 |
| Ansell, S; Arndt, C; Buckner, J; Christianson, T; Galanis, E; Gill, P; Litzow, M; Moynihan, T | 1 |
| Briones, J; Camós, M; Colomo, L; Escoda, L; Espinosa, I; Estany, C; Gutiérrez-García, G; López-Guillermo, A; Martínez, S; Martino, R; Mercadal, S; Montserrat, E; Pedro, C; Ribera, JM; Xicoy, B | 1 |
| Barada, WM; Bazarbachi, A; Beydoun, A; Hourani, R; Masroujeh, R; Otrock, ZK | 1 |
| Byrne, JL; Das-Gupta, EP; Devereux, S; Gonzalez, J; Haynes, AP; Ho, A; Ingram, W; McMillan, A; Mufti, GJ; Pagliuca, A; Russell, NH; Shaw, BE | 1 |
| Arkenau, T; Cunningham, D; Horwich, A; Murphy, F; Norman, A; Oates, J; Powles, R; Sirohi, B; Wotherspoon, A | 1 |
| Donati, PA; Genitori, L; Giordano, F; Mussa, F; Sandri, A; Sanzo, M; Sardi, I | 1 |
| Ansell, SM; Costa, LJ; Inwards, DJ; Johnston, PB; Litzow, MR; Micallef, IN; Porrata, LF | 1 |
| Bacon, P; Blijlevens, N; D'Addio, A; Einsele, H; Maertens, J; McCann, S; Niederwieser, D; Quinn, B; Rabitsch, W; Roosaar, A; Ruutu, T; Schouten, H; Schwenkglenks, M; Stone, R; Vorkurka, S | 1 |
| Gil, L; Komarnicki, M; Kozlowska-Skrzypczak, M; Mol, A; Poplawski, D; Styczynski, J | 1 |
| Boyett, JM; Dhall, G; Dunkel, IJ; Finlay, JL; Gardner, SL; Goldman, S; Packer, RJ; Pollack, IF; Rosenblum, MK; Stanley, P; Wallace, D; Yates, AJ; Zimmerman, RA | 1 |
| Alinari, L; Baccarani, M; Derenzini, E; Fanti, S; Gandolfi, L; Musuraca, G; Stefoni, V; Tani, M; Venturini, F; Zinzani, PL | 1 |
| SEASHORE, HG | 1 |
| Bensinger, WI; Gooley, T; Gopal, AK; Holmberg, L; Maloney, D; Press, O; Zaucha, R | 1 |
| Cook, G; Crawley, C; Fields, P; Hickling, R; Hunter, A; Mahendra, P; Marcus, R; Peniket, A; Wilson, K | 1 |
| Brault, P; Decaudin, D; Escande, MC; Girodet, J; Mariani, P; Mathiot, C; Precupanu, CM; Zanni, M | 1 |
| Benvegnú, DM; Bonfanti, G; Frediani, AV; Gonçalves, TL; Rocha, JB | 1 |
| Arpaci, F; Ataergin, S; Kilic, S; Komurcu, S; Kuzhan, O; Ozet, A; Ozturk, B; Ozturk, M | 1 |
| Crump, M; Keating, A; Kuruvilla, J; Pintilie, M; Seshadri, T; Tsang, R; Zadeh, S | 1 |
| Adam, Z; Bolcák, K; Cerný, J; Fakan, F; Hájek, R; Krejcí, M; Kren, L; Mayer, J; Neubauer, J; Pour, L; Smardová, L; Soumarová, R; Vanícek, J; Veselý, K | 1 |
| Engman, CA; Hill, JM; Meehan, KR | 1 |
| Barreira, AA; Barros, GM; Barros, JC; Brum, DG; Burt, RK; Hamerschlak, N; Kutner, JM; Madeira, MI; Mastropietro, AP; Moraes, DA; Neto, JZ; Oliveira, EA; Oliveira, MC; Paes, AT; Pieroni, F; Porto, PP; Ribeiro, AA; Rodrigues, M; Santana, CL; Santos, AC; Simões, BP; Stracieri, AB; Tylberi, CP; Voltarelli, JC | 1 |
| Cerno, M; Damiani, D; Fanin, R; Geromin, A; Patriarca, F; Rinaldi, C; Skert, C; Sperotto, A; Stocchi, R; Tiribelli, M; Zaja, F | 1 |
| Domm, J; Eckrich, MJ; Frangoul, H; Ho, R; Whitlock, JA | 1 |
| Barzal, J; Mlot, B; Oborska, S; Pielichowski, W; Rzepecki, P | 1 |
| García-Sanz, R; González-López, TJ; Graciani, IF; Hermida, G; San Miguel, JF; Vázquez, L | 1 |
| Kuruvilla, J | 1 |
| Blumenfeld, Z; Zuckerman, T | 1 |
| Qiao, W; Wang, C; Wang, T; Xing, Y; Zhao, J | 1 |
| Butler, JB; Cooke, A; Demers, A; Liu, HW; Nugent, Z; Rubinger, M; Schroeder, G; Seftel, MD; Szwajcer, D | 1 |
| Boesen, AM; Browett, P; Cunningham, D; Grigg, A; Hancock, B; Holte, H; Hoskin, P; Jack, A; Linch, DC; Maclennan, K; Qian, W; Smith, P; Trneny, M; Yung, L | 1 |
| BRAESTRUP, CB; SINGER, G; WYCKOFF, HO | 2 |
| HERSCHER, LW; WRIGHT, N | 1 |
| Havrdová, E; Kemlink, D; Kobylka, P; Kovárová, I; Kozák, T; Krasulová, E; Lhotáková, P; Pohlreich, D; Trneny, M; Vacková, B | 1 |
| Asmar, L; Beveridge, R; Boehm, KA; Mandanas, R; McGaughey, D; Orloff, G; Rifkin, R; Spitzer, G; Zhan, F | 1 |
| Ali-Osman, F; Beaven, A; Chao, NJ; Chute, J; Crout, CA; Davis, P; Decastro, C; Diehl, L; Edwards, J; Gasparetto, C; Gockerman, JP; Horwitz, M; Koh, LP; Long, GD; Moore, JO; Morris, A; Niedzwiecki, D; Prosnitz, L; Rizzieri, DA | 1 |
| Donaldson, MR; Lane, N; Smith, JL; Stetson, CL | 1 |
| Schneider, AE; Talmon, GA | 1 |
| Cairo, MS; Gross, TG; Harris, RE; Harrison, L; Henry, MM; Lynch, J; Perkins, SL; Smith, LM; Termuhlen, AM; Vlachos, A; Warkentin, P | 1 |
| Huh, J; Kim, JE; Kim, S; Kim, SW; Lee, DH; Lee, JS; Park, CJ; Suh, C; Yoo, C | 1 |
| Dong, HQ; Ji, BX; Liu, CY; Liu, YO; Su, L; Sun, WL; Wan, SG; Xu, J; Zhang, P | 1 |
| Abboud, CN; Becker, MW; Bernstein, SH; Constine, LS; Friedberg, JW; Ifthikharuddin, JJ; Liesveld, JL; Loughner, JE; Milner, LA; Phillips, GL; Vesole, DH | 1 |
| Berthou, C; Deconinck, E; Delwail, V; François, S; Gastinne, T; Gyan, E; Milpied, N; Monjanel, H; Moreau, A; Perrodeau, E | 1 |
| Choma, M; Chybicka, A; Cornish, J; Gorczyńska, E; Grund, G; Kowalczyk, JR; Peters, C; Sykora, KW; Wachowiak, J | 1 |
| Bockova, J; Brandejsova, R; Bystricka, E; Chvojkova, I; Mazur, E; Mjartanova, D; Scudlova, J; Streinerova, K; Vasilieva, E; Visokaiova, M; Vitkova, J; Vodickova, M; Vokurka, S; Vrabcova, M | 1 |
| Kim, JH; Lee, WH; Suk, K; Zheng, LT | 1 |
| Cai, JL; Delioukina, M; Forman, SJ; Gaal, K; Kogut, N; Nademanee, A; Palmer, JM; Popplewell, L; Tsai, NC | 1 |
| Glass, B; Griesinger, F; Hasenkamp, J; Hohloch, K; Lakhani, VJ; Meller, J; Riggert, J; Sahlmann, CO; Trümper, L; Wulf, G | 1 |
| Hamed, SS; Roth, CM | 1 |
| Bartlett, NL; Cashen, AF; Foyil, KV; Grove, LE; Kennedy, DA | 1 |
| Dib, M; Gagnadoux, F; Paris, A; Rousselet, MC; Tazi, A; Urban, T | 1 |
| Barzal, J; Gawronski, K; Mlot, B; Oborska, S; Pielichowski, W; Rzepecki, P; Wasko-Grabowska, A | 1 |
| Barzał, J; Gawroński, K; Młot, B; Oborska, S; Rzepecki, P; Szczylik, C; Waśko-Grabowska, A | 1 |
| Chang, HC; De La Rosa, M; Han, L; Lupov, IP; Oza, K; Pelloso, D; Robertson, MJ; Sahu, RP; Schwartz, A; Travers, JB; Voiles, L | 1 |
| Abramson, JS; Armand, P; Brown, JR; Chen, YB; Feng, Y; Fisher, DC; Freedman, AS; Jacobsen, ED; LaCasce, AS; Lane, AA; McAfee, SL; Neuberg, DS; Spitzer, TR | 1 |
| Crump, M; Keating, A; Kuruvilla, J; Massey, C; Puig, N; Seshadri, T; Tsang, R; Villa, D | 1 |
| Madtes, DK; Till, BG | 1 |
| de Rooij, M; Huijgens, PC; Visser, OJ; Wondergem, MJ; Zijlstra, JM; Zweegman, S | 1 |
| Avigdor, A; Avivi, I; Levi, I; Nagler, A; Or, R; Patachenko, P; Rowe, JM; Shimoni, A; Yeshurun, M; Zwas, T | 1 |
| Briere, J; Bron, D; Cogliatti, S; Cuccuini, W; Gaulard, P; Gisselbrecht, C; Hirchaud, E; Houlgatte, R; Mounier, N; Rosenwald, A; Soulier, J; Sundstrom, C; Thieblemont, C; Voelker, HU; Ysebaert, L | 1 |
| Ardeshna, K; Kayani, I; Linch, DC; Lowry, L; Moore, S; Peggs, K; Qian, W; Thomson, K | 1 |
| Adam, Z; Adamová, Z; Brejcha, M; Hájek, R; Kodet, R; Koukalová, R; Krejčí, M; Mayer, J; Moulis, M; Nebeský, T; Pour, L; Rehák, Z; Szturz, P; Zahradová, L | 1 |
| Ma, X; Ren, C; Sheng, Z; Wang, B; Xia, B; Zhang, W | 1 |
| Aznar Oroval, E; García-Lozano, T; Juan Bañón, JL; Lorente Alegre, P | 1 |
| Adachi, Y; Arimura, Y; Endo, T; Ishii, Y; Sawada, T; Yasui, H | 1 |
| Andersen, NS; Bentzen, H; Brown, P; Delabie, J; Ehinger, M; Elonen, E; Eriksson, M; Geisler, CH; Jerkeman, M; Karjalainen-Lindsberg, ML; Kimby, E; Kolstad, A; Kuittinen, O; Laurell, A; Lauritzsen, GF; Nilsson-Ehle, H; Nordström, M; Pedersen, LB; Ralfkiaer, E; Räty, R; Sundström, C | 1 |
| Beuthien-Baumann, B; Bornhäuser, M; Ehninger, G; Kroschinsky, F; Middeke, JM; Ordemann, R; Platzbecker, U; Platzek, I; Stöhlmacher, J; van den Hoff, J; Zietz, C | 1 |
| Ahmed, AB; Bruserud, O; Hatfield, KJ; Kittang, AO; Reikvam, H; Sjo, M; Tvedt, TH | 1 |
| Cooney, JP; Kruger, PC; Turner, JH | 1 |
| Anderson, D; Greaves, P; Gribben, JG; Lillington, D; Lister, TA; Matthews, J; Montoto, S | 1 |
| Burbury, K; Khot, A; Li, J | 1 |
| Cheng, AL; Huang, HC; Kuo, SH; Lin, CW | 1 |
| Ambinder, R; Ayala, E; Burns, LJ; Carter, S; Fenske, T; Fisher, R; Horowitz, M; Mineshi, S; Moskowitz, CH; Press, OW; Stadtmauer, EA; Tomblyn, M; Vose, JM | 1 |
| Berdel, WE; Demant, A; Evers, G; Kessler, T; Köhler, G; Krug, U; Kuhlmann, M; Mesters, R; Mikesch, JH; Mohr, M; Müller-Tidow, C; Pohlen, M; Schliemann, C; Schmidt, E; Thoennissen, GB; Thoennissen, NH; Wessling, J | 1 |
| Aslan, D; Cetin, M; Eroglu, C; Eser, B; Kaynar, L; Keklik, M; Kurnaz, F; Mentes, S; Orhan, O; Sahin, C; Sivgin, S; Soyuer, S; Unal, A; Yildiz, OG | 1 |
| Bembnista, E; Czyz, A; Dytfeld, D; Gil, L; Kazmierczak, M; Komarnicki, M; Kozlowska-Skrzypczak, M; Lojko-Dankowska, A; Matuszak, M; Nowicki, A | 1 |
| Armitage, JO; Bierman, PJ; Bociek, RG; Loberiza, FR; Vose, JM; Whalen, V; William, BM | 1 |
| Czajczynska, A; Gramatzki, M; Günther, A; Humpe, A; Kneba, M; Nickelsen, M; Raff, T; Repp, R; Schrappe, M; Schrauder, A; Schub, N | 1 |
| Blijlevens, NM; de Haan, AF; Donnelly, JP; Herbers, AH; van der Velden, WJ | 1 |
| Go, A; Guo, R; Parthasarathy, M; Rodriguez, T; Smith, S; Sobol, U; Stiff, P; Vimr, R | 1 |
| Calandrelli, M; Capelli, D; Chiarucci, M; Gini, G; Inglese, E; Leoni, P; Mancini, G; Mancini, S; Montanari, M; Offidani, M; Olivieri, A; Poloni, A; Raggetti, G; Scortechini, I | 1 |
| Chung, JS; Kim, H; Kim, JS; Lee, GW; Lee, HS; Lee, WS; Shin, HJ; Song, MK; Yhim, HY | 1 |
| Allen, MS; Armitage, JO; Bierman, PJ; Bociek, RG; Loberiza, FR; Vose, JM; William, BM | 1 |
| Ardeshna, KM; Bird, A; Goldstone, AH; Kothari, J; Lambert, J; Linch, DC; Morris, E; Peggs, KS; Thomson, KJ; Virchis, AE | 1 |
| Buck, A; Duell, J; Einsele, H; Knop, S; Maeder, U; Rasche, L; Rosenwald, A; Strifler, S | 1 |
| WOOD, CA | 1 |
| CHARTERIS, AA | 1 |
| BATHO, HF; EVANS, AM; MIBUS, SA; MOFFAT, RG; NASH, RD | 1 |
| Belada, D; Berková, A; Bolomská, I; Burešová, L; Campr, V; Klener, P; Kozák, T; Kubáčková, K; Matuška, M; Pirnos, J; Přibylová, J; Pytlík, R; Sýkorová, A; Trněný, M; Vášová, I | 1 |
| Bentzen, H; Bogsrud, TV; Brown, Pde N; Delabie, J; Ehinger, M; Elonen, E; Fagerli, UM; Frederiksen, H; Geisler, CH; Grønbæk, K; Hansen, PB; Jerkeman, M; Karjalainen-Lindsberg, ML; Kimby, E; Kolstad, A; Kostova-Aherdan, K; Laurell, A; Lauritzsen, GF; Lehmann, AK; Loft, A; Nilsson-Ehle, H; Pedersen, LB; Ralfkiaer, E; Räty, R; Schildt, J; Sundstrom, C | 1 |
| Auger-Quittet, S; Daures, JP; Duny, Y; Quittet, P | 1 |
| Daw, S; Hayward, J; Hewitt, M; Kirkwood, A; McCarthy, K; Morland, B; Shankar, A | 1 |
| Caballero, MD; Cabrero-Calvo, M; García-Sanz, R; Labrador, J; Mateos, MV; Pérez-López, E; Vázquez, L | 1 |
| D'Sa, S; Dorman, J; Marzolini, MA; Thomson, KJ | 1 |
| Borchmann, P; Engert, A; Monsef, I; Rancea, M; Skoetz, N; Will, A | 1 |
| Arranz, R; Bargay, J; Bello, JL; Caballero, MD; Conde, E; Coronado, M; González-Barca, E; Grande, C; Hernández, MT; Marín-Niebla, A; Martín, A; Montes-Moreno, S; Panizo, C; Pardal, E; Pérez-Ceballos, E | 1 |
| Ancochea, Á; Fernández-Rodriguez, C; García-Pallarols, F; Gimeno, E; Salar, A; Sánchez-González, B | 1 |
| Bates, A; Cooke, R; Cunningham, D; Falk, SJ; Gilson, D; Hancock, BW; Harris, SJ; Horwich, A; Hoskin, PJ; Linch, DC; Lister, A; Lucraft, HH; Radford, J; Stevens, AM; Swerdlow, AJ; Syndikus, I; Williams, MV | 1 |
| Argnani, L; Maglie, R; Pellegrini, C; Pileri, S; Zinzani, PL | 1 |
| Nagai, H | 1 |
| Advani, RH; Agarwal-Hashmi, R; Donaldson, SS; Garfin, PM; Kharbanda, S; Link, MP; Luna-Fineman, S; Porteus, M; Weinberg, KI | 1 |
| Banat, A; Basara, N; Derigs, G; Flohr, T; Frickhofen, N; Gramatzki, M; Hess, G; Kirschey, S; Kolbe, K; Link, H; Meyer, RG; Peter, N; Schmitz, N; Schulz, A; Theobald, M; Weidmann, E; Wolf, HH | 1 |
| Barriere, J; Borchiellini, D; Boscagli, A; Coso, D; Garnier, G; Gastaud, L; Gutnecht, J; Martin, N; Naman, H; Petit, E; Peyrade, F; Re, D; Rossignol, B; Saudes, L; Thyss, A | 1 |
| Akpek, G; Aljurf, M; Artz, A; Bredeson, CN; Chen, YB; Cooke, KR; Ho, VT; Lane, AA; Lazarus, HM; Logan, B; McCarthy, P; Olsson, R; Pasquini, MC; Saber, W; Zhu, X | 1 |
| Ford, PA; Grant, SJ; Keck, G; Mick, R | 1 |
| Caimi, PF; Campagnaro, EL; Cooper, BW; Creger, RJ; de Lima, M; Fox, R; Fu, P; Gerson, SL; Lazarus, HM; Reese-Koc, J; Silva Rondon, CH; William, BM | 1 |
| Abidi, MH; Ayash, L; Bhutani, D; Deol, A; Dyson, G; Jain, T; Kim, S; Lum, LG; Ratanatharathorn, V; Uberti, JP; Veeraputhiran, M | 1 |
| Bachy, E; Casasnovas, O; Freyer, G; Guitton, J; Hénin, E; Ribrag, V; Salles, G; Sebban, C; Tilly, H; Tod, M; You, B | 1 |
| Gore, A; Gupta, A; Jain, R; Jeevangi, N; Kannan, S; Khattry, N; Nair, R; Saikia, T; Thippeswamy, R | 1 |
| Bojic, M; Greinix, H; Hermann, A; Jäger, U; Kalhs, P; Lamm, W; Leiner, M; Mitterbauer, M; Rabitsch, W; Schörgenhofer, C; Schulenburg, A; Sillaber, C; Skrabs, K; Sperr, WR; Wohlfarth, P | 1 |
| Ai, W; Bence-Bruckler, I; Bierman, P; Braunschweig, I; Chen, AI; Comeau, T; Costa, LJ; Craig, M; Fay, JW; Flinn, I; Flowers, CR; Freytes, CO; Horwitz, ME; Kato, K; Laneuville, P; Le-Rademacher, J; Lill, M; Mason, J; Mineishi, S; Pasquini, MC; Pulsipher, MA; Rodriguez, TE; Rondelli, D; Shea, TC; Shore, TB; Smith, AJ; Vaughan, W; Waller, EK; Wang, Y; Xu, C; Yeager, AM; Yeh, RF | 1 |
| Boulahdour, H; Daguindau, E; Deconinck, E; Helias, P; Philippe, L; Puyraveau, M | 1 |
| Ardeshna, KM; Foley, M; Kothari, J; Lambert, J; Linch, DC; Mackenzie, S; Morris, E; Peggs, KS; Thomson, K; Virchis, AE | 1 |
| Abboud, C; Cashen, AF; Ceriotti, C; DiPersio, J; Fletcher, T; Gao, F; Ghobadi, A; Stockerl-Goldstein, K; Vij, R | 1 |
| Bhat, V; Khattry, N; Toshniwal, M; Vira, H | 1 |
| Butcher, B; Chong, G; Cull, G; Fay, K; Filshie, R; Gandhi, MK; Gill, D; Grigg, A; Hahn, U; Hertzberg, M; Hicks, RJ; Ho, SJ; Hofman, MS; Johnston, A; Kannourakis, G; Lewis, ID; Milliken, S; Renwick, W; Seymour, JF; Taper, J; Trotman, J; Warburton, P; Watson, AM; Wirth, A | 1 |
| Amorim, S; Bachy, E; Bay, JO; Bento, L; Bonifazi, F; Bouabdallah, R; Boumendil, A; Ceballos, P; Crawley, C; Damaj, G; Dreger, P; Finel, H; Gribben, J; Guilhot, F; Haenel, A; Huynh, A; Johnson, R; Le Gouill, S; Malladi, R; McQuaker, G; Metzner, B; Monjanel, H; Montoto, S; Nicolas-Virelizier, E; Orchard, K; Pohlreich, D; Poiré, X; Rambaldi, A; Rossi, G; Russell, NH; Thomson, K; Tilly, H | 1 |
| Cassaday, RD; Cowan, A; Ermoian, R; Gopal, AK; Graf, SA; Holmberg, LA; Press, OW; Shadman, M; Smith, SD; Stevenson, PA; Till, BG; Tseng, YD | 1 |
| Alenxandrova, K; Arfi-Rouche, J; Bourhis, JH; Castilla-Llorente, C; Danu, A; Ghez, D; Khalife-Saleh, N; Koscielny, S; Lapierre, V; Lazarovici, J; Legoupil, C; Michot, JM; Pilorge, S; Ribrag, V; Saleh, K | 1 |
| Lavolé, J; Le Goff, M; Mallet, V; Oudjit, A; Sogni, P | 1 |
| Braziel, RM; Chansky, K; Chen, AI; Dunlap, JB; Fan, G; Gay, ND; Leonard, JT; Maziarz, RT; Okada, CY; Raess, PW; Stentz, A | 1 |
| Baars, JW; Brouwer, R; Chamuleau, MED; de Jong, D; de Wreede, LC; Demandt, AMP; Doorduijn, JK; Hardi, L; Kersten, MJ; Kluin, PM; Nijland, M; Oosten, LEM; Siemes, C; Smeekes, OS; Stevens, WBC; Thielen, FW; Uyl-de Groot, CA; van Imhoff, GW; Veelken, H | 1 |
| Ansuinelli, M; Canfora, M; Cantonetti, M; Capria, S; Caputo, MD; Di Rocco, A; Giannarelli, D; Gumenyuk, S; Marchesi, F; Mengarelli, A; Palombi, F; Papa, E; Pisani, F; Provenzano, I; Pupo, L; Renzi, D; Romano, A; Serrao, A; Spadea, A; Trisolini, SM | 1 |
| Akhtar, S; Elhassan, TAM; Elshenawy, MA; Maghfoor, I; Shahzad Rauf, M | 1 |
| Ahmed, S; Alousi, A; Anderlini, P; Andersson, BS; Champlin, R; Dabaja, B; Fanale, M; Gulbis, A; Hosing, C; Jones, RB; Kebriaei, P; Ma, J; Milgrom, S; Myers, A; Nieto, Y; Oki, Y; Pinnix, C; Popat, U; Qazilbash, M; Shpall, EJ; Thall, PF; Timmons, M; Valdez, BC | 1 |
| Fornecker, LM; Guffroy, A; Korganow, AS; Martin, M; Meyer, A | 1 |
| Boehm, A; Keil, F; Koller, E; Menschel, E; Moestl, M; Noesslinger, T; Panny, M; Simanek, R | 1 |
| Billio, A; Borghero, C; Calimeri, T; Carli, G; Cascavilla, N; Centurioni, R; Chiusolo, P; Codeluppi, K; Fama, A; Fanin, R; Federici, I; Ferrero, S; Finotto, S; Gherlinzoni, F; Ghione, P; Giannoccaro, M; Lanza, F; Loseto, G; Marino, D; Matera, R; Mazzone, AM; Mosna, F; Olivieri, A; Olivieri, J; Orciuolo, E; Pelosini, M; Perali, G; Rattotti, S; Saraceni, F; Sgherza, N; Sica, S; Stefani, PM; Tisi, MC; Tomei, G; Zaja, F | 1 |
| Abou Mourad, Y; Clissa, C; Connors, JM; Gerrie, AS; Guiducci, B; Isidori, A; Loscocco, F; Nantel, SH; Power, M; Sanford, D; Savage, KJ; Scott, DW; Sehn, LH; Song, K; Sutherland, H; Toze, C; Tsang, ES; Villa, D; Visani, G | 1 |
| Bettarello, G; Costa, LJM; da Matta Abreu, M; Dos Santos, KB; Hallack Neto, AE; Mayrink, GTC; Mota, MA; Pereira, J; Ribeiro, LC | 1 |
| Anagnostopoulos, A; Batsis, I; Bouziana, S; Constantinou, V; Gavriilaki, E; Mallouri, D; Marvaki, A; Sakellari, I; Sotiropoulos, D; Vardi, A | 1 |
| Barnett, MH; Barnett, Y; Ford, CD; Hendrawan, K; Khoo, ML; Kyle, KA; Ma, DDF; Ma, KC; Massey, JC; Milliken, ST; Moore, JJ; Sutton, IJ; Zaunders, JJ; Zivadinov, R | 1 |
| Bando-Polaino, I; Cabezas-Camarero, S; de la Orden García, V; Díaz-Rubio, E; García-Barberán, V; Llovet García, P; Mediero-Valeros, B; Merino Menéndez, S; Pérez-Segura, P; Subhi-Issa, AI | 1 |
| Abounader, D; Andritsos, L; Benson, DM; Bolwell, B; Dean, R; Devine, SM; Efebera, YA; Elder, P; Hill, B; Hofmeister, CC; Jagadeesh, D; Jaglowski, S; Kalaycio, M; Majhail, NS; Penza, S; Pohlman, B; Rosko, A; Sharma, N; Singer, S; Sobecks, R; Vasu, S; William, BM; Zhao, Q | 1 |
| Bishton, M; Campbell, R; Cheah, CY; Cochrane, T; De Mel Widanalage, S; Gilbertson, M; Hapgood, G; Hawkes, E; Hill, K; Johnston, A; Lee, HP; Manos, K; Nelson, N; Ng, M; Ng, ZY; Opat, S; Poon, M; Purtill, D; Ratnasingam, S; Ritchie, D; Schwarer, A; Seymour, J; Shorten, S; Sunny, T; Tam, C; Xin, L | 1 |
| Barlogie, B; Mouhieddine, TH; Teruya-Feldstein, J | 1 |
| Arora, R; Hildebrandt, GC; Munker, R; Qasrawi, A; Ramlal, R | 1 |
| Abraham, J; Borel, C; Bouabdallah, K; Bouabdallah, R; Casasnovas, RO; Chantepie, S; Damaj, G; Delapierre, B; Delette, C; Durot, E; Fornecker, LM; Garciaz, S; Gastinne, T; Gressin, R; Gyan, E; Houot, R; Hueso, T; Ibrahim, A; Le Gouill, S; Lemal, R; Malak, S; Morello, R; Peyrade, F; Tchernonog, E; Tessoulin, B; Tournilhac, O | 1 |
| Ahmed, S; Ahn, KW; Aljurf, M; Bacher, U; Badawy, SM; Bejanyan, N; Cairo, M; Cerny, J; Epperla, N; Farhadfar, N; Fenske, TS; Freytes, CO; Gale, RP; Hamadani, M; Haverkos, B; He, Y; Hossain, N; Inwards, D; Jagadeesh, D; Kamble, RT; Kenkre, VP; Kharfan-Dabaja, MA; Lazarus, HM; Lazaryan, A; Lekakis, L; Litovich, C; Majhail, NS; Mei, M; Murthy, HS; Mussetti, A; Nathan, S; Nishihori, T; Olsson, RF; Ramakrishnan Geethakumari, P; Savani, BN; Sureda, A; Yared, JA | 1 |
| Böhmer, LH; Chitu, DA; de Jong, D; de Jongh, E; de Weerdt, O; Doorduijn, JK; Hoogendoorn, M; Kersten, MJ; Kibbelaar, RE; Kluin-Nelemans, HC; Leys, RBL; Lugtenburg, PJ; MacKenzie, MA; Minnema, MC; Snijders, TJF; van Gelder, M; van Marwijk Kooij, R; Van't Veer, MB; Zijlstra, JM | 1 |
| An, HY; Choi, JY; Hong, KT; Kang, HJ; Shin, HY | 1 |
| Ballotta, L; Capria, S; Celentano, M; Ferrara, F; Marchesi, F; Mengarelli, A; Papa, E; Pedata, M; Picardi, A; Regazzo, G; Riccardi, C; Riemma, C; Terrenato, I; Trisolini, S | 1 |
| Kelsey, P; Kirkland, K; Lambert, J; Malladi, R; Morley, N; Paul, R; Pearce, R; Peniket, A; Perry, J; Snowden, JA | 1 |
| Allione, B; Calimeri, T; Cattaneo, C; Donadoni, G; Facchetti, F; Ferrari, D; Ferreri, AJM; Foppoli, M; Fumagalli, L; Lleshi, A; Pecciarini, L; Ponzoni, M; Re, A; Rigacci, L; Rossi, G; Sassone, M; Spina, M; Verga, L | 1 |
| Alencar, AJ; Moskowitz, CH | 1 |
| Mathen, P; Smart, DK | 1 |
| Akkurt, DM; Cinli, TA; Demir, I; Durusoy, SS; Gunes, AK; Ince, I; Ozkan, G; Pehlivan, M; Sarifakiogullari, S; Serin, I | 1 |
| Birkmann, J; Blaudszun, AR; Bornhäuser, M; Ehninger, G; Fiedler, F; Fricke, S; Hänel, A; Hänel, M; Herbst, R; Kroschinsky, F; Kürzel, S; Schaefer-Eckart, K; Stahl, L | 1 |
| Bosch, M; Danyluk, P; Dusyk, T; Elemary, M; Hahn, L; Lim, H; Sabry, W; Stakiw, J | 1 |
| de Lima, VCC; Filho, JS; Germano, JN; Matias Vieira, GM; Moura, FL; Sapelli, J | 1 |
| Grommes, C; Modelevsky, L; Reiss, SN; Yerram, P | 1 |
| Bouabdallah, K; Casasnovas, RO; Costes-Tertrais, D; Damaj, G; Dartigeas, C; Delette, C; Fogarty, P; Fornecker, LM; Garciaz, S; Gastinne, T; Gressin, R; Houot, R; Hueso, T; Le Gouill, S; Malak, S; Oberic, L; Ribrag, V; Tchernonog, E; Thieblemont, C | 1 |
| Abraham, J; Agbetiafa, K; Ahle, G; Bonmati, C; Bouabdallah, K; Bouabdallah, R; Bourget, P; Casasnovas, O; Charron, C; Chauchet, A; Chinot, O; Choquet, S; Cornillon, J; Damaj, G; Delwail, V; Dorvaux, V; Fabbro, M; Fornecker, LM; Ghesquières, H; Giordan, Q; Gressin, R; Gyan, E; Hoang-Xuan, K; Houillier, C; Houot, R; Jabeur, W; Jardin, F; Le Garff-Tavernier, M; Malaise, D; Marolleau, JP; Moluçon-Chabrot, C; Morschhauser, F; Nichelli, L; Oberic, L; Peyrade, F; Plessier, A; Roland, V; Schenone, L; Schmitt, A; Soussain, C; Taillandier, L; Tanguy, ML; Tempescul, A; Thieblemont, C; Touitou, V; Ursu, R; Wantz-Mézières, S; Waultier-Rascalou, A; Willems, L | 1 |
| Bazan, JG; Zeidan, YH | 1 |
| Ghraichy, M; Jelcic, I; Martin, R; Müller, AM; Ruder, J; Schanz, U; Trück, J; von Niederhäusern, V | 1 |
| Chari, A; Cho, HJ; Jakubowski, R; Moshier, E; Mouhieddine, TH; Parekh, S; Puliafito, B; Rattu, M; Richard, S; Richter, J; Rodriguez, C; Rossi, A; Sanchez, L; Steinberg, A; Thibaud, S | 1 |
| Attenberger, U; Brossart, P; Garbe, S; Heine, A; Holderried, T; Kersting, L; Koch, D; Köksal, M; Leitzen, C; Sarria, GR; Scafa, D; Schmeel, LC; Schoroth, F; Zoga, E | 1 |
| Fatkhudinov, T; Gordon, K; Gulidov, I; Koryakin, S | 1 |
| Akino, Y; Mabuchi, N; Masai, N; Ogawa, K; Oh, RJ; Shiomi, H | 1 |
| Avni, B; Cohen, YI; Grisariu, S; Lebel, E; Shaulov, A; Stepensky, P; Zimran, E | 1 |
| Topkan, E; Yilmaz, B | 1 |
| Jiang, XX; Lai, JL; Lei, KJ; Li, A; Li, B; Li, XK; Liu, J; Liu, SP; Ye, XJ; Zhou, L | 1 |
| Blank, JL; Thelen, DG | 1 |
32 review(s) available for etoposide and carmustine
| Article | Year |
|---|---|
[Treatment of relapses and failures in disseminated Hodgkin's disease].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplantation; Carmustine; Cisplatin; Cyclophosphamide; Cytarabine; Dacarbazine; Doxorubicin; Epirubicin; Etoposide; Hodgkin Disease; Humans; Ifosfamide; Mechlorethamine; Melphalan; Methotrexate; Mitoguazone; Prednisone; Procarbazine; Remission Induction; Transplantation, Autologous; Transplantation, Homologous; Vinblastine; Vincristine | 1991 |
What is the value of autologous bone marrow transplantation in the treatment of relapsed or resistant Hodgkin's disease?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Carmustine; Cyclophosphamide; Cytarabine; Drug Resistance; Etoposide; Hematopoietic Cell Growth Factors; Hematopoietic Stem Cells; Hodgkin Disease; Humans; Melphalan; Neutropenia; Pilot Projects; Randomized Controlled Trials as Topic; Registries; Time Factors; Transplantation, Autologous | 1991 |
New drugs and new delivery techniques.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aziridines; Benzoquinones; Bleomycin; Brain Neoplasms; Carboplatin; Carmustine; Cisplatin; Etoposide; Humans; Infusions, Intra-Arterial; Interferons; Nitrosourea Compounds; Organoplatinum Compounds; Rats | 1985 |
High-dose, potentially myeloablative chemotherapy and autologous bone marrow transplantation for patients with advanced Hodgkin's disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Carmustine; Cyclophosphamide; Drug Administration Schedule; Etoposide; Female; Hodgkin Disease; Humans; Leukocyte Count; Lung Diseases; Male; Middle Aged; Platelet Count; Remission Induction | 1989 |
High dose chemotherapy in solid tumours in adults.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Breast Neoplasms; Carcinoma, Small Cell; Carmustine; Cell Separation; Cisplatin; Colonic Neoplasms; Cyclophosphamide; Etoposide; Glioma; Humans; Lung Neoplasms; Male; Melanoma; Melphalan; Neoplasms; Testicular Neoplasms; Whole-Body Irradiation | 1986 |
Overview of the clinical relevance of autologous bone marrow transplantation.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Drug Evaluation; Drug Resistance; Etoposide; Hodgkin Disease; Humans; Leukemia; Leukemia, Lymphoid; Lymphoma; Melphalan; Neoplasm Recurrence, Local; Neoplasms; Thioguanine; Transplantation, Autologous | 1986 |
Clinical studies of autologous bone marrow transplantation in Hodgkin's disease.
Topics: Alkylating Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Carmustine; Cell Separation; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Drug Resistance; Etoposide; Hodgkin Disease; Humans; Lomustine; Pulmonary Fibrosis; Risk; Thioguanine; Transplantation, Autologous; Whole-Body Irradiation | 1986 |
High dose chemotherapy with autologous bone marrow rescue for high grade gliomas of the brain: a potential for improvement in therapeutic results.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; Combined Modality Therapy; Etoposide; Glioblastoma; Glioma; Humans; Lomustine; Teniposide | 1984 |
Intensive chemotherapy for solid tumours--current clinical applications.
Topics: Antineoplastic Agents; Carmustine; Cyclophosphamide; Drug Administration Schedule; Drug Therapy, Combination; Etoposide; Forecasting; Humans; Melphalan; Neoplasms | 1982 |
[Treatment strategy to obtain cure for recurrent advanced breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms; Carboplatin; Carmustine; Chemotherapy, Adjuvant; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Neoplasm Recurrence, Local; Thiotepa | 1994 |
Intensive therapy and autotransplantation in Hodgkin's disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone Marrow Transplantation; Carmustine; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Digestive System Diseases; Etoposide; Heart Diseases; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lung Diseases; Melphalan; Multicenter Studies as Topic; Podophyllotoxin; Recurrence; Remission Induction; Salvage Therapy; Survival Rate; Treatment Outcome; Whole-Body Irradiation | 1994 |
Hemolytic uremic syndrome after high dose chemotherapy with autologous stem cell support.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Fatal Outcome; Female; Hematopoietic Stem Cell Transplantation; Hemolytic-Uremic Syndrome; Humans; Hypertension; Immunoglobulins, Intravenous; Male; Middle Aged; Plasma; Remission Induction; Renal Insufficiency; Retinal Vein Occlusion; Thiotepa; Thrombocytopenia; Transplantation, Autologous; Vincristine | 1995 |
Peripheral blood progenitor cell transplantation: a single centre experience comparing two mobilisation regimens in 67 patients.
Topics: Adolescent; Adult; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carmustine; Cell Movement; Colony-Forming Units Assay; Cyclophosphamide; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Kidney Diseases; Leukapheresis; Leukocyte Count; Male; Melphalan; Middle Aged; Neoplasms; Podophyllotoxin; Retrospective Studies; Thiotepa; Transplantation Conditioning | 1996 |
[Dose-effect of chemotherapy in bronchial small-cell cancer].
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carcinoma, Small Cell; Carmustine; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Etoposide; Humans; Lung Neoplasms; Randomized Controlled Trials as Topic; Time Factors | 1997 |
Chemotherapy for advanced esthesioneuroblastoma: the Mayo Clinic experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Esthesioneuroblastoma, Olfactory; Etoposide; Fatal Outcome; Female; Humans; Ifosfamide; Lymphatic Metastasis; Male; Mesna; Methotrexate; Middle Aged; Mitomycin; Nasal Cavity; Nose Neoplasms; Paranasal Sinus Neoplasms; Remission Induction; Retrospective Studies; Survival Analysis; Treatment Outcome; Vincristine | 1998 |
Progressive multifocal leukoencephalopathy after autologous bone marrow transplantation and alpha-interferon immunotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Encephalitis; Etoposide; Female; Humans; Immunoglobulins, Intravenous; Immunosuppression Therapy; Injections, Spinal; Interferon-alpha; Interleukin-12; Leukoencephalopathy, Progressive Multifocal; Lymphoma, Non-Hodgkin; Magnetic Resonance Imaging; Melphalan; Memory Disorders; Middle Aged; Podophyllotoxin; Transplantation Conditioning; Transplantation, Autologous; Vincristine | 1999 |
Induction therapy of adult acute lymphocytic leukemia without the use of vincristine or prednisone.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Controlled Clinical Trials as Topic; Cyclophosphamide; Cytarabine; Dactinomycin; Doxorubicin; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Male; Mercaptopurine; Methotrexate; Middle Aged; Mitoxantrone; Multicenter Studies as Topic; Neutropenia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Prospective Studies; Randomized Controlled Trials as Topic; Recombinant Proteins; Remission Induction; Survival Analysis; Treatment Outcome; Vincristine | 2001 |
[Role of high-dose chemotherapy with hemopoietic stem-cell support in the treatment of adult patients with high-grade glioma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Blood-Brain Barrier; Brain Neoplasms; Carmustine; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Etoposide; Glioma; Hematopoietic Stem Cell Transplantation; Humans; Neoplasm Recurrence, Local; Transplantation, Autologous | 2001 |
[Primary cardiac lymphoma: cytological diagnosis and treatment with response to polychemotherapy and hematopoietic precursor autotransplant. Presentation of a case a review of the literature].
Topics: Antineoplastic Combined Chemotherapy Protocols; Atrial Flutter; Carmustine; Cyclophosphamide; Cytarabine; Doxorubicin; Echocardiography, Transesophageal; Etoposide; Heart Failure; Heart Neoplasms; Heart Septum; Hematopoietic Stem Cell Transplantation; Humans; Hydrocortisone; Immunocompetence; Injections, Spinal; Lymphoma, Large B-Cell, Diffuse; Magnetic Resonance Imaging; Male; Melphalan; Methotrexate; Middle Aged; Pleural Effusion; Prednisone; Remission Induction; Tomography, X-Ray Computed; Transplantation Conditioning; Transplantation, Autologous; Vincristine | 2002 |
Autologous stem cell transplantation in patients with mantle cell lymphoma.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Etoposide; Female; Finland; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Life Tables; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Prednisone; Prognosis; Recurrence; Remission Induction; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vincristine | 2002 |
Non-hodgkins lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Humans; Idarubicin; Ifosfamide; Leucovorin; Lymphoma, Non-Hodgkin; Methotrexate; Prednisolone; Prednisone; Vincristine | 2003 |
Long-term follow up of high-dose chemotherapy with autologous stem cell rescue in adults with Ewing tumor.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Busulfan; Carmustine; Cisplatin; Cohort Studies; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Life Tables; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Prognosis; Retrospective Studies; Risk Factors; Sarcoma, Ewing; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vincristine | 2005 |
Autologous stem cell transplantation for chronic lymphocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Dexamethasone; Etoposide; Evidence-Based Medicine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Melphalan; Neoplasm, Residual; Neoplasms, Second Primary; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Whole-Body Irradiation | 2007 |
[Interdigitating dendritic cell sarcoma of lower extremities resistant to high dose chemotherapy BEAM with peripheral blood stem cell transplantation].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carmustine; Cytarabine; Dendritic Cell Sarcoma, Interdigitating; Drug Resistance, Neoplasm; Etoposide; Humans; Leg; Male; Melphalan; Peripheral Blood Stem Cell Transplantation; Positron-Emission Tomography; Soft Tissue Neoplasms; Tibia; Tomography, X-Ray Computed | 2009 |
Syngeneic transplant in mantle cell lymphoma: a rare event and review of the literature.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Humans; Lymphoma, Mantle-Cell; Male; Prednisolone; Remission Induction; Stem Cell Transplantation; Vincristine | 2009 |
Standard therapy of advanced Hodgkin lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dacarbazine; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Mechlorethamine; Melphalan; Methylprednisolone; Positron-Emission Tomography; Prednisone; Procarbazine; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Salvage Therapy; Transplantation, Autologous; Treatment Outcome; Vinblastine; Vincristine; Vindesine | 2009 |
Intensified therapy followed by autologous stem-cell transplantation (ASCT) versus conventional therapy as first-line treatment of follicular lymphoma: a meta-analysis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Interferon alpha-2; Interferon-alpha; Lymphoma, Follicular; Male; Melphalan; Middle Aged; Neoplasms, Second Primary; Prednisone; Recombinant Proteins; Remission Induction; Survival Analysis; Teniposide; Transplantation, Autologous; Treatment Outcome; Vincristine; Whole-Body Irradiation | 2013 |
High-dose etoposide in allogeneic stem cell transplantation.
Topics: Adenine Nucleotides; Anthracyclines; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Busulfan; Carboplatin; Carmustine; Clinical Trials as Topic; Clofarabine; Cyclophosphamide; Dose Fractionation, Radiation; Drug Administration Schedule; Etoposide; Humans; Ifosfamide; Leukemia; Leukemia, Myeloid, Acute; Lomustine; Mucositis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Radiotherapy, Adjuvant; Severity of Illness Index; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Whole-Body Irradiation | 2012 |
Outcomes after (90) Yttrium-ibritumomab tiuxetan-BEAM in diffuse large B-cell lymphoma: a meta-analysis.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemoradiotherapy; Cytarabine; Disease-Free Survival; Etoposide; Humans; Lymphoma, Large B-Cell, Diffuse; Melphalan; Radiopharmaceuticals; Treatment Outcome | 2014 |
[Treatment strategy of Hodgkin lymphoma].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brentuximab Vedotin; Carmustine; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dacarbazine; Dexamethasone; Doxorubicin; Etoposide; Hodgkin Disease; Humans; Immunoconjugates; Mechlorethamine; Melphalan; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Positron-Emission Tomography; Prednisone; Procarbazine; Prognosis; Radiotherapy, Adjuvant; Rituximab; Vinblastine; Vincristine | 2014 |
[Sinusoidal obstruction syndrome after BeAM conditioning regiment for autologous stem cell transplantation: Imputability of bendamustine? Report of two cases and literature review].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Carmustine; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Melphalan; Middle Aged; Transplantation Conditioning; Transplantation, Autologous | 2018 |
Autologous Stem Cell Transplantation in the Management of Relapsed Non-Hodgkin Lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials, Phase III as Topic; Cyclophosphamide; Cytarabine; Etoposide; Humans; Immunotherapy, Adoptive; Lymphoma, Large B-Cell, Diffuse; Randomized Controlled Trials as Topic; Recurrence; Salvage Therapy; Stem Cell Transplantation; Transplantation, Autologous | 2021 |
184 trial(s) available for etoposide and carmustine
| Article | Year |
|---|---|
Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) subsequent to chemotherapy improves collection of blood stem cells for autografting in patients not eligible for bone marrow harvest.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Dexamethasone; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Leukapheresis; Male; Melphalan; Middle Aged; Recombinant Proteins; Recurrence; Transplantation, Autologous | 1992 |
A prospective randomized study of two alternating, non cross-resistant chemotherapies for advanced Hodgkin's disease.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Dacarbazine; Doxorubicin; Etoposide; Female; Hodgkin Disease; Humans; Male; Mechlorethamine; Mitoguazone; Prednisone; Procarbazine; Prospective Studies; Survival Rate; Vinblastine; Vincristine | 1992 |
High-dose carmustine, etoposide, and cisplatin and autologous bone marrow transplantation for relapsed and refractory lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Carmustine; Cisplatin; Combined Modality Therapy; Etoposide; Humans; Lymphoma; Middle Aged; Recurrence; Survival Analysis; Transplantation, Autologous; Treatment Outcome | 1992 |
Carboplatin combined with carmustine and etoposide in the treatment of glioblastoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carmustine; Etoposide; Glioma; Humans; Middle Aged; Survival Analysis | 1992 |
BEAM autografting in lymphoma--experience at one centre.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Female; Humans; Lymphoma; Male; Melphalan; Middle Aged; Survival Rate; Transplantation, Autologous | 1992 |
GM-CSF instead of autologous bone-marrow transplantation after the BEAM regimen.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cytarabine; Drug Evaluation; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoiesis; Hematopoietic System; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Transplantation, Autologous | 1991 |
[Autotransplantation in acute nonlymphoid leukemia].
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Busulfan; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Humans; Leukemia, Myeloid, Acute; Remission Induction; Transplantation, Autologous | 1991 |
Double intensive consolidation chemotherapy in adult acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Prognosis; Survival Analysis | 1991 |
Cisplatin and etoposide combination therapy for primary glial tumors: preliminary results.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Cisplatin; Combined Modality Therapy; Etoposide; Follow-Up Studies; Glioblastoma; Glioma; Humans; Middle Aged | 1991 |
BAVC regimen in CR AML patients.
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Child; Child, Preschool; Cytarabine; Etoposide; Follow-Up Studies; Graft Survival; Humans; Infant; Italy; Leukemia, Myeloid, Acute; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Survival Rate; Transplantation, Autologous | 1991 |
The Parma international randomized study in relapsed non Hodgkin lymphoma: 1st interim analysis of 128 patients (as 15 January 1991: 153 patients).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Etoposide; Humans; Lymphoma, Non-Hodgkin; Middle Aged; Remission Induction; Transplantation, Autologous | 1991 |
Single or double consolidation treatment according to remission status after initial therapy in metastatic neuroblastoma: first results of LMCE 3 study in 40 patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Carmustine; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; France; Humans; Infant; Life Tables; Male; Neuroblastoma; Remission Induction; Reoperation; Survival Analysis; Transplantation, Autologous; Vincristine | 1991 |
A single center experience with bone marrow transplantation for high risk neuroblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Carmustine; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; France; Humans; Infant; Male; Neuroblastoma; Organoplatinum Compounds; Remission Induction; Reoperation; Survival Rate; Teniposide; Vincristine | 1991 |
alpha-Interferon for remission maintenance: preliminary report on the Southwest Oncology Group Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Humans; Interferon-alpha; Melphalan; Multiple Myeloma; Prednisone; Remission Induction; Vincristine | 1991 |
High-dose multi-agent chemotherapy followed by bone marrow 'rescue' for malignant astrocytomas of childhood and adolescence.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; Child; Combined Modality Therapy; Etoposide; Female; Glioblastoma; Humans; Male; Spinal Cord Neoplasms; Thiotepa; Transplantation, Autologous | 1990 |
PARMA international protocol: pilot study on 50 patients and preliminary analysis of the ongoing randomized study (62 patients).
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Etoposide; Female; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Pilot Projects; Prospective Studies; Random Allocation; Remission Induction; Survival Rate; Transplantation, Autologous | 1991 |
Double intensive consolidation chemotherapy in adult acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Amsacrine; Analysis of Variance; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Pilot Projects; Proportional Hazards Models; Remission Induction | 1991 |
Comparison of etoposide and cisplatin with bis-chloro-ethylnitrosourea, thiotepa, vincristine, and cyclophosphamide for salvage treatment in small cell lung cancer. A Southwest Oncology Group Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Carmustine; Cisplatin; Cyclophosphamide; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Randomized Controlled Trials as Topic; Thiotepa; Vincristine | 1990 |
Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard- and high-risk acute lymphocytic leukemia.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Female; Humans; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Risk Factors; Vincristine | 1990 |
Combination chemotherapy including VP-16 for poor prognosis germ cell neoplasms.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Doxorubicin; Etoposide; Evaluation Studies as Topic; Follow-Up Studies; Humans; Male; Nausea; Neoplasms, Germ Cell and Embryonal; Prednisone; Prognosis; Prospective Studies; Teratoma; Testicular Neoplasms; Vinblastine; Vindesine; Vomiting | 1988 |
GM-CSF accelerates neutrophil recovery after autologous bone marrow transplantation for Hodgkin's disease.
Topics: Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Colony-Stimulating Factors; Combined Modality Therapy; Cytarabine; Drug Evaluation; Etoposide; Granulocytes; Hodgkin Disease; Humans; Leukocyte Count; Macrophages; Melphalan; Neutropenia; Neutrophils; Postoperative Complications; Recombinant Proteins; Transplantation, Autologous | 1989 |
Overview of the clinical relevance of autologous bone marrow transplantation.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Drug Evaluation; Drug Resistance; Etoposide; Hodgkin Disease; Humans; Leukemia; Leukemia, Lymphoid; Lymphoma; Melphalan; Neoplasm Recurrence, Local; Neoplasms; Thioguanine; Transplantation, Autologous | 1986 |
Current results of a multicenter trial in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Administration Schedule; Etoposide; Humans; Melphalan; Multiple Myeloma; Neoplasm Staging; Prednisone; Random Allocation; Vincristine | 1986 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Mesna; Middle Aged; Prospective Studies; Recurrence; Salvage Therapy; Survival Analysis; Transplantation, Homologous | 1995 |
Randomized study of recombinant human granulocyte colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignancies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Leukocyte Count; Lymphoma; Male; Middle Aged; Neutropenia; Neutrophils; Prospective Studies; Recombinant Proteins; Survival Rate; Transplantation, Autologous | 1994 |
High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cell Movement; Cohort Studies; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Hodgkin Disease; Humans; Leukocyte Count; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multivariate Analysis; Platelet Count; Prognosis; Transplantation, Autologous; Whole-Body Irradiation | 1994 |
Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: a study of 464 patients. Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplantation; Carmustine; Confidence Intervals; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Middle Aged; Prednisolone; Prospective Studies; Remission Induction; Risk Factors; Transplantation, Autologous; Vindesine | 1994 |
Granulocyte colony-stimulating factor following peripheral-blood progenitor-cell transplant in non-Hodgkin's lymphoma.
Topics: Adult; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cohort Studies; Combined Modality Therapy; Cytarabine; Etoposide; Female; Flow Cytometry; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Leukocyte Count; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Platelet Count | 1995 |
Transplantation of enriched and purged peripheral blood progenitor cells from a single apheresis product in patients with non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Component Removal; Bone Marrow Purging; Carmustine; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 18; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplastic Stem Cells; Polymerase Chain Reaction; Remission Induction; Salvage Therapy; Translocation, Genetic; Treatment Outcome; Whole-Body Irradiation | 1995 |
Economic analysis of prophylactic G-CSF after mini-BEAM salvage chemotherapy for Hodgkin's and non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Fever; Granulocyte Colony-Stimulating Factor; Hodgkin Disease; Humans; Length of Stay; Lymphoma, Non-Hodgkin; Melphalan; Neutropenia; Retrospective Studies; Salvage Therapy | 1995 |
High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16-213) with or without cisplatin (CBV +/- P) and autologous transplantation for patients with Hodgkin's disease who fail to enter a complete remission after combination chemotherapy.
Topics: Actuarial Analysis; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Diseases; Bone Marrow Transplantation; Carmustine; Cisplatin; Cyclophosphamide; Dacarbazine; Disease-Free Survival; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Leucovorin; Male; Mechlorethamine; Methotrexate; Prednisolone; Prednisone; Procarbazine; Remission Induction; Salvage Therapy; Survival Analysis; Treatment Outcome; Vinblastine; Vincristine | 1995 |
Short-term weekly chemotherapy followed by high-dose therapy with autologous bone marrow transplantation for lymphoblastic and Burkitt's lymphomas in adult patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplantation; Burkitt Lymphoma; Carmustine; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Leucovorin; Male; Methotrexate; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Remission Induction; Survival Rate; Transplantation, Autologous; Vincristine | 1995 |
Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: application to LNH-87 protocol. The GELA. (Groupe d'Etude des Lymphomes de l'Adulte).
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; France; Humans; Lymphoma, Non-Hodgkin; Methotrexate; Methylprednisolone; Middle Aged; Mitoxantrone; Prednisolone; Prognosis; Remission Induction; Survival Rate; Transplantation, Autologous; Vindesine | 1993 |
Phase I/II study incorporating intravenous hydroxyurea into high-dose chemotherapy for patients with primary refractory or relapsed and refractory intermediate-grade and high-grade malignant lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mouth Mucosa; Recurrence; Remission Induction; Risk Factors; Stomatitis; Survival Analysis | 1995 |
BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cytarabine; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Multivariate Analysis; Prognosis; Recurrence; Remission Induction; Survival Rate; Transplantation, Autologous | 1995 |
High-dose cyclophosphamide, carmustine, and etoposide followed by allogeneic bone marrow transplantation in patients with lymphoid malignancies who had received prior dose-limiting radiation therapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Radiotherapy Dosage; Transplantation, Homologous | 1995 |
Phase I trial of dacarbazine with cyclophosphamide, carmustine, etoposide, and autologous stem-cell transplantation in patients with lymphoma and multiple myeloma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Etoposide; Feasibility Studies; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Hypocalcemia; Hypotension; Lymphoma; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Remission Induction; Transplantation, Autologous | 1994 |
High-dose consolidation with local radiation and bone marrow rescue in patients with advanced neuroblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Carmustine; Child; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Etoposide; Follow-Up Studies; Humans; Infant; Melphalan; Neoplasm Recurrence, Local; Neuroblastoma; Radiotherapy, High-Energy; Remission Induction; Survival Rate | 1994 |
Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Dose-Response Relationship, Drug; Etoposide; Female; Follow-Up Studies; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Survival Rate | 1993 |
[High-dose busulfan, VP-16 and ACNU therapy with stem cell transplantation for the treatment of children with acute leukemia].
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Carmustine; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Male; Nimustine | 1993 |
Intensive therapy with cyclophosphamide, carmustine, etoposide +/- cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Hodgkin Disease; Humans; Male; Middle Aged; Multivariate Analysis; Risk Factors; Survival Analysis | 1994 |
Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin's Disease Study Group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dexamethasone; Etoposide; Female; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Prospective Studies; Survival Analysis; Treatment Outcome | 1994 |
Comparison of the Cox model and the regression tree procedure in analysing a randomized clinical trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bias; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Etoposide; Female; Glioma; Humans; Male; Middle Aged; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic; Regression Analysis; Survival Analysis; Treatment Outcome | 1993 |
Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in patients with refractory lymphoma undergoing autologous bone marrow transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone Marrow Transplantation; Carmustine; Cyclophosphamide; Etoposide; Female; Humans; Lymphoma; Male; Middle Aged; Mitoxantrone | 1994 |
Role of granulocyte-macrophage colony stimulating factor (GM-CSF) after autologous bone marrow transplantation for Hodgkin's disease.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Double-Blind Method; Etoposide; Granulocyte-Macrophage Colony-Stimulating Factor; Hodgkin Disease; Humans; Middle Aged | 1993 |
The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Female; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Prognosis; Risk; Survival Rate; Transplantation, Autologous | 1993 |
Cisplatin-CBV with autologous bone marrow transplantation for relapsed Hodgkin's disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Hearing Loss; Hodgkin Disease; Humans; Kidney Diseases; Male; Middle Aged; Prognosis; Remission Induction; Salvage Therapy; Survival Rate; Transplantation, Autologous; Treatment Outcome | 1993 |
Post-5-fluorouracil human marrow: stem cell characteristics and renewal properties after autologous marrow transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Carmustine; Cells, Cultured; Colony-Forming Units Assay; Colony-Stimulating Factors; Cyclophosphamide; Etoposide; Fluorouracil; Growth Substances; Hematopoietic Stem Cells; Hodgkin Disease; Humans; Interleukins; Leukocyte Count; Neoplasms; Platelet Count; Transplantation, Autologous | 1993 |
Dose intensification of etoposide in the BEAM ABMT protocol for malignant lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Dose-Response Relationship, Drug; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Lymphoma; Male; Melphalan; Middle Aged | 1995 |
High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized italian multicenter s
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplantation; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Female; Fluorouracil; Humans; Leucovorin; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Prednisone; Prospective Studies; Salvage Therapy; Vincristine | 1996 |
High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Bone Marrow Diseases; Carmustine; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukapheresis; Life Tables; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Polymerase Chain Reaction; Recombinant Proteins; Remission Induction; Salvage Therapy; Survival Analysis; Transplantation, Autologous; Treatment Outcome; Whole-Body Irradiation | 1996 |
Comparison of four cytokine regimens for mobilization of peripheral blood stem cells: IL-3 alone and combined with GM-CSF or G-CSF.
Topics: Adult; Bone Marrow; Breast Neoplasms; Busulfan; Carboplatin; Carmustine; Cyclophosphamide; Drug Administration Schedule; Drug Synergism; Etoposide; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Interleukin-3; Leukapheresis; Leukemia; Leukocyte Count; Lymphoma; Male; Middle Aged; Neutrophils; Prospective Studies; Thiotepa; Whole-Body Irradiation | 1996 |
Phase II study of intensive CEV (carboplatin, epirubicin and VP-16) plus G-CSF (granulocyte-colony stimulating factor) in extensive small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Carmustine; Cyclophosphamide; Epirubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged | 1995 |
Peripheral blood progenitor cell transplantation: a single centre experience comparing two mobilisation regimens in 67 patients.
Topics: Adolescent; Adult; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carmustine; Cell Movement; Colony-Forming Units Assay; Cyclophosphamide; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Kidney Diseases; Leukapheresis; Leukocyte Count; Male; Melphalan; Middle Aged; Neoplasms; Podophyllotoxin; Retrospective Studies; Thiotepa; Transplantation Conditioning | 1996 |
High-dose chemotherapy and autologous peripheral blood progenitor cell transplant for the treatment of Hodgkin's disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Therapy; Cryopreservation; Cyclophosphamide; Cytarabine; Etoposide; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Hodgkin Disease; Humans; Leukapheresis; Male; Middle Aged; Recombinant Proteins; Transplantation, Autologous | 1996 |
Factors for rapid and sustained hematopoietic reconstitution by circulating progenitor-cell transplantation in non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Prognosis | 1996 |
High-dose chemotherapy followed by autologous hematopoietic rescue for Hodgkin's disease patients following first relapse after chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Remission Induction; Survival Rate | 1996 |
Correlation of in vitro drug sensitivity testing results with response to chemotherapy and survival: comparison of non-small cell lung cancer and small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Evaluation Studies as Topic; Humans; Lomustine; Lung Neoplasms; Mechlorethamine; Methotrexate; Palliative Care; Predictive Value of Tests; Prospective Studies; Specimen Handling; Survival Analysis; Treatment Outcome; Tumor Cells, Cultured; Vincristine | 1996 |
Contemporary chemotherapy issues for children with brainstem gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Brain Stem; Carboplatin; Carmustine; Dose-Response Relationship, Drug; Etoposide; Glioma; Humans; Neoplasm Recurrence, Local; Thiotepa; Vincristine | 1996 |
BAVC regimen and autograft for acute myelogenous leukemia in second complete remission.
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Etoposide; Female; Follow-Up Studies; Humans; Infant; Leukemia, Myeloid, Acute; Male; Middle Aged; Time Factors; Transplantation Conditioning; Transplantation, Autologous | 1996 |
Autologous bone marrow transplantation for patients with acute myeloblastic leukemia in relapse after autologous blood stem cell transplantation.
Topics: Acute Disease; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Life Tables; Male; Middle Aged; Recurrence; Risk; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 1996 |
Peripheral blood progenitor cell mobilization with Dexa-Beam/G-CSF, ether lipid purging, and autologous transplantation after high-dose CBV treatment: a safe and effective regimen in patients with poor risk malignant lymphomas.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Carmustine; Cell Movement; Cyclophosphamide; Cytarabine; Dexamethasone; Dose-Response Relationship, Drug; Etoposide; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Leukapheresis; Lymphoma; Melphalan; Middle Aged; Phospholipid Ethers; Risk Factors; Transplantation Conditioning | 1996 |
Recombinant methionyl human stem cell factor and filgrastim for peripheral blood progenitor cell mobilization and transplantation in non-Hodgkin's lymphoma patients--results of a phase I/II trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Colony-Forming Units Assay; Cyclophosphamide; Drug Therapy, Combination; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoiesis; Hematopoietic Stem Cells; Humans; Leukapheresis; Leukocyte Count; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recombinant Proteins; Stem Cell Factor | 1997 |
Randomized trial showing equivalent efficacy of filgrastim 5 micrograms/kg/d and 10 micrograms/kg/d following high-dose chemotherapy and autologous bone marrow transplantation in high-risk lymphomas.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Mesna; Middle Aged; Neutropenia; Patient Selection; Recombinant Proteins; Thiotepa | 1997 |
Sequential high-dose therapy and autologous stem cell transplantation for treatment of mantle cell lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Dexamethasone; Dose-Response Relationship, Drug; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunophenotyping; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Staging; Prospective Studies; Transplantation, Autologous | 1997 |
High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: a prognostic model for treatment outcomes.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Multivariate Analysis; Prognosis; Risk Factors; Survival Rate; Treatment Outcome | 1997 |
Transplantation in patients with multiple myeloma: a multicenter comparative analysis of peripheral blood stem cell and allogeneic transplant.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Busulfan; Carmustine; Cause of Death; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Survival Rate; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Whole-Body Irradiation | 1997 |
Progressive disease after ABMT for Hodgkin's disease.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Retrospective Studies; Transplantation Conditioning; Treatment Outcome | 1997 |
Efficient peripheral blood stem cell mobilization with low-dose G-CSF (50 microg/m2) after salvage chemotherapy for lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukapheresis; Leukocyte Count; Lymphoma; Male; Middle Aged; Recombinant Proteins; Salvage Therapy | 1997 |
Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimens--a Southwest Oncology Group trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cause of Death; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Recurrence; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 1998 |
High-dose chemotherapy with BUCY or BEAC and unpurged peripheral blood stem cell infusion in patients with low-grade non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Survival Rate; Transplantation, Autologous | 1998 |
High dose chemotherapy with autologous bone marrow rescue for children with diffuse pontine brain stem tumors. Children's Cancer Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Brain Neoplasms; Brain Stem; Carboplatin; Carmustine; Child; Child, Preschool; Cohort Studies; Combined Modality Therapy; Etoposide; Female; Humans; Male; Pons; Survival Rate; Thiotepa | 1998 |
Long-term results of autologous marrow transplantation for relapsed or refractory male or female germ cell tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Female; Germinoma; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Middle Aged; Ovarian Neoplasms; Recurrence; Retrospective Studies; Testicular Neoplasms; Transplantation, Autologous | 1998 |
Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dex-BEAM).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Salvage Therapy; Survival Rate; Treatment Outcome | 1998 |
Treatment of patients with malignant lymphoma with Mini-BEAM reduces the yield of CD34+ peripheral blood stem cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Melphalan | 1998 |
Early stem cell transplantation for chronic lymphocytic leukaemia: a chance for cure?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chlorambucil; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Female; Fluorouracil; Follow-Up Studies; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Hydrocortisone; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Melphalan; Methotrexate; Methylprednisolone; Middle Aged; Mitomycins; Prednisone; Prospective Studies; Treatment Outcome; Vincristine | 1998 |
Myeloablative chemotherapy with autologous bone marrow rescue in young children with recurrent malignant brain tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Brain Neoplasms; Carboplatin; Carmustine; Child; Child, Preschool; Combined Modality Therapy; Etoposide; Female; Humans; Infant; Male; Myeloablative Agonists; Neoplasm Recurrence, Local; Survival Analysis; Thiotepa; Transplantation, Autologous; Treatment Outcome | 1998 |
Correlation between granulocyte/macrophage-colony-forming units and CD34+ cells in apheresis products from patients treated with different chemotherapy regimens and granulocyte-colony-stimulating factor to mobilize peripheral blood progenitor cells.
Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Component Removal; Carmustine; Cell Separation; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Epirubicin; Etoposide; Female; Flow Cytometry; Granulocyte Colony-Stimulating Factor; Granulocytes; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; Ifosfamide; Macrophages; Male; Melphalan; Neoplasms; Prednisolone; Vincristine | 1998 |
The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cisplatin; Cohort Studies; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Etoposide; Female; Humans; Italy; Life Tables; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prognosis; Recurrence; Salvage Therapy; Severity of Illness Index; Survival Analysis; Treatment Outcome | 1998 |
Phase I and pharmacokinetic study of preirradiation chemotherapy with BCNU, cisplatin, etoposide, and accelerated radiation therapy in patients with high-grade glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Brain Neoplasms; Carmustine; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Female; Glioma; Humans; Male; Middle Aged; Survival Analysis | 1998 |
Dexa-BEAM is not effective in patients with relapsed or resistant aggressive high-grade non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dexamethasone; Drug Resistance, Multiple; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukocyte Count; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Staging; Recurrence; Survival Analysis; Time Factors | 1999 |
Interstitial chemotherapy plus systemic chemotherapy for glioblastoma patients: improved survival in sequential studies.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carmustine; Catheters, Indwelling; Cisplatin; Combined Modality Therapy; Etoposide; Glioblastoma; Humans; Postoperative Care; Survival Analysis | 1999 |
Regimen-related toxicity of myeloablative chemotherapy with BCNU, thiotepa, and etoposide followed by autologous stem cell rescue for children with newly diagnosed glioblastoma multiforme: report from the Children's Cancer Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Child; Child, Preschool; Combined Modality Therapy; Etoposide; Female; Glioblastoma; Hematopoietic Stem Cell Transplantation; Humans; Male; Pilot Projects; Survival Analysis; Thiotepa; Transplantation, Autologous | 1999 |
Salvage chemotherapy with IAPVP-16 for advanced refractory or relapsed follicular lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Recurrence; Salvage Therapy; Survival Rate; Treatment Outcome | 1999 |
Protracted results of dose-intensive therapy using cyclophosphamide, carmustine, and continuous infusion etoposide with autologous stem cell support in patients with relapse or refractory Hodgkin's disease: a phase II study from the North American Marrow
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Etoposide; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Infusions, Intravenous; Middle Aged; North America; Recurrence; Transplantation, Autologous; Treatment Outcome | 1999 |
Treatment of newly diagnosed glioblastoma multiforme with carmustine, cisplatin and etoposide followed by radiotherapy. A phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cisplatin; Combined Modality Therapy; Disease Progression; Etoposide; Female; Glioblastoma; Humans; Male; Middle Aged; Radiotherapy; Survival Analysis | 1999 |
A phase I study of high-dose BCNU, etoposide and escalating-dose thiotepa (BTE) with hematopoietic progenitor cell support in adults with recurrent and high-risk brain tumors.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined Modality Therapy; Dose-Response Relationship, Drug; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Risk Factors; Survival Analysis; Thiotepa; Treatment Outcome | 1999 |
Efficacy of autologous stem cell transplantation in mantle cell lymphoma: a 3-year follow-up study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Neoplasms, Second Primary; Recurrence; Survival Rate; Transplantation, Autologous; Treatment Outcome; Whole-Body Irradiation | 2000 |
Intensified preparative regimens and autologous transplantation in refractory or relapsed intermediate grade non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Salvage Therapy; Survival Rate; Transplantation, Autologous; Treatment Outcome; Whole-Body Irradiation | 2000 |
Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Infant; Infections; Lung Diseases; Male; Melphalan; Middle Aged; Retrospective Studies; Transplantation, Autologous | 2000 |
High-dose immunosuppressive therapy with PBPC support in the treatment of poor risk multiple sclerosis.
Topics: Adolescent; Adult; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Carmustine; CD4-CD8 Ratio; Cytarabine; Etoposide; Female; Fever; Follow-Up Studies; Graft Survival; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infections; Leukapheresis; Lymphocyte Subsets; Magnetic Resonance Imaging; Male; Melphalan; Middle Aged; Multiple Sclerosis; Neutropenia; Prognosis; Severity of Illness Index | 2000 |
Dexamethasone, carmustine, etoposide, cytarabine, and melphalan (dexa-BEAM) followed by high-dose chemotherapy and stem cell rescue--a highly effective regimen for patients with refractory or relapsed indolent lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dexamethasone; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Melphalan; Middle Aged; Remission Induction; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous | 2000 |
Dexa-BEAM: an effective regimen for cytoreduction prior to high-dose chemotherapy with autologous stem cell support for patients with relapsed/refractory mantle-cell lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dexamethasone; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Salvage Therapy; Survival Analysis; Transplantation, Autologous | 2000 |
Prospective randomized clinical trial comparing high-dose ifosfamide + GM-CSF vs high-dose cyclophosphamide + GM-CSF for blood progenitor cell mobilization.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cryopreservation; Cyclophosphamide; Cytarabine; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Hodgkin Disease; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Recombinant Proteins; Regression Analysis; Survival Rate; Transplantation, Autologous | 2000 |
Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study.
Topics: Adult; Age Factors; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Methotrexate; Methylprednisolone; Prognosis; Prospective Studies; Remission Induction; Risk Factors; Statistics, Nonparametric; Vindesine | 2000 |
Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cyclosporine; Cytarabine; Etoposide; Female; Graft vs Tumor Effect; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunosuppressive Agents; Lymphoma, Non-Hodgkin; Male; Melphalan; Methotrexate; Middle Aged; Pilot Projects; Risk Factors; Survival Rate; Transplantation Chimera; Vidarabine | 2000 |
Antiemetic efficacy of three serotonin antagonists during high-dose chemotherapy and autologous stem cell transplantation in malignant lymphoma.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Female; Granisetron; Hematopoietic Stem Cell Transplantation; Humans; Indoles; Lymphoma; Male; Melphalan; Nausea; Ondansetron; Serotonin Antagonists; Transplantation, Autologous; Tropisetron; Vomiting | 2000 |
A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Cisplatin; Cyclophosphamide; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Ifosfamide; Lymphatic Irradiation; Male; Middle Aged; Models, Biological; Prognosis; Recurrence; Salvage Therapy; Survival Rate; Treatment Outcome | 2001 |
A prospective study of intensive induction therapy with high-dose consolidation in patients with aggressive non-Hodgkin's lymphoma and two or three adverse prognostic factors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Feasibility Studies; Female; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Prognosis; Prospective Studies; Treatment Outcome | 2000 |
Immunoablative therapy with autologous stem cell transplantation in the treatment of poor risk multiple sclerosis.
Topics: Adrenal Cortex Hormones; Adult; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Drug Therapy, Combination; Etoposide; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lymphocyte Depletion; Magnetic Resonance Imaging; Melphalan; Middle Aged; Multiple Sclerosis; Patient Selection; T-Lymphocytes | 2001 |
Dose escalation of cytotoxic drugs using haematopoietic growth factors: a randomized trial to determine the magnitude of increase provided by GM-CSF.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dexamethasone; Dose-Response Relationship, Drug; Double-Blind Method; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Hodgkin Disease; Humans; Leukocyte Count; Male; Maximum Tolerated Dose; Melphalan; Middle Aged; Neoplasm Staging; Treatment Outcome | 2001 |
Daunorubicin continuous infusion induces more toxicity than bolus infusion in acute lymphoblastic leukemia induction regimen: a randomized study.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Etoposide; Female; Gram-Negative Bacterial Infections; Humans; Immunocompromised Host; Infusions, Intravenous; Injections, Intravenous; Life Tables; Male; Methotrexate; Middle Aged; Neutropenia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Remission Induction; Survival Analysis; Thrombocytopenia; Treatment Outcome; Vincristine | 2001 |
Autologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MS.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Female; Gadolinium; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Image Enhancement; Magnetic Resonance Imaging; Male; Melphalan; Middle Aged; Multiple Sclerosis, Chronic Progressive; Preoperative Care; Transplantation, Autologous; Treatment Outcome | 2001 |
Idiotype vaccination following ABMT can stimulate specific anti-idiotype immune responses in patients with B-cell lymphoma.
Topics: Acetylmuramyl-Alanyl-Isoglutamine; Adjuvants, Immunologic; Antibodies, Anti-Idiotypic; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Dendritic Cells; Disease-Free Survival; Drug Resistance, Neoplasm; Etoposide; Feasibility Studies; Female; Follow-Up Studies; Hemocyanins; Humans; Ifosfamide; Immunity, Cellular; Immunoglobulin Idiotypes; Lymphocyte Activation; Lymphoma, B-Cell; Male; Polysorbates; Receptors, Antigen, B-Cell; Safety; Squalene; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vaccination; Whole-Body Irradiation | 2001 |
Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin's disease.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Cyclophosphamide; Dose-Response Relationship, Drug; Etoposide; Female; Hodgkin Disease; Humans; Lomustine; Lung Diseases, Interstitial; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Middle Aged; Salvage Therapy; Stem Cell Transplantation; Survival Rate; Therapeutic Equivalency; Transplantation, Autologous | 2001 |
Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Ifosfamide; Male; Melphalan; Middle Aged; Mitoguazone; Recurrence; Salvage Therapy; Transplantation, Autologous; Vinblastine; Vinorelbine | 2002 |
The impact of autologous stem cell transplantation on the prognosis of mantle cell lymphoma: a joint analysis of two prospective studies with 46 patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carmustine; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunophenotyping; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Neoplasm Staging; Prednisolone; Prednisone; Prognosis; Survival Rate; Time Factors; Transplantation, Autologous; Treatment Outcome; Vincristine; Whole-Body Irradiation | 2000 |
Autologous transplantation for aggressive non-Hodgkin's lymphoma: results of a randomized trial evaluating graft source and minimal residual disease.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm, Residual; Proportional Hazards Models; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2002 |
Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cause of Death; Cytarabine; Dexamethasone; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Recurrence; Salvage Therapy | 2002 |
Allogeneic stem-cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH (+/- fludarabine) conditioning combined with post-transplant donor-lymphocyte infusion.
Topics: Adolescent; Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Blood Donors; Carmustine; Cytarabine; Disease Progression; Etoposide; Female; Graft Survival; Graft vs Host Disease; Humans; Immunosuppression Therapy; Lymphocyte Transfusion; Lymphoproliferative Disorders; Male; Melphalan; Middle Aged; Monitoring, Physiologic; Secondary Prevention; Stem Cell Transplantation; Survival Rate; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2001 |
A randomized trial of chemotherapy with carmustine, etoposide, cytarabine, and melphalan (BEAM) plus peripheral stem cell transplantation (PBSCT) vs single-agent high-dose chemotherapy followed by BEAM plus PBSCT in patients with relapsed Hodgkin's diseas
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Hodgkin Disease; Humans; Melphalan; Prognosis; Recurrence; Stem Cell Transplantation; Transplantation, Autologous | 2002 |
Randomized study to evaluate the use of high-dose therapy as part of primary treatment for "aggressive" lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemotherapy, Adjuvant; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Germany; Humans; L-Lactate Dehydrogenase; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Prednisolone; Prognosis; Prospective Studies; Radiotherapy, Adjuvant; Risk; Stem Cell Transplantation; Survival Analysis; Transplantation, Autologous; Treatment Outcome; Vincristine | 2002 |
[Effectiveness of high-dose polychemotherapy and autologous hemopoietic cell transplantation in patients with low-grade non-Hodgkin lymphoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Prednisone; Survival Analysis; Transplantation, Autologous; Treatment Outcome; Vincristine | 2002 |
High-dose cyclophosphamide, BCNU, and VP-16 (CBV) conditioning before allogeneic stem cell transplantation for patients with non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Blood Platelets; Carmustine; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infections; Liver Diseases; Lung Diseases; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutrophils; Recurrence; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2003 |
[Effectiveness of dose-intensive polychemotherapy with autologous hemopoietic cell transplantation for high-grade non-Hodgkin lymphoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Prednisone; Survival Analysis; Transplantation, Autologous; Treatment Outcome; Vincristine | 2003 |
Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation.
Topics: Adolescent; Adoptive Transfer; Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Lymphocytosis; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Remission Induction; T-Lymphocytes | 2003 |
BEAC or BEAM for high-dose therapy in patients with non-Hodgkin's lymphoma? A single centre analysis on toxicity and efficacy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Podophyllotoxin; Prognosis; Survival Rate; Transplantation, Autologous | 2003 |
The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: a Southwest Oncology Group phase II trial.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Disease Management; Etoposide; Female; Hodgkin Disease; Humans; Male; Middle Aged; Prognosis; Proportional Hazards Models; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Whole-Body Irradiation | 2003 |
High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease-Free Survival; Etoposide; Female; Humans; Lymphoma, T-Cell, Peripheral; Male; Melphalan; Middle Aged; Neoplasm Staging; Peripheral Blood Stem Cell Transplantation; Prognosis; Retrospective Studies; Risk Factors; Salvage Therapy; Transplantation, Autologous; Treatment Outcome; Whole-Body Irradiation | 2003 |
Autologous peripheral blood stem cell transplantation with BCVAC conditioning in childhood acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infant; Infant, Newborn; Leukemia, Myeloid; Male; Prognosis; Recurrence; Risk Factors; Transplantation Conditioning | 2004 |
Phase I study of involved-field radiotherapy preceding autologous stem cell transplantation for patients with high-risk lymphoma or Hodgkin's disease.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prospective Studies; Radiation Injuries; Radiotherapy Dosage; Radiotherapy, Conformal; Recurrence; Statistics as Topic; Stem Cell Transplantation; Transplantation, Autologous | 2004 |
Results of autologous transplantation in lymphoma are not improved by increasing the dose of etoposide in the BEAM regimen: a single-centre sequential-cohort study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cohort Studies; Cytarabine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma; Male; Melphalan; Middle Aged; Multivariate Analysis; Retrospective Studies; Time Factors; Transplantation Conditioning; Transplantation, Autologous | 2004 |
Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antigens, CD20; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Etoposide; Female; Humans; Iodine Radioisotopes; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Melphalan; Middle Aged; Radioimmunotherapy; Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome | 2005 |
CD8+ T-cell-depleted, matched unrelated donor, allogeneic bone marrow transplantation for advanced AML using busulfan-based preparative regimens.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Carmustine; CD8-Positive T-Lymphocytes; Cyclophosphamide; Etoposide; Female; Graft Survival; Graft vs Host Disease; Histocompatibility; Histocompatibility Testing; Humans; Leukemia, Myeloid, Acute; Lymphocyte Depletion; Male; Middle Aged; Salvage Therapy; Survival Analysis; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2005 |
Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG).
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hodgkin Disease; Humans; Infusions, Intravenous; Injections, Subcutaneous; Male; Melphalan; Methotrexate; Middle Aged; Peripheral Blood Stem Cell Transplantation; Recurrence; Treatment Outcome; Vincristine | 2005 |
High-dose carmustine, etoposide, and cisplatin for autologous stem cell transplantation with or without involved-field radiation for relapsed/refractory lymphoma: an effective regimen with low morbidity and mortality.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Drug Resistance, Neoplasm; Etoposide; Female; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasms, Second Primary; Peripheral Blood Stem Cell Transplantation; Radiotherapy, Adjuvant; Salvage Therapy; Survival Analysis; Transplantation, Autologous | 2005 |
Phase II trial of carmustine, cisplatin, and oral etoposide chemotherapy before radiotherapy for grade 3 astrocytoma (anaplastic astrocytoma): results of North Central Cancer Treatment Group trial 98-72-51.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Female; Humans; Male; Middle Aged; Radiotherapy Dosage; Survival Rate | 2005 |
Phase I study for poor-prognosis lymphoma: augmentation of the "BEAM" regimen with escalating dose melphalan using amifostine cytoprotection and autologous hematopoietic stem cell transplantation--a preliminary report.
Topics: Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Cytoprotection; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Melphalan; Middle Aged; Radiation-Protective Agents; Transplantation, Autologous | 2004 |
The comparative effects of povidone-iodine and normal saline mouthwashes on oral mucositis in patients after high-dose chemotherapy and APBSCT--results of a randomized multicentre study.
Topics: Adult; Aged; Anti-Infective Agents, Local; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Humans; Male; Melphalan; Middle Aged; Mouth Mucosa; Mouthwashes; Peripheral Blood Stem Cell Transplantation; Povidone-Iodine; Sex Factors; Sodium Chloride; Stomatitis; Transplantation, Autologous | 2005 |
Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease-Free Survival; Etoposide; Female; Humans; Infusions, Intravenous; Injections, Subcutaneous; Lymphoma, B-Cell; Male; Melphalan; Middle Aged; Rituximab; Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome | 2005 |
BAVC regimen and autologous bone marrow transplantation for APL patients in second molecular remission: updated results.
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Child; Cytarabine; Etoposide; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Remission Induction; Salvage Therapy; Transplantation, Autologous | 2005 |
High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Therapy; Cytarabine; Dexamethasone; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Feasibility Studies; Female; Hodgkin Disease; Humans; Infusions, Intravenous; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Salvage Therapy; Stem Cell Transplantation; Survival Rate; Transplantation, Autologous; Treatment Outcome | 2005 |
First-line autologous stem cell transplantation in primary CNS lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neoplasms; Combined Modality Therapy; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunocompetence; Lymphoma; Male; Melphalan; Middle Aged; Neurotoxicity Syndromes; Radiotherapy, Adjuvant; Recurrence; Remission Induction; Survival Rate; Transplantation, Autologous | 2005 |
Augmented high-dose regimen of cyclophosphamide, carmustine, and etoposide with autologous hematopoietic stem cell transplantation for relapsed and refractory aggressive non-Hodgkin's lymphoma.
Topics: Adult; Aged; Carmustine; Cyclophosphamide; Drug Therapy, Combination; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Survival Rate; Transplantation, Autologous; Treatment Outcome | 2005 |
Upfront double high-dose chemotherapy with DICEP followed by BEAM and autologous stem cell transplantation for poor-prognosis aggressive non-Hodgkin lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; L-Lactate Dehydrogenase; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Podophyllotoxin; Prednisone; Prognosis; Prospective Studies; Recurrence; Remission Induction; Risk Factors; Stem Cell Transplantation; Survival Rate; Transplantation, Autologous; Vincristine | 2006 |
Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL study.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carmustine; Cisplatin; Combined Modality Therapy; Cytarabine; Dexamethasone; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Hodgkin Disease; Humans; Ifosfamide; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Podophyllotoxin; Remission Induction; Rituximab; Salvage Therapy; Stem Cell Transplantation; Survival Rate; Transplantation, Autologous; Treatment Outcome | 2006 |
Outpatient autologous hematopoietic stem cell transplantation for patients with relapsed follicular lymphoma.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Gastrointestinal Diseases; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Follicular; Male; Melphalan; Middle Aged; Neutropenia; Podophyllotoxin; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous | 2006 |
Efficacy of single-dose pegfilgrastim after chemotherapy for the mobilization of autologous peripheral blood stem cells in patients with malignant lymphoma or multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dexamethasone; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Lymphoma; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Polyethylene Glycols; Recombinant Proteins; Remission Induction; Transplantation, Autologous; Treatment Outcome | 2006 |
High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neoplasms; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; Lymphoma; Male; Methotrexate; Methylprednisolone; Middle Aged; Remission Induction; Stem Cell Transplantation; Transplantation, Autologous | 2006 |
Morbidity and transplant-related mortality of CBV and BEAM preparative regimens for patients with lymphoid malignancies undergoing autologous stem-cell transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid; Male; Melphalan; Middle Aged; Morbidity; Mortality; Podophyllotoxin; Transplantation Conditioning; Transplantation, Autologous | 2006 |
Initial chemotherapy with mitoxantrone, chlorambucil, prednisone impairs the collection of stem cells in patients with indolent lymphomas--results of a randomized comparison by the German Low-Grade Lymphoma Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chlorambucil; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Female; Germany; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Mitoxantrone; Prednisolone; Prednisone; Prospective Studies; Survival Rate; Treatment Outcome; Vincristine | 2007 |
Combination chemotherapy followed by autologous stem cell transplant for enteropathy-associated T cell lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Celiac Disease; Combined Modality Therapy; Cytarabine; Enteral Nutrition; Epirubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Immunosuppressive Agents; Lymphoma, T-Cell, Peripheral; Male; Melphalan; Methotrexate; Middle Aged; Peripheral Blood Stem Cell Transplantation; Podophyllotoxin; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2007 |
Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA AML-13 study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Etoposide; Feasibility Studies; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Infusions, Intravenous; Injections, Subcutaneous; Kaplan-Meier Estimate; Lenograstim; Leukemia, Myeloid; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Recombinant Proteins; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2007 |
High-dose chemotherapy using BEAM without autologous rescue followed by reduced-intensity conditioning allogeneic stem-cell transplantation for refractory or relapsing lymphomas: a comparison of delayed versus immediate transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lymphoma; Male; Melphalan; Remission Induction; Transplantation Conditioning; Transplantation, Homologous | 2007 |
Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Transplantation Conditioning; Transplantation, Autologous; Treatment Failure | 2008 |
Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: a prospective study from the GEL-TAMO Study Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Podophyllotoxin; Prednisone; Prognosis; Prospective Studies; Risk Assessment; Stem Cell Transplantation; Survival Analysis; Transplantation, Autologous; Vincristine | 2008 |
A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Carboplatin; Carmustine; Cytarabine; Double-Blind Method; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Polyethylene Glycols; Recombinant Proteins; Transplantation, Autologous | 2008 |
Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Lymphoma, T-Cell, Peripheral; Male; Melphalan; Middle Aged; Neoplasms, Second Primary; Peripheral Blood Stem Cell Transplantation; Prednisone; Remission Induction; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vincristine | 2008 |
Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Female; Fluorodeoxyglucose F18; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Positron-Emission Tomography; Predictive Value of Tests; Prognosis; Prospective Studies; Radiopharmaceuticals; Remission Induction; Salvage Therapy; Survival Analysis; Transplantation, Autologous; Vincristine | 2008 |
Treatment of oral mucositis after peripheral blood SCT with ATL-104 mouthwash: results from a randomized, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Double-Blind Method; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Melphalan; Middle Aged; Mouthwashes; Phytohemagglutinins; Pilot Projects; Placebos; Recombinant Proteins; Stomatitis | 2009 |
Brazilian experience with two conditioning regimens in patients with multiple sclerosis: BEAM/horse ATG and CY/rabbit ATG.
Topics: Adult; Animals; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Graft Rejection; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Horses; Humans; Male; Melphalan; Middle Aged; Multiple Sclerosis; Quality of Life; Rabbits; Transplantation Conditioning | 2010 |
Predictive value of (18)F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Child; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Positron-Emission Tomography; Predictive Value of Tests; Prednisolone; Prednisone; Proportional Hazards Models; Radiopharmaceuticals; Rituximab; Teniposide; Tomography, X-Ray Computed; Transplantation, Autologous; Treatment Outcome; Vincristine; Young Adult | 2010 |
Final analysis of the UKLG LY02 trial comparing 6-8 cycles of CHOP with 3 cycles of CHOP followed by a BEAM autograft in patients <65 years with poor prognosis histologically aggressive NHL.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Neoplasm Staging; Prednisolone; Prognosis; Recurrence; Survival Analysis; Transplantation Conditioning; Treatment Outcome; Vincristine; Young Adult | 2010 |
Pegfilgrastim appears equivalent to daily dosing of filgrastim to treat neutropenia after autologous peripheral blood stem cell transplantation in patients with non-Hodgkin lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Staging; Neutropenia; Podophyllotoxin; Polyethylene Glycols; Recombinant Proteins; Transplantation, Autologous; Young Adult | 2010 |
Overcoming drug resistance in mantle cell lymphoma using a combination of dose-dense and intense therapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Disease-Free Survival; Drug Resistance, Neoplasm; Etoposide; Female; Gene Frequency; Glutathione S-Transferase pi; Glutathione Transferase; Granulocyte Colony-Stimulating Factor; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Mitoxantrone; Peripheral Blood Stem Cell Transplantation; Polymorphism, Genetic; Survival Analysis; Time Factors; Treatment Outcome | 2010 |
Autologous peripheral blood stem cell transplantation in children with refractory or relapsed lymphoma: results of Children's Oncology Group study A5962.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Child, Preschool; Cyclophosphamide; Drug Resistance, Neoplasm; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Hodgkin Disease; Humans; Lung Diseases; Lymphoma, Non-Hodgkin; Male; Peripheral Blood Stem Cell Transplantation; Recurrence; Remission Induction; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous; Young Adult | 2011 |
BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: a single center comparative analysis of efficacy and toxicity.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult | 2011 |
Clinical outcome of autologous peripheral blood stem cell transplantation in opticospinal and conventional forms of secondary progressive multiple sclerosis in a Chinese population.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; China; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Humans; Male; Melphalan; Middle Aged; Multiple Sclerosis, Chronic Progressive; Neuromyelitis Optica; Peripheral Blood Stem Cell Transplantation; Recurrence; Remission Induction; Spinal Cord; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult | 2011 |
A Phase I trial: dose escalation of melphalan in the "BEAM" regimen using amifostine cytoprotection.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillation; Carmustine; Combined Modality Therapy; Cytarabine; Cytoprotection; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Lymphoma; Male; Maximum Tolerated Dose; Melphalan; Middle Aged; Mucositis; Pancytopenia; Peripheral Blood Stem Cell Transplantation; Postoperative Complications; Transplantation Conditioning; Transplantation, Autologous; Young Adult | 2011 |
Long-term follow-up of tandem high-dose therapy with autologous stem cell support for adults with high-risk age-adjusted international prognostic index aggressive non-Hodgkin Lymphomas: a GOELAMS pilot study.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Peripheral Blood Stem Cell Transplantation; Pilot Projects; Quality of Life; Remission Induction; Risk Factors; Rituximab; Transplantation, Autologous | 2011 |
Treosulfan-based preparative regimens for allo-HSCT in childhood hematological malignancies: a retrospective study on behalf of the EBMT pediatric diseases working party.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Child; Child, Preschool; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Hematologic Neoplasms; Humans; Infant; Male; Melphalan; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2011 |
The risk factors for oral mucositis and the effect of cryotherapy in patients after the BEAM and HD-l-PAM 200 mg/m(2) autologous hematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cryotherapy; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Prospective Studies; Risk Factors; Stomatitis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult | 2011 |
High-dose therapy and autologous hematopoietic cell transplantation in peripheral T cell lymphoma (PTCL): analysis of prognostic factors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Child, Preschool; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, T-Cell, Peripheral; Male; Melphalan; Middle Aged; Prospective Studies; Survival Rate; Transplantation, Autologous; Whole-Body Irradiation | 2011 |
Tandem high-dose therapy in relapsed and refractory B-cell lymphoma: results of a prospective phase II trial of myeloablative chemotherapy, followed by escalated radioimmunotherapy with (131)I-anti-CD20 antibody and stem cell rescue.
Topics: Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Dexamethasone; Disease-Free Survival; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Etoposide; Humans; Iodine Radioisotopes; Kaplan-Meier Estimate; Lymphoma, B-Cell; Male; Melphalan; Middle Aged; Myeloablative Agonists; Prospective Studies; Radioimmunotherapy; Recurrence; Rituximab; Salvage Therapy; Stem Cell Transplantation | 2011 |
A triple-drug combination to prevent nausea and vomiting following BEAM chemotherapy before autologous hematopoietic stem cell transplantation.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Carmustine; Cytarabine; Dexamethasone; Drug Therapy, Combination; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Male; Melphalan; Morpholines; Nausea; Ondansetron; Palonosetron; Quinuclidines; Transplantation, Autologous; Treatment Outcome; Vomiting | 2011 |
Efficiency of supersaturated calcium phosphate mouth rinse treatment in patients receiving high-dose melphalan or BEAM prior to autologous blood stem cell transplantation: a single-center experience.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Calcium Phosphates; Carmustine; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Mouthwashes; Multiple Myeloma; Stomatitis; Transplantation Conditioning; Treatment Outcome; Young Adult | 2011 |
A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma.
Topics: Adult; Aged; Analysis of Variance; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Early Termination of Clinical Trials; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Odds Ratio; Prognosis; Proportional Hazards Models; Recurrence; Risk Factors; Sample Size; Stem Cell Transplantation; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2012 |
MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cytarabine; Dexamethasone; Etoposide; Female; Genes, myc; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Immunotherapy; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Podophyllotoxin; Rituximab; Salvage Therapy; Transplantation, Autologous; Treatment Failure; Young Adult | 2012 |
Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Podophyllotoxin; Prognosis; Recurrence; Rituximab; Survival Rate; Transplantation, Autologous | 2012 |
Iodine-131 rituximab radioimmunotherapy with BEAM conditioning and autologous stem cell transplant salvage therapy for relapsed/refractory aggressive non-Hodgkin lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease-Free Survival; Etoposide; Humans; Iodine Radioisotopes; Lymphoma, Non-Hodgkin; Melphalan; Middle Aged; Radioimmunotherapy; Rituximab; Salvage Therapy; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous | 2012 |
Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT C
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Large B-Cell, Diffuse; Melphalan; Middle Aged; Prospective Studies; Radioimmunotherapy; Recurrence; Rituximab; Transplantation, Autologous; Young Adult | 2013 |
Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carmustine; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Melphalan; Middle Aged; Pyrazines; Recurrence; Remission Induction; Survival Analysis; Transplantation, Autologous | 2014 |
Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Humans; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Multivariate Analysis; Neoplasm, Residual; Prognosis; Radioimmunotherapy; Stem Cell Transplantation; Time Factors; Transplantation, Autologous; Treatment Outcome | 2014 |
Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Etoposide; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Ifosfamide; Kaplan-Meier Estimate; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Positron-Emission Tomography; Prednisone; Prognosis; Prospective Studies; Radiopharmaceuticals; Remission Induction; Rituximab; Transplantation, Autologous; Treatment Outcome; Vincristine | 2014 |
Rituximab combined with DexaBEAM followed by high dose therapy as salvage therapy in patients with relapsed or refractory B-cell lymphoma: mature results of a phase II multicentre study.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dexamethasone; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Humans; Kaplan-Meier Estimate; Lymphoma, B-Cell; Male; Melphalan; Middle Aged; Patient Selection; Prospective Studies; Recurrence; Remission Induction; Rituximab; Salvage Therapy; Young Adult | 2015 |
Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes.
Topics: Adult; Aged; Busulfan; Carmustine; Cyclophosphamide; Cytarabine; Drug Combinations; Etoposide; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Melphalan; Middle Aged; North America; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous | 2016 |
Phase II Study of Propylene Glycol-Free Melphalan Combined with Carmustine, Etoposide, and Cytarabine for Myeloablative Conditioning in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.
Topics: Adolescent; Adult; Aged; Carmustine; Cytarabine; Etoposide; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Melphalan; Myeloablative Agonists; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult | 2016 |
Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carmustine; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Fluorodeoxyglucose F18; Humans; Ifosfamide; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Podophyllotoxin; Positron-Emission Tomography; Prednisone; Retreatment; Rituximab; Treatment Outcome; Vincristine; Young Adult | 2017 |
Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cytarabine; Deoxycytidine; Etoposide; Gemcitabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Melphalan; Middle Aged; Salvage Therapy; Survival Analysis; Transplantation, Autologous; Young Adult | 2018 |
LEAM versus CBV for conditioning in autologous hematopoietic stem cell transplantation for lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lomustine; Lymphoma; Male; Methotrexate; Prednisolone; Prospective Studies; Transplantation Conditioning; Transplantation, Autologous | 2019 |
Prospective phase II clinical trial of autologous haematopoietic stem cell transplant for treatment refractory multiple sclerosis.
Topics: Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Progression-Free Survival; Prospective Studies; Transplantation, Autologous; Treatment Outcome; Young Adult | 2019 |
Bortezomib maintenance after R-CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Netherlands; Prednisone; Progression-Free Survival; Remission Induction; Rituximab; Transplantation, Autologous; Treatment Failure; Vincristine; Young Adult | 2020 |
A dose-dense short-term therapy for human immunodeficiency virus/acquired immunodeficiency syndrome patients with high-risk Burkitt lymphoma or high-grade B-cell lymphoma: safety and efficacy results of the "CARMEN" phase II trial.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Burkitt Lymphoma; Carmustine; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; HIV Infections; Humans; Lymphoma, B-Cell; Male; Melphalan; Middle Aged; Transplantation, Autologous | 2021 |
Dexa-BEAM versus MIFAP as salvage regimen for recurrent lymphoma: a prospective randomized multicenter phase II trial with a median follow-up of 14.4 years.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dexamethasone; Etoposide; Follow-Up Studies; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Melphalan; Neoplasm Recurrence, Local; Prospective Studies; Salvage Therapy | 2022 |
387 other study(ies) available for etoposide and carmustine
| Article | Year |
|---|---|
Cell-based screen for identification of inhibitors of tubulin polymerization.
Topics: Animals; Brain Neoplasms; Bucladesine; Cell Differentiation; Drug Screening Assays, Antitumor; Formazans; Glioma; Rats; Tubulin; Tumor Cells, Cultured | 1996 |
Design, synthesis, and biological evaluation of analogues of the antitumor agent, 2-(4-[(7-chloro-2-quinoxalinyl)oxy]phenoxy)propionic acid (XK469).
Topics: Animals; Antineoplastic Agents; Drug Design; Drug Screening Assays, Antitumor; Humans; Mice; Quinoxalines; Stereoisomerism; Structure-Activity Relationship; Transplantation, Heterologous; Tumor Cells, Cultured | 2001 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Chemotherapeutic trials on human malignant astrocytomas in organ culture.
Topics: Antineoplastic Agents; Astrocytoma; Carmustine; Cell Survival; Cyanides; Drug Evaluation, Preclinical; Etoposide; Humans; Lomustine; Luciferases; Methylprednisolone; NAD; Organ Culture Techniques | 1977 |
Intensive induction therapy for small cell carcinoma of the lung.
Topics: Aged; Antineoplastic Agents; Bone Marrow; Carcinoma, Small Cell; Carmustine; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Etoposide; Female; Humans; Lung Neoplasms; Male; Methotrexate; Middle Aged; Procarbazine; Remission, Spontaneous; Vincristine | 1979 |
Combination chemotherapy with 4'Demethylepipodophyllotoxin 9-(4,6-0-ethylidene-beta-D-glucopyranoside), VP 16-213 (NSC 141540) in L1210 leukemia.
Topics: Animals; Antineoplastic Agents; Carmustine; Cyclophosphamide; Cytarabine; Dactinomycin; Daunorubicin; Drug Therapy, Combination; Etoposide; Female; Fluorouracil; Leukemia L1210; Male; Mercaptopurine; Methotrexate; Mice; Mice, Inbred DBA; Podophyllotoxin; Vincristine | 1976 |
Autologous peripheral blood stem cell transplantation after high dose therapy in patients with advanced lymphomas.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion, Autologous; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Leukapheresis; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Podophyllotoxin; Salvage Therapy; Whole-Body Irradiation | 1992 |
Doxorubicin sensitivity pattern in a panel of small-cell lung-cancer cell lines: correlation to etoposide and vincristine sensitivity and inverse correlation to carmustine sensitivity.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Small Cell; Carmustine; Cell Division; Cisplatin; Cytarabine; DNA Topoisomerases, Type II; Doxorubicin; Drug Resistance; Drug Screening Assays, Antitumor; Etoposide; Humans; Lung Neoplasms; Membrane Glycoproteins; Tumor Cells, Cultured | 1992 |
BEAM regimen and G-CSF in HTLV-I-associated T-cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Drug Therapy, Combination; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoiesis; Humans; Leukemia-Lymphoma, Adult T-Cell; Melphalan; Middle Aged | 1992 |
Allogeneic bone marrow transplantation for hematological malignancies following etoposide, cyclophosphamide, and fractionated total body irradiation.
Topics: Acute Disease; Adolescent; Adult; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Drug Therapy, Combination; Etoposide; Female; Humans; Injections, Intravenous; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Transplantation, Homologous; Whole-Body Irradiation | 1992 |
High-dose chemotherapy and autologous bone marrow transplantation for relapsed and refractory Hodgkin's disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Female; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Survival Rate; Transplantation, Autologous | 1992 |
Pharmacokinetics of high-dose etoposide after short-term infusion.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Carmustine; Cyclophosphamide; Cytarabine; Drug Interactions; Etoposide; Humans; Infusions, Intravenous; Mass Spectrometry; Middle Aged; Time Factors | 1992 |
High-dose hydroxyurea in autologous bone marrow transplantation: a promising "new" agent.
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms; Carmustine; Chemotherapy, Adjuvant; Cyclophosphamide; Drug Administration Schedule; Etoposide; Humans; Hydroxyurea; Lymphoma, Non-Hodgkin; Middle Aged; Remission Induction; Survival Rate; Thiotepa | 1992 |
Mini-BEAM followed by BEAM and ABMT for very poor risk Hodgkin's disease.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Female; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Risk Factors; Time Factors | 1992 |
Effect of etoposide, carmustine, vincristine, 5-fluorouracil, or methotrexate on radiobiologically oxic and hypoxic cells in a C3H mouse mammary carcinoma in situ.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma in Situ; Carmustine; Cell Division; Cell Hypoxia; Combined Modality Therapy; Etoposide; Female; Fluorouracil; Male; Mammary Neoplasms, Experimental; Methotrexate; Mice; Mice, Inbred C3H; Vincristine | 1992 |
High-dose cyclophosphamide, carmustine, and etoposide followed by autologous peripheral stem cell transplantation for patients with relapsed Hodgkin's disease.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Probability; Recurrence | 1991 |
Intensive combination chemotherapy and autologous bone marrow transplantation leads to the reappearance of Philadelphia chromosome-negative cells in chronic myelogenous leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cyclophosphamide; Etoposide; Female; Follow-Up Studies; Granulocytes; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Interferon Type I; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes, Mononuclear; Macrophages; Male; Metaphase; Middle Aged; Philadelphia Chromosome; Remission Induction; Time Factors | 1991 |
Use of recombinant human hematopoietic growth factors and autologous bone marrow transplantation to attenuate the neutropenic trough of high-dose therapy.
Topics: Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Blood Specimen Collection; Bone Marrow Transplantation; Carmustine; Colony-Stimulating Factors; Cyclophosphamide; Etoposide; Granulocyte Colony-Stimulating Factor; Granulocytes; Hodgkin Disease; Humans; Male; Neutropenia; Neutrophils; Pain; Recombinant Proteins | 1990 |
Multifactorial mechanisms associated with broad cross-resistance of ovarian carcinoma cells selected by cyanomorpholino doxorubicin.
Topics: Bleomycin; Blotting, Western; Carmustine; Cisplatin; Cross Reactions; Dinitrochlorobenzene; DNA; DNA Repair; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance; Etoposide; Female; Gamma Rays; gamma-Glutamyltransferase; Glutathione; Glutathione Reductase; Glutathione Transferase; Humans; In Vitro Techniques; Methionine; Ovarian Neoplasms; Time Factors; Tumor Cells, Cultured; Vinblastine | 1991 |
High-dose chemotherapy with autologous bone marrow rescue: haematopoietic reconstitution by non-cryopreserved marrow.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Carmustine; Cyclophosphamide; Etoposide; Humans; Middle Aged; Neoplasms; Remission Induction; Tissue Preservation; Transplantation, Autologous | 1991 |
Myeloablative combination chemotherapy without total body irradiation for neuroblastoma.
Topics: Adrenal Gland Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Infant; Male; Melphalan; Neuroblastoma; Pelvic Neoplasms; Radiotherapy Dosage; Retroperitoneal Neoplasms; Survival Rate; Thiotepa; Whole-Body Irradiation | 1991 |
Increased survival after treatments with anticancer agents of Chinese hamster cells expressing the human Mr 27,000 heat shock protein.
Topics: Animals; Antineoplastic Agents; Arsenic; Arsenites; Blotting, Western; Carmustine; Cell Line; Cell Survival; Colchicine; Cricetinae; Dactinomycin; Daunorubicin; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance; Etoposide; Fluorouracil; Heat-Shock Proteins; Humans; Hydrogen Peroxide; Pentosyltransferases; Sodium Compounds; Teniposide; Vincristine | 1991 |
Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease.
Topics: Adolescent; Adult; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Follow-Up Studies; Hodgkin Disease; Humans; Male; Middle Aged; Recurrence; Survival Analysis; Transplantation, Autologous | 1991 |
Treatment of relapsed and refractory Hodgkin's disease with high dose chemotherapy and autologous bone marrow transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Carmustine; Child; Combined Modality Therapy; Cyclophosphamide; Drug Resistance; Etoposide; Female; Hodgkin Disease; Humans; Life Tables; Male; Neoplasm Recurrence, Local; Prognosis; Proportional Hazards Models; Remission Induction; Salvage Therapy; Survival Analysis; Transplantation, Autologous; Whole-Body Irradiation | 1991 |
High dose cyclophosphamide, BCNU and VP-16 with autologous blood stem cell support for refractory multiple myeloma.
Topics: Blood Transfusion, Autologous; Bone Marrow Transplantation; Carmustine; Cyclophosphamide; Dose-Response Relationship, Drug; Etoposide; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Middle Aged; Multiple Myeloma; Transplantation, Autologous | 1990 |
Treatment of refractory and relapsed Hodgkin's disease: intensive chemotherapy and autologous bone marrow or peripheral blood stem cell support.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Carmustine; Child; Cyclophosphamide; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Hodgkin Disease; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Survival Rate; Time Factors | 1990 |
The Stanford experience with high-dose etoposide cytoreductive regimens and autologous bone marrow transplantation in Hodgkin's disease and non-Hodgkin's lymphoma: preliminary data.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Drug Evaluation; Etoposide; Follow-Up Studies; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Prospective Studies; Transplantation, Autologous; Whole-Body Irradiation | 1991 |
Etoposide with lonidamine or pentoxifylline as modulators of alkylating agent activity in vivo.
Topics: Alkylating Agents; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carmustine; Cisplatin; Colony-Forming Units Assay; Cyclophosphamide; Etoposide; Fibrosarcoma; Hematopoietic Stem Cells; Indazoles; Male; Melphalan; Mice; Mice, Inbred C3H; Pentoxifylline; Sarcoma, Experimental | 1991 |
Autologous bone marrow transplantation for refractory or relapsed Hodgkin's disease: the Memorial Sloan-Kettering Cancer Center experience using high-dose chemotherapy with or without hyperfractionated accelerated total lymphoid irradiation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cause of Death; Combined Modality Therapy; Cyclophosphamide; Drug Resistance; Etoposide; Hodgkin Disease; Humans; Lymphatic Irradiation; Recurrence; Survival Rate | 1991 |
Autologous bone marrow transplantation for advanced stage mycosis fungoides.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cisplatin; Combined Modality Therapy; Etoposide; Female; Hospitalization; Humans; Incidence; Male; Middle Aged; Mycosis Fungoides; Prognosis; Sepsis; Skin Neoplasms; Transplantation, Autologous | 1991 |
BEAM protocol and autologous bone marrow transplantation in first chemosensitive relapse of non-Hodgkin's lymphomas.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Child; Cytarabine; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Retrospective Studies | 1990 |
Diabetes mellitus or an impaired glucose tolerance as a potential complicating factor in patients treated with high-dose therapy and autologous bone marrow transplantation.
Topics: Adult; Bone Marrow Transplantation; Carmustine; Cyclophosphamide; Cytarabine; Diabetes Mellitus; Dose-Response Relationship, Drug; Etoposide; Female; Glucose; Graft Rejection; Heart; Hodgkin Disease; Humans; Kidney; Liver; Lymphoma, Non-Hodgkin; Male; Middle Aged; Retrospective Studies | 1990 |
Pharmacokinetics of very high-dose oral melphalan in cancer patients.
Topics: Adenocarcinoma; Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Bone Marrow Transplantation; Carmustine; Etoposide; Female; Humans; Injections, Intravenous; Lymphoma; Male; Melanoma; Melphalan; Middle Aged; Time Factors | 1990 |
Evaluation of cytoreductive therapy prior to high dose treatment with autologous bone marrow transplantation in relapsed and refractory Hodgkin's disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Chi-Square Distribution; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Epirubicin; Etoposide; Evaluation Studies as Topic; Hodgkin Disease; Humans; Male; Melphalan; Prednisone; Premedication; Remission Induction; Vincristine | 1990 |
Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Etoposide; Female; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Remission Induction; Survival Rate | 1990 |
Double intensive consolidation chemotherapy (ICC) for acute myeloid leukemia.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Etoposide; France; Humans; Leukemia, Myeloid, Acute; Life Tables; Middle Aged; Neutropenia; Survival Rate | 1990 |
BVAC ablative chemotherapy followed by autologous bone marrow transplantation for patients with advanced lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Humans; Lymphoma; Middle Aged; Survival Analysis; Time Factors | 1990 |
BAVC regimen and autologous bone marrow transplantation in patients with acute myelogenous leukemia in second remission.
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival Analysis | 1990 |
High-dose chemotherapy and unpurged autologous bone marrow transplantation for acute leukemia in second or subsequent remission.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Granulocytes; Humans; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Platelet Count; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Survival Rate | 1990 |
Allogeneic marrow transplantation for refractory Hodgkin's disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Doxorubicin; Etoposide; Female; Hodgkin Disease; Humans; Male; Mechlorethamine; Prednisone; Procarbazine; Remission Induction; Vinblastine; Vincristine | 1989 |
Recombinant human granulocyte colony-stimulating factor hastens granulocyte recovery after high-dose chemotherapy and autologous bone marrow transplantation in Hodgkin's disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Colony-Stimulating Factors; Cyclophosphamide; Drug Evaluation; Etoposide; Granulocyte Colony-Stimulating Factor; Granulocytes; Hematopoiesis; Hodgkin Disease; Humans; Leukocyte Count; Platelet Count; Recombinant Proteins | 1989 |
Long-term endocrine toxicity of myeloablative treatment followed by autologous bone marrow/blood derived stem cell transplantation in patients with malignant lymphohematopoietic disorders.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Endocrine System Diseases; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Libido; Lymphoma; Male; Menstruation Disturbances; Middle Aged; Ovarian Diseases; Whole-Body Irradiation | 1989 |
High-dose therapy and autologous peripheral blood stem cell transplantation for patients with lymphoma.
Topics: Actuarial Analysis; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion, Autologous; Carmustine; Child; Cyclophosphamide; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Leukapheresis; Lymphoma, Non-Hodgkin; Male; Middle Aged | 1989 |
Treatment of multiple myeloma by high dose chemotherapy, total body irradiation and autologous blood stem cell autograft.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Etoposide; Evaluation Studies as Topic; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Remission Induction; Transplantation, Autologous; Whole-Body Irradiation | 1989 |
High-dose combination chemotherapy with cyclophosphamide, carmustine, etoposide, and autologous bone marrow transplantation in 60 patients with relapsed Hodgkin's disease: the M. D. Anderson experience.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Hodgkin Disease; Humans; Male; Middle Aged | 1989 |
Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Follow-Up Studies; Hodgkin Disease; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Remission Induction; Risk Factors | 1989 |
High dose melphalan, BCNU and etoposide with autologous bone marrow transplantation for Hodgkin's disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Etoposide; Female; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged | 1989 |
Autologous bone marrow transplantation in patients with AML in second complete remission (CR).
Topics: Adolescent; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Etoposide; Evaluation Studies as Topic; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Remission Induction; Transplantation, Autologous | 1989 |
Progenitor cell numbers (CFU-GM, CFU-D, and CFU-Mix) and hemopoietic recovery following autologous marrow transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Colony-Forming Units Assay; Cyclophosphamide; Etoposide; Hematopoiesis; Hematopoietic Stem Cells; Humans; Neoplasms; Time Factors; Transplantation, Autologous; Whole-Body Irradiation | 1989 |
[High-doses chemotherapy followed by bone marrow autograft in the treatment of small cell bronchial cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carcinoma, Small Cell; Carmustine; Combined Modality Therapy; Etoposide; Humans; Lung Neoplasms; Melphalan; Procarbazine | 1987 |
Results of recent salvage chemotherapy regimens for lymphoma and Hodgkin's disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Drug Evaluation; Etoposide; Humans; Ifosfamide; Lymphoma; Methotrexate; Methylprednisolone; Mitoguazone; Transplantation, Autologous | 1988 |
Phase II studies of combinations of drugs with high dose carboplatin in neuroblastoma (800 mg/m2 to 1 g 250/m2): a report from the LMCE group.
Topics: Carboplatin; Carmustine; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Therapy, Combination; Etoposide; Humans; Methoxyhydroxyphenylglycol; Neuroblastoma; Organoplatinum Compounds | 1988 |
Intensive chemotherapy with high doses of BCNU, etoposide, cytosine arabinoside, and melphalan (BEAM) followed by autologous bone marrow transplantation: toxicity and antitumor activity in 26 patients with poor-risk malignancies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Etoposide; Female; Hematologic Diseases; Humans; Leukemia, Lymphoid; Lymphoma; Male; Melphalan; Middle Aged; Recurrence; Remission Induction; Thymoma; Thymus Neoplasms | 1988 |
Effect of fluosol-DA/carbogen on etoposide/alkylating agent antitumor activity.
Topics: Alkylating Agents; Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carbon Dioxide; Carmustine; Cell Division; Cell Survival; Drug Combinations; Etoposide; Fluorocarbons; Hydroxyethyl Starch Derivatives; Male; Mice; Mice, Inbred Strains; Neoplasms, Experimental; Organoplatinum Compounds; Oxygen | 1988 |
Intraocular involvement of Burkitt's lymphoma in a Bedouin child.
Topics: Abdominal Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Burkitt Lymphoma; Carmustine; Child, Preschool; Cyclophosphamide; Cytarabine; Etoposide; Eye Neoplasms; Female; Humans; Hydrocortisone; Methotrexate; Vincristine; Vitreous Body | 1987 |
Ifosfamide and VP-16213 combination chemotherapy combined with ablative chemotherapy and autologous marrow transplantation as salvage treatment for malignant lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Humans; Ifosfamide; Lymphoma; Melphalan; Methotrexate; Middle Aged; Mitoguazone; Podophyllotoxin | 1988 |
Repeated high-dose chemotherapy followed by purged autologous bone marrow transplantation as consolidation therapy in metastatic neuroblastoma.
Topics: Abdominal Neoplasms; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone Marrow Transplantation; Carmustine; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Gastrointestinal Diseases; Humans; Infant; Infections; Melphalan; Neuroblastoma; Teniposide; Thoracic Neoplasms; Transplantation, Autologous; Vincristine | 1987 |
Sequential pilot studies of intensive postremission chemotherapy for acute nonlymphocytic leukemia.
Topics: Acute Disease; Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia; Male; Middle Aged; Mitoxantrone; Pilot Projects; Thioguanine | 1987 |
Autologous bone marrow transplantation for patients with acute myelogenous leukemia in complete remission.
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Evaluation Studies as Topic; Humans; Leukemia, Myeloid, Acute; Lymphocyte Depletion; Postoperative Complications; Remission Induction; Transplantation, Autologous | 1987 |
High-dose cyclophosphamide, carmustine, and etoposide and autologous bone marrow transplantation for relapsed Hodgkin's disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Drug Administration Schedule; Etoposide; Female; Hodgkin Disease; Humans; Male; Middle Aged; Neutropenia; Recurrence; Thrombocytopenia | 1986 |
High-dose cyclophosphamide, BCNU, and etoposide followed by autologous bone marrow rescue as treatment for adult acute leukemia in relapse.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cyclophosphamide; Etoposide; Humans; Leukemia; Middle Aged; Recurrence; Transplantation, Autologous | 1986 |
High-dose therapy followed by autologous bone marrow transplantation (ABMT) in previously untreated non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Female; Humans; Lymph Nodes; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Staging; Risk | 1986 |
Vitamin A: failure to demonstrate in mice an anti-tumour effect, whether combined with cytotoxic drugs or not.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Cyclophosphamide; Etoposide; Female; Leukemia L1210; Leukemia, Experimental; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Neoplasm Transplantation; Neoplasms, Experimental; Teniposide; Vitamin A | 1986 |
High-dose carmustine and high-dose etoposide: a treatment regimen resulting in enhanced hepatic toxicity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Chemical and Drug Induced Liver Injury; Combined Modality Therapy; Drug Evaluation; Etoposide; Humans | 1986 |
Massive chemotherapy with non-frozen autologous bone marrow transplantation in 13 cases of refractory Hodgkin's disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Bone Marrow Diseases; Bone Marrow Transplantation; Carmustine; Cyclophosphamide; Etoposide; Female; Hodgkin Disease; Humans; Male | 1985 |
High-dose chemoradiotherapy and bone marrow transplantation in patients with refractory lymphoma.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cyclophosphamide; Drug Therapy, Combination; Etoposide; Female; Humans; Lymphoma; Male; Transplantation, Autologous; Transplantation, Homologous; Whole-Body Irradiation | 1983 |
Repeated high-dose cyclophosphamide, BCNU and VP-16-213 and autologous bone marrow transplantation in adult acute lymphocytic leukemia in first remission.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Humans; Leukemia, Lymphoid; Male; Middle Aged | 1984 |
Pharmacokinetic studies in lung cancer patients.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Carboplatin; Carmustine; Cisplatin; Cyclophosphamide; Etoposide; Humans; Ifosfamide; Lung Neoplasms; Naphthacenes; Organoplatinum Compounds | 1984 |
Perspectives for the use of high-dose chemotherapy in the treatment of solid malignant tumors.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Drug Evaluation; Etoposide; Humans; Melphalan; Neoplasms; Whole-Body Irradiation | 1984 |
High-dose combination chemotherapy with autologous bone marrow transplantation in adult solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow Transplantation; Carmustine; Cyclophosphamide; Drug Evaluation; Etoposide; Female; Humans; Ifosfamide; Leukocyte Count; Male; Middle Aged; Neoplasms; Pilot Projects; Platelet Count; Time Factors; Transplantation, Autologous; Vincristine | 1980 |
Response of L1210 leukemia to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea plus 4'-demethylepipodophyllotoxin-9-(4,6-O-2-thenylidene-beta-D-glucopyranoside).
Topics: Animals; Carmustine; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Etoposide; Female; Leukemia L1210; Mice; Mice, Inbred Strains; Podophyllotoxin; Prognosis | 1981 |
Clostridium septicum abscess in hepatic metastases: successful medical management.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms; Carmustine; Ceftazidime; Cisplatin; Clindamycin; Clostridium Infections; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Etoposide; Female; Fluorouracil; Gases; Granulocyte Colony-Stimulating Factor; Humans; Imipenem; Immunocompromised Host; Liver Abscess; Liver Neoplasms; Methotrexate; Neutropenia; Sepsis | 1994 |
Administration of three cytokines instead of bone marrow transplantation in an HIV+ patient with high-grade lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cyclophosphamide; Cytarabine; Cytokines; Doxorubicin; Drug Therapy, Combination; Erythropoietin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Lymphoma, AIDS-Related; Melphalan; Prednisolone; Vincristine | 1994 |
Visual hallucinations following treatment with vincristine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cyclophosphamide; Doxorubicin; Etoposide; Hallucinations; Humans; Lymphoma, T-Cell; Male; Melphalan; Methotrexate; Middle Aged; Multiple Myeloma; Prednisolone; Prednisone; Procarbazine; Salvage Therapy; Serotonin; Structure-Activity Relationship; Vincristine | 1994 |
Expression of adhesion molecules on CD34+ cells: CD34+ L-selectin+ cells predict a rapid platelet recovery after peripheral blood stem cell transplantation.
Topics: Adult; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bone Marrow; Bone Marrow Cells; Carboplatin; Carmustine; Cell Adhesion Molecules; Cell Movement; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Epirubicin; Etoposide; Female; Fluorouracil; Gene Expression; Granulocyte Colony-Stimulating Factor; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Ifosfamide; L-Selectin; Leukocyte Count; Male; Melphalan; Middle Aged; Neoplasms; Neutrophils; Platelet Count; Podophyllotoxin; Receptors, Very Late Antigen; Thiotepa | 1995 |
High-dose chemotherapy and autologous peripheral stem cell transplantation in patients with relapsing malignant lymphomas--first experience in the Slovak Republic.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carboplatin; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lymphoma; Mitoxantrone; Salvage Therapy; Slovakia | 1995 |
A marrow harvest procedure under local anesthesia.
Topics: Anesthesia, Local; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Breast Neoplasms; Carmustine; Combined Modality Therapy; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Lung Neoplasms; Mitoxantrone; Outpatients; Pain Measurement; Thiotepa; Tissue Preservation; Transplantation, Autologous | 1995 |
Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Blood Cells; Bone Marrow; Bone Marrow Transplantation; Carmustine; Cell Survival; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Female; Glyoxal; Graft Survival; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Hodgkin Disease; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Multivariate Analysis; Prednimustine; Prednisolone; Prednisone; Procarbazine; Radiotherapy; Retrospective Studies; Salvage Therapy; Vinblastine; Vincristine | 1995 |
Time-course of the recovery of cellular immune function after high-dose chemotherapy and peripheral blood progenitor cell transplantation for high-grade non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Diseases; Busulfan; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Killer Cells, Lymphokine-Activated; Killer Cells, Natural; Leukapheresis; Lymphocyte Count; Lymphocyte Subsets; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Melphalan; Mesna; Middle Aged; Podophyllotoxin; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Time Factors; Treatment Outcome; Vincristine | 1995 |
Autologous stem cell transplantation for refractory and relapsed Hodgkin's disease: factors predictive of prolonged survival.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Prognosis; Remission Induction; Sex Factors; Survival Analysis | 1995 |
Bone marrow transplantation through standard central venous catheters.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Catheterization, Central Venous; Catheters, Indwelling; Cyclophosphamide; Etoposide; Humans; Neoplasms; Transplantation, Autologous; Transplantation, Homologous; Transplantation, Isogeneic; Whole-Body Irradiation | 1995 |
High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen-related toxicity.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Retrospective Studies; Transplantation, Autologous; Treatment Outcome | 1995 |
Effective mobilisation of peripheral blood progenitor cells with 'Dexa-BEAM' and G-CSF: timing of harvesting and composition of the leukapheresis product.
Topics: Adult; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukapheresis; Lymphoma; Male; Melphalan; Middle Aged; Salvage Therapy; Time Factors | 1993 |
Prolonged impairment of hematopoiesis after high-dose therapy followed by autologous bone marrow transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Busulfan; Carmustine; Cell Count; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Female; Follow-Up Studies; Hematopoiesis; Hematopoietic Cell Growth Factors; Humans; Male; Melphalan; Methotrexate; Middle Aged; Mitoxantrone; Multivariate Analysis; Neoplasms; Prognosis; Radiation Injuries; Treatment Outcome; Vincristine; Whole-Body Irradiation | 1995 |
Delayed neutrophil recovery after BEAM chemotherapy and autologous bone marrow transplantation for lymphoma is not associated with increased mortality from infection.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cell Count; Combined Modality Therapy; Cytarabine; Etoposide; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Melphalan; Middle Aged; Neutropenia; Opportunistic Infections; Survival Analysis | 1995 |
Multidrug resistance gene and P-glycoprotein expression in anaplastic carcinoma of the thyroid.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma; Carmustine; Cyclophosphamide; Doxorubicin; Drug Resistance, Multiple; Etoposide; Female; Gene Expression; Humans; Immunoenzyme Techniques; Male; Middle Aged; Peplomycin; Polymerase Chain Reaction; RNA, Messenger; Thyroid Neoplasms | 1994 |
Carmustine, Ara C, cyclophosphamide and etoposide with autologous bone marrow transplantation in relapsed or refractory lymphoma: a dose-finding study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Lymphoma; Male; Middle Aged; Transplantation, Autologous | 1994 |
Schedule-dependent cytotoxicity of topotecan alone and in combination chemotherapy regimens.
Topics: Alkylating Agents; Animals; Antineoplastic Combined Chemotherapy Protocols; Aphidicolin; Camptothecin; Carmustine; Cell Cycle; Cell Death; Cell Line; Cisplatin; Cricetinae; Cricetulus; DNA Damage; DNA Repair; DNA, Neoplasm; Doxorubicin; Drug Synergism; Etoposide; Fibroblasts; Hydroxyurea; Lung; Melphalan; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan | 1994 |
[Excretion of beta-2-microglobulin and Tamm-Horsfall protein in patients undergoing a conditioning regimen before bone marrow transplantation].
Topics: Adjuvants, Immunologic; Adult; beta 2-Microglobulin; Bone Marrow Transplantation; Busulfan; Carmustine; Cyclophosphamide; Drug Therapy, Combination; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Kidney Tubules; Male; Mucoproteins; Preoperative Care; Uromodulin | 1994 |
Total body irradiation and high-dose cyclophosphamide, BCNU and VP-16 (CBV) as a new preparatory regimen for allogeneic bone marrow transplantation in patients with advanced hematologic malignancies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Graft vs Host Disease; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Recurrence; Time Factors; Transplantation, Homologous; Whole-Body Irradiation | 1994 |
Autologous bone marrow transplantation using TBI and CBV for disseminated high/intermediate grade cutaneous non-epidermotropic non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Staging; Remission Induction; Skin Neoplasms; Time Factors; Transplantation, Autologous; Whole-Body Irradiation | 1994 |
Pregnancy after autologous bone marrow transplantation for malignant lymphomas.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Infant, Newborn; Lymphoma, Large B-Cell, Diffuse; Mechlorethamine; Melphalan; Podophyllotoxin; Prednisone; Pregnancy; Pregnancy Outcome; Procarbazine; Remission Induction; Salvage Therapy; Vincristine | 1994 |
Quality and functional capacity of the bone marrow microenvironment of autologous blood stem cell transplantation (ABSCT) recipients.
Topics: Bone Marrow; Carmustine; Cells, Cultured; Colony-Forming Units Assay; Connective Tissue; Cyclophosphamide; Cytarabine; Etoposide; Graft Survival; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Melphalan; Multiple Myeloma; Transplantation, Autologous; Whole-Body Irradiation | 1994 |
Mouse subrenal capsule assay chemosensitivity and DNA flow cytometry parameters of human melanoma metastases.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; DNA, Neoplasm; Etoposide; Female; Flow Cytometry; Humans; Male; Melanoma; Mice; Middle Aged; Subrenal Capsule Assay; Vincristine | 1994 |
Germ cell failure and Leydig cell insufficiency in post-pubertal males after autologous bone marrow transplantation with BEAM for lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Follicle Stimulating Hormone; Humans; Leydig Cells; Luteinizing Hormone; Lymphoma; Male; Melphalan; Spermatozoa; Transplantation, Autologous | 1994 |
Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in refractory lymphoma patients undergoing autologous bone marrow transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Chemotherapy, Adjuvant; Cyclophosphamide; Etoposide; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Mitoxantrone | 1994 |
Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine, and etoposide.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prognosis; Prospective Studies; Survival Rate; Transplantation, Autologous | 1993 |
High-dose chemotherapy and hematopoietic stem cell rescue in patients with relapsed Hodgkin's disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Survival Rate | 1993 |
Antibody response to murine anti-GD2 monoclonal antibodies: correlation with patient survival.
Topics: Animals; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Antibody Formation; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cisplatin; Enzyme-Linked Immunosorbent Assay; Etoposide; Gangliosides; Humans; Melphalan; Mice; Neoplasm Staging; Neuroblastoma; Prognosis; Radiotherapy Dosage; Survival Analysis; Survival Rate; Thiotepa | 1994 |
Pentostatin increases the acute toxicity of high dose cyclophosphamide.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Synergism; Etoposide; Fatal Outcome; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Methylprednisolone; Pentostatin; Prednisone; Rats; Rats, Inbred Lew; Salvage Therapy; Shock, Cardiogenic; Ventricular Fibrillation; Vidarabine; Vincristine | 1993 |
High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: long-term follow-up in 128 patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Child; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Follow-Up Studies; Hodgkin Disease; Humans; Male; Middle Aged; Pregnancy; Prognosis; Survival Rate; Transplantation, Autologous | 1993 |
High-dose cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation in patients with lymphoid malignancies who have received dose-limiting radiation therapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Humans; Lymphoma; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Transplantation, Autologous | 1993 |
Comparison of preparative transplantation regimens using carmustine/etoposide/cisplatin or busulfan/etoposide/cyclophosphamide in lymphoid malignancies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Etoposide; Humans; Lymphoma; Middle Aged; Survival Analysis; Treatment Outcome | 1993 |
High-dose cyclophosphamide, etoposide and BCNU (CVB) with autologous stem cell rescue in malignant lymphomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Colony-Forming Units Assay; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Follow-Up Studies; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Staging; Salvage Therapy; Stem Cell Transplantation; Time Factors; Transplantation, Autologous | 1993 |
Haemolytic uraemic syndrome and renal dysfunction following BEAC (BCNU, etoposide, ara-C, cyclophosphamide) +/- TBI and autologous BMT for malignant lymphomas.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Child; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Female; Glomerular Filtration Rate; Hemolytic-Uremic Syndrome; Humans; Kidney; Lymphoma; Male; Middle Aged; Transplantation, Autologous; Whole-Body Irradiation | 1993 |
Yttrium 90-labeled antiferritin followed by high-dose chemotherapy and autologous bone marrow transplantation for poor-prognosis Hodgkin's disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Ferritins; Hodgkin Disease; Humans; Male; Neoplasm Proteins; Prognosis; Radioimmunotherapy; Survival Rate; Yttrium Radioisotopes | 1993 |
A mononuclear cell dose of 3 x 10(8)/kg predicts early multilineage recovery in patients with malignant lymphoma treated with carmustine, etoposide, Ara-C and melphalan (BEAM) and peripheral blood progenitor cell transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Granulocytes; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Leukapheresis; Leukocyte Count; Leukocytes, Mononuclear; Lymphoma; Lymphoma, Non-Hodgkin; Macrophages; Male; Melphalan | 1995 |
Factors influencing prognosis after dose-intensive therapy for recurrent or refractory Hodgkin's disease. Results of sequential trials: a case for treating patients with resistant disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Carmustine; Clinical Trials as Topic; Cohort Studies; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Drug Resistance; Etoposide; Female; Hodgkin Disease; Humans; Male; Middle Aged; Mitoxantrone; Prognosis; Recurrence; Survival Rate; Thiotepa; Treatment Outcome; Vinblastine | 1995 |
Pneumocystis carinii pneumonia in adults with acute leukaemia: is there a need for primary chemoprophylaxis?
Topics: Aclarubicin; Acute Disease; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cohort Studies; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Etoposide; Female; Finland; Humans; Immunocompromised Host; Incidence; Leukemia; Male; Mercaptopurine; Methotrexate; Middle Aged; Mitoxantrone; Pneumonia, Pneumocystis; Prednisone; Premedication; Retrospective Studies; Thioguanine; Trimethoprim, Sulfamethoxazole Drug Combination; Vincristine | 1996 |
High-dose carmustine, etoposide and melphalan ('BEM') with autologous stem cell transplantation: a dose-toxicity study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Dose-Response Relationship, Drug; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Liver Function Tests; Lymphoma; Male; Melphalan; Middle Aged; Multiple Myeloma; Respiratory Function Tests; Retrospective Studies; Transplantation, Autologous | 1996 |
Hemolytic uremic syndrome after autologous BMT without TBI.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Hemolytic-Uremic Syndrome; Hodgkin Disease; Humans; Male; Transplantation Conditioning; Transplantation, Autologous; Whole-Body Irradiation | 1996 |
Induction of apoptotic cell death by DNA topoisomerase II inhibitors.
Topics: Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carmustine; Cell Survival; Cyclophosphamide; DNA Damage; DNA Topoisomerases, Type II; Etoposide; HeLa Cells; Humans; Intercalating Agents; Suramin; Topoisomerase II Inhibitors | 1995 |
Effective autologous peripheral blood stem cell transplantation in plasma cell leukemia followed by T-large granular lymphocyte expansion: a case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Plasma Cell; Lymphocyte Count; Male; Melphalan; Mitoxantrone; Prednisone; Remission Induction; T-Lymphocyte Subsets; Transplantation Conditioning; Vincristine; Whole-Body Irradiation | 1996 |
Successful mobilisation of blood stem cells following previous autologous bone marrow transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Blood Cells; Bone Marrow; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Epirubicin; Etoposide; Hematopoietic Stem Cells; Humans; Ifosfamide; Leukapheresis; Lymphoma, Follicular; Male; Melphalan; Methotrexate; Podophyllotoxin; Prednisolone; Prednisone; Transplantation Conditioning; Transplantation, Autologous; Vincristine | 1996 |
t(9;13)(q34;q12) chromosomal translocation persisting 4 years post autologous bone marrow transplantation for secondary AML despite morphological remission.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Benzene; Bone Marrow; Bone Marrow Transplantation; Carmustine; Chromosomes, Human, Pair 13; Chromosomes, Human, Pair 9; Combined Modality Therapy; Etoposide; Follow-Up Studies; Humans; Leukemia, Myeloid; Male; Melphalan; Myelodysplastic Syndromes; Neoplastic Stem Cells; Occupational Diseases; Occupational Exposure; Pancytopenia; Remission Induction; Solvents; Translocation, Genetic; Transplantation, Homologous | 1996 |
Improved priming for mobilization of and optimal timing for harvest of peripheral blood stem cells.
Topics: Adolescent; Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Cells; Blood Transfusion, Autologous; Bone Marrow; Carmustine; Cyclophosphamide; Cytarabine; Drug Administration Schedule; Drug Synergism; Epirubicin; Etoposide; Female; Filgrastim; Fluorouracil; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Hematopoietic Stem Cells; Humans; Injections, Subcutaneous; Leukapheresis; Leukocyte Count; Male; Melphalan; Middle Aged; Neoplasms; Recombinant Proteins | 1996 |
Peripheral blood stem cell support does not accelerate haemopoietic recovery from miniBEAM chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Melphalan; Middle Aged | 1996 |
An apoptotic response to photodynamic therapy with endogenous protoporphyrin in vivo.
Topics: Animals; Apoptosis; Carmustine; Colonic Neoplasms; DNA Fragmentation; Doxorubicin; Etoposide; Mice; Paclitaxel; Photochemotherapy; Protoporphyrins | 1996 |
Treatment of relapsed non-Hodgkin's lymphoma after BEAM chemotherapy and autologous transplantation by BU/CY chemotherapy and salvage transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Epirubicin; Etoposide; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Injections, Spinal; Lymphoma, B-Cell, Marginal Zone; Male; Melphalan; Methotrexate; Prednisone; Recurrence; Remission Induction; Retreatment; Salvage Therapy; Stomach Neoplasms; Transplantation Conditioning; Tumor Lysis Syndrome; Vincristine | 1997 |
Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high-risk diffuse large-cell lymphoma.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplantation; Carmustine; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leucovorin; Leukapheresis; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Methotrexate; Middle Aged; Mitoxantrone; Pilot Projects; Prednisone; Risk; Survival Analysis; Transplantation, Autologous; Treatment Outcome; Vincristine | 1997 |
Long-term haematological reconstitution following BEAM and autologous transplantation of circulating progenitor cells in non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Hemoglobins; Humans; Leukocyte Count; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neutrophils; Platelet Count; Transplantation Conditioning | 1997 |
Alternating mini-BEAM/ESHAP as salvage therapy for refractory non-Hodgkin's lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Cytarabine; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Methylprednisolone; Middle Aged; Myeloproliferative Disorders; Neutropenia; Salvage Therapy; Survival Rate; Time Factors | 1997 |
Visual pathway glioma: an erratic tumour with therapeutic dilemmas.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Child, Preschool; Cranial Nerve Neoplasms; Cyclophosphamide; Dactinomycin; Etoposide; Female; Glioma; Humans; Infant; Magnetic Resonance Imaging; Male; Neurofibromatosis 1; Optic Chiasm; Optic Nerve Diseases; Vincristine; Visual Cortex | 1997 |
Sequential intensive treatment with the F-MACHOP regimen (+/- radiotherapy) and autologous stem cell transplantation for primary systemic CD30 (Ki-1)--positive anaplastic large cell lymphoma in adults.
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Etoposide; Female; Fluorouracil; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Large-Cell, Anaplastic; Male; Methotrexate; Middle Aged; Prednisone; Prognosis; Prospective Studies; Remission Induction; Transplantation Conditioning; Transplantation, Autologous; Vincristine | 1997 |
Blast crisis of chronic myelogenous leukemia in long-lasting systemic lupus erythematosus: regression of both diseases after autologous bone marrow transplantation.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; Blast Crisis; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Female; Humans; Idarubicin; Immunologic Factors; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lupus Erythematosus, Systemic; Methotrexate; Prednisone; Remission Induction; Transplantation, Autologous; Vincristine | 1997 |
Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carmustine; Cisplatin; Cyclin-Dependent Kinases; Cytarabine; Doxorubicin; Drug Administration Schedule; Drug Synergism; Etoposide; Flavonoids; Fluorouracil; Humans; Lung Neoplasms; Paclitaxel; Piperidines; Tumor Stem Cell Assay | 1997 |
Salvage chemotherapy with mini-BEAM for relapsed or refractory non-Hodgkin's lymphoma prior to autologous bone marrow transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cytarabine; Etoposide; Humans; Lymphoma, Non-Hodgkin; Melphalan; Middle Aged; Recurrence; Salvage Therapy; Treatment Outcome | 1997 |
BEAM chemotherapy and autologous haemopoietic progenitor cell transplantation as front-line therapy for high-risk patients with diffuse large cell lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Leucovorin; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Methotrexate; Middle Aged; Prednisone; Survival Rate; Treatment Outcome; Vincristine | 1997 |
High-dose chemotherapy for relapsed and refractory diffuse large B-cell lymphoma: mediastinal localization predicts for a favorable outcome.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Humans; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Mediastinal Neoplasms; Middle Aged; Recurrence; Retrospective Studies; Treatment Outcome | 1998 |
[Superhigh-dosage chemotherapy with the transplantation of autologous hemopoietic precursor cells in patients with a prognostically unfavorable relapse and resistant course of lymphogranulomatosis].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Prognosis; Radiotherapy, Adjuvant; Recurrence; Remission Induction; Transplantation, Autologous | 1997 |
BCNU is a caspase-mediated inhibitor of drug-induced apoptosis.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Carmustine; Caspase 3; Caspases; Cysteine Endopeptidases; Dexamethasone; Etoposide; Humans; Lymphoma, B-Cell; Tumor Cells, Cultured | 1998 |
Preclinical evaluation of 9-chloro-2-methylellipticinium acetate alone and in combination with conventional anticancer drugs for the treatment of human brain tumor xenografts.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Carmustine; Chemical and Drug Induced Liver Injury; Cisplatin; Drug Screening Assays, Antitumor; Ellipticines; Etoposide; Feasibility Studies; Female; Glioma; Humans; Injections, Intraperitoneal; Injections, Intravenous; Mice; Mice, Nude; Neoplasm Transplantation; Survival Rate; Transplantation, Heterologous | 1998 |
Systemic chemotherapy alone for patients with non-acquired immunodeficiency syndrome-related central nervous system lymphoma: a pilot study of the BOMES protocol.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neoplasms; Disease Progression; Etoposide; Female; Humans; Lymphoma, AIDS-Related; Male; Methotrexate; Methylprednisolone Hemisuccinate; Middle Aged; Pilot Projects; Prospective Studies; Survival Rate; Treatment Outcome; Vincristine | 1998 |
Autologous stem cell transplantation (ASCT) for poor prognostic Hodgkin's disease (HD): comparative results with two CBV regimens and importance of disease status at transplant.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Cyclophosphamide; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Middle Aged; Prognosis; Survival Rate; Transplantation, Autologous | 1998 |
Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Dexamethasone; Etoposide; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Hodgkin Disease; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Melphalan; Methotrexate; Middle Aged; Mitoguazone; Salvage Therapy; Time Factors | 1998 |
Peripheral blood stem cell transplantation as front-line therapy in patients aged 61 to 65 years: a pilot study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Pilot Projects; Prednisone; Survival Rate; Transplantation, Autologous; Vincristine | 1998 |
High-dose chemotherapy and autologous transplantation in lymphomatous polyposis in second remission: three case reports and literature review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Intestinal Polyps; Lymphoma, B-Cell; Male; Melphalan; Middle Aged; Prednisone; Transplantation, Autologous; Vincristine | 1998 |
Autologous stem-cell transplantation for non-Hodgkin's lymphomas: the role of graft purging and radiotherapy posttransplantation--results of a retrospective analysis on 120 patients autografted in a single institution.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Prognosis; Recurrence; Remission Induction; Retrospective Studies | 1998 |
Autotransplantation for relapsed or refractory Hodgkin's disease: long-term follow-up and analysis of prognostic factors.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Prognosis; Radiotherapy, Adjuvant; Recurrence; Transplantation, Autologous | 1998 |
Mobilizing peripheral blood stem cells with high-dose G-CSF alone is as effective as with Dexa-BEAM plus G-CSF in lymphoma patients.
Topics: Adolescent; Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Colony-Forming Units Assay; Cytarabine; Dexamethasone; Etoposide; Female; Filgrastim; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hospitalization; Humans; Lymphoma; Male; Melphalan; Middle Aged; Recombinant Proteins; Retrospective Studies | 1998 |
Treatment of human B-cell precursor leukemia in SCID mice using a combination of the investigational biotherapeutic agent B43-PAP with cytosine arabinoside.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Doxorubicin; Etoposide; Female; Humans; Immunotoxins; Male; Mice; Mice, SCID; N-Glycosyl Hydrolases; Neoplasm Transplantation; Plant Proteins; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Ribosome Inactivating Proteins, Type 1; Specific Pathogen-Free Organisms; Treatment Outcome | 1996 |
Regimen-related toxicity and non-relapse mortality with high-dose cyclophosphamide, carmustine (BCNU) and etoposide (VP16-213) (CBV) and CBV plus cisplatin (CBVP) followed by autologous stem cell transplantation in patients with Hodgkin's disease.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Cyclophosphamide; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Transplantation Conditioning; Transplantation, Autologous | 1999 |
Sodium and potassium excretion changes and bone marrow recovery after chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carcinoma, Small Cell; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Female; Hodgkin Disease; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Multiple Myeloma; Potassium; Sodium | 1999 |
Dose-intensive chemotherapy for breast cancer with brain metastases: a case series.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Carboplatin; Carmustine; Cisplatin; Cyclophosphamide; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Neoplasm Metastasis; Remission Induction; Survival Analysis; Thiotepa | 1999 |
Safety and efficacy of a continuous infusion, patient controlled anti-emetic pump to facilitate outpatient administration of high-dose chemotherapy.
Topics: Adult; Ambulatory Care; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carmustine; Cyclophosphamide; Cytarabine; Dexamethasone; Diphenhydramine; Etoposide; Evaluation Studies as Topic; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Infusion Pumps; Infusions, Intravenous; Lorazepam; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Nausea; Patient Acceptance of Health Care; Prospective Studies; Safety; Self Care; Thiotepa; Vomiting | 1999 |
Intensified prophylaxis of febrile neutropenia with ofloxacin plus rifampin during severe short-duration neutropenia in patients with lymphoma.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Carmustine; Cyclophosphamide; Etoposide; Female; Fever; Hodgkin Disease; Humans; Length of Stay; Lymphoma; Male; Middle Aged; Neutropenia; Ofloxacin; Opportunistic Infections; Rifampin; Salvage Therapy | 1999 |
Tamoxifen inhibits particulate-associated protein kinase C activity, and sensitises cultured human glioblastoma cells not to etoposide but to gamma-radiation and BCNU.
Topics: Antineoplastic Agents; Carmustine; Cell Division; Drug Synergism; Etoposide; Gamma Rays; Glioblastoma; Humans; Immunohistochemistry; Protein Kinase C; Receptors, Estrogen; Tamoxifen; Transforming Growth Factor beta; Tumor Cells, Cultured | 1999 |
High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Child, Preschool; Chlorambucil; Cohort Studies; Combined Modality Therapy; Cytarabine; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Incidence; Infant; Leukemia, Myeloid; Life Tables; Lomustine; Male; Mechlorethamine; Melphalan; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Podophyllotoxin; Prednisolone; Prednisone; Procarbazine; Retrospective Studies; Risk; Salvage Therapy; Vinblastine; Vincristine | 1999 |
Autologous bone marrow transplantation in non-Hodgkin's lymphoma patients: effect of a brief course of G-CSF on harvest and recovery.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Transplantation Conditioning; Transplantation, Autologous | 1999 |
Rapid regression of chemotherapy refractory lymphocyte predominant Hodgkin's disease after administration of rituximab (anti CD 20 mono- clonal antibody) and interleukin-2.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cyclophosphamide; Cytarabine; Dacarbazine; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Hodgkin Disease; Humans; Idarubicin; Ifosfamide; Immunization, Passive; Interleukin-2; Male; Melphalan; Middle Aged; Prednisone; Procarbazine; Remission Induction; Rituximab; Salvage Therapy; Vinblastine; Vincristine | 1999 |
Hematologic toxic reaction to radiation therapy adjuvant to autologous peripheral blood stem cell transplantation for recurrent or refractory Hodgkin disease.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Disease Progression; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunosuppressive Agents; Male; Middle Aged; Neoplasm Recurrence, Local; Platelet Count; Radiation Injuries; Radiotherapy, Adjuvant; Retrospective Studies; Thrombocytopenia; Transplantation, Autologous | 2000 |
Prognostic factors for the clinical outcome of patients with follicular lymphoma following high-dose therapy and peripheral blood stem cell transplantation (PBSCT).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Follicular; Male; Melphalan; Middle Aged; Prognosis; Recurrence; Transplantation, Autologous | 2000 |
Oxidative burst measurement in patients treated with cytostatics: influence of G-CSF and role as a prognostic factor.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dexamethasone; Escherichia coli; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; N-Formylmethionine Leucyl-Phenylalanine; Prognosis; Respiratory Burst; Tetradecanoylphorbol Acetate | 2000 |
High-dose therapy with hematopoietic cell transplantation for patients with central nervous system involvement by non-Hodgkin's lymphoma.
Topics: Actuarial Analysis; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Carmustine; Central Nervous System; Central Nervous System Neoplasms; Cognition Disorders; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Disease Progression; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Myelitis, Transverse; Neoplasm Invasiveness; Quality of Life; Radiation Injuries; Survival Analysis; Survival Rate; Transplantation Conditioning; Treatment Outcome; Whole-Body Irradiation | 2000 |
Effects of SU101 in combination with cytotoxic agents on the growth of subcutaneous tumor xenografts.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cell Division; Cell Survival; Cisplatin; Etoposide; Glioblastoma; Head and Neck Neoplasms; Humans; Isoxazoles; Leflunomide; Lung Neoplasms; Mice; Mice, Nude; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2000 |
Long-term follow-up of autologous stem-cell transplantation for follicular and transformed follicular lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Carmustine; Cataract; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease Progression; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Infections; Life Tables; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Neoplasms, Radiation-Induced; Neoplasms, Second Primary; Prognosis; Remission Induction; Retrospective Studies; Survival Analysis; Sweden; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Whole-Body Irradiation | 2000 |
Mobilization kinetics of peripheral blood progenitor cells after IAPVP-16 salvage chemotherapy plus G-CSF in lymphoproliferative disorders.
Topics: Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cell Count; Cyclophosphamide; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Kinetics; Leukapheresis; Lymphoma; Lymphoproliferative Disorders; Male; Middle Aged; Regression Analysis; Salvage Therapy; Time Factors | 2000 |
High-dose carmustine, thiotepa and etoposide followed by autologous bone marrow rescue for the treatment of high risk central nervous system tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Central Nervous System Neoplasms; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Combined Modality Therapy; Disease-Free Survival; Etoposide; Female; Graft Survival; Hematologic Diseases; Humans; Infant; Kidney Diseases; Lung Diseases; Male; Middle Aged; Multiple Organ Failure; Nervous System Diseases; Survival Rate; Thiotepa; Transplantation, Autologous; Treatment Outcome | 2000 |
High-dose BEAM chemotherapy with autologous peripheral blood progenitor-cell transplantation for unselected patients with primary refractory or relapsed Hodgkin's disease.
Topics: Adolescent; Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; L-Lactate Dehydrogenase; Male; Melphalan; Middle Aged; Prognosis; Recurrence; Transplantation, Autologous | 2000 |
[The 1st results of the combined therapy of recurrent and refractory forms of lymphogranulomatosis (polychemotherapy, radiation therapy and the removal of the residual mediastinal formation)].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemotherapy, Adjuvant; Cytarabine; Dexamethasone; Etoposide; Female; Hodgkin Disease; Humans; Male; Mediastinal Neoplasms; Melphalan; Middle Aged; Neoplasm, Residual; Prognosis; Radiotherapy, Adjuvant; Recurrence; Salvage Therapy | 2000 |
Patients with mantle-cell lymphoma relapsing after autologous stem cell transplantation may be rescued by allogeneic transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Transplantation Conditioning; Transplantation, Homologous; Whole-Body Irradiation | 2000 |
Feasibility and toxicity of high-dose chemotherapy supported by peripheral blood stem cell transplantation in elderly patients (>/=60 years) with non-Hodgkin's lymphoma: comparison with patients <60 years treated within the same protocol.
Topics: Adolescent; Adult; Age Factors; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Disease Progression; Etoposide; Female; Graft Survival; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Infections; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Podophyllotoxin; Survival Rate; Time Factors; Transplantation Conditioning | 2000 |
Favorable treatment outcome in non-Hodgkin's lymphoma patients with "poor" mobilization of peripheral blood progenitor cells.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; California; Carmustine; Costs and Cost Analysis; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Graft Survival; Health Care Costs; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Remission Induction; Treatment Outcome; Whole-Body Irradiation | 2000 |
An evaluation of the permeability of chemotherapy gloves to three cancer chemotherapy drugs.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Carmustine; Equipment Design; Etoposide; Gloves, Protective; Humans; Latex; Nitriles; Occupational Exposure; Paclitaxel; Permeability; Time Factors | 1999 |
Rescue of haemopoiesis by a combination of growth factors including stem-cell factor.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Carmustine; Cytarabine; Epoetin Alfa; Erythrocyte Transfusion; Erythropoietin; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoiesis; Hematopoietic Cell Growth Factors; Humans; Lymphoma, Non-Hodgkin; Melphalan; Platelet Transfusion; Recombinant Proteins; Treatment Outcome | 2000 |
Recurrent penicillin-resistant pneumococcal sepsis after matched unrelated donor (MUD) transplantation for refractory T cell lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Bone Marrow Transplantation; Carmustine; Cefotaxime; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Cytomegalovirus Infections; Doxorubicin; Drug Therapy, Combination; Etoposide; Humans; Idarubicin; Immunocompromised Host; Immunosuppressive Agents; Levofloxacin; Lymphoma, T-Cell; Male; Melphalan; Ofloxacin; Penicillin Resistance; Pneumococcal Infections; Prednisone; Recurrence; Rifampin; Splenectomy; Streptococcus pneumoniae; Transplantation Conditioning; Vincristine | 2000 |
Acute myeloid leukemia and lung cancer occurring in a chronic lymphocytic leukemia patient treated with fludarabine and autologous peripheral blood stem-cell transplantation.
Topics: Acute Disease; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Fatal Outcome; Genetic Predisposition to Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid; Lung Neoplasms; Male; Middle Aged; Neoplasm, Residual; Neoplasms, Multiple Primary; Neoplasms, Second Primary; Recombinant Proteins; Risk; Smoking; Transplantation Conditioning; Transplantation, Autologous; Vidarabine | 2000 |
[Intramedullary spread of a cerebral oligodendroglioma. Two case reports].
Topics: Abducens Nerve Diseases; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carmustine; Chemotherapy, Adjuvant; Child; Combined Modality Therapy; Etoposide; Fatal Outcome; Female; Frontal Lobe; Humans; Intracranial Hypertension; Magnetic Resonance Imaging; Middle Aged; Neoplasm Invasiveness; Oligodendroglioma; Paralysis; Prognosis; Radiography; Radiotherapy, Adjuvant; Spinal Cord Neoplasms | 2000 |
Complete remission of generalized relapsed extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type of the gastrointestinal tract after high-dose chemotherapy and autologous peripheral stem cell transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Dose-Response Relationship, Drug; Etoposide; Female; Gastrointestinal Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Melphalan; Middle Aged; Remission Induction; Transplantation, Autologous | 2000 |
[Role of high-dose BEAM-chemotherapy and autologous hemopoietic stem cell transplantation in the treatment of drug-resistant Hodgkin disease].
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cytarabine; Dexamethasone; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Retrospective Studies; Risk Factors; Survival Analysis; Transplantation, Autologous; Treatment Outcome | 2000 |
High-dose therapy and autologous hematopoietic-cell transplantation for follicular lymphoma beyond first remission: the Stanford University experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Follicular; Male; Middle Aged; Neural Tube Defects; Prognosis; Recurrence; Remission Induction; Retrospective Studies; Survival Analysis; Transplantation, Autologous; Treatment Outcome; Whole-Body Irradiation | 2001 |
Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV).
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Incidence; Leukemia; Lymphoma, Non-Hodgkin; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Transplantation, Autologous | 2001 |
Shunt-related abdominal metastases in an infant with medulloblastoma: long-term remission by systemic chemotherapy and surgery.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carmustine; Cerebellar Neoplasms; Combined Modality Therapy; Cranial Irradiation; Craniotomy; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Hydrocephalus; Hydroxyurea; Infant; Liver Neoplasms; Magnetic Resonance Imaging; Male; Medulloblastoma; Neoplasm Recurrence, Local; Pelvic Neoplasms; Peritoneal Neoplasms; Remission Induction; Ventriculoperitoneal Shunt | 2001 |
Autologous stem cell transplantation for follicular lymphoma: no benefit for early transplant?
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Dexamethasone; Dose-Response Relationship, Drug; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Follicular; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Survival Analysis; Time Factors; Transplantation, Autologous; Treatment Outcome | 2001 |
Pulmonary toxicity syndrome following CDEP (cyclophosphamide, dexamethasone, etoposide, cisplatin) chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lung Diseases, Fungal; Male; Middle Aged; Multiple Myeloma; Pneumonia, Pneumocystis; Syndrome; Transplantation Conditioning | 2001 |
Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dacarbazine; Dexamethasone; Diagnosis, Differential; Disease-Free Survival; Doxorubicin; Etoposide; False Negative Reactions; False Positive Reactions; Fibrosis; Fluorodeoxyglucose F18; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Life Tables; Mediastinal Neoplasms; Melphalan; Neoplasm Recurrence, Local; Predictive Value of Tests; Prednisone; Procarbazine; Prospective Studies; Radiopharmaceuticals; Radiotherapy, Adjuvant; Remission Induction; Salvage Therapy; Tomography, Emission-Computed; Transplantation, Autologous; Vinblastine; Vincristine | 2001 |
High-dose therapy in patients with Hodgkin's disease: the use of selected CD34(+) cells is as safe as unmanipulated peripheral blood progenitor cells.
Topics: Adolescent; Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Etoposide; Feasibility Studies; Female; Follow-Up Studies; Graft Survival; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Infections; Male; Melphalan; Middle Aged; Neutropenia; Radiotherapy, Adjuvant; Retrospective Studies; Risk; Safety; Salvage Therapy; Survival Analysis; Survival Rate; Transplantation Conditioning; Treatment Outcome | 2001 |
A novel type of metastatically spreading subcutaneous aspergillosis without epidermal lesions following allogeneic stem cell transplantation.
Topics: Adult; Amphotericin B; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Aspergillosis; Bleomycin; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dacarbazine; Deoxycytidine; Dexamethasone; Doxorubicin; Etoposide; Fatal Outcome; Gemcitabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunocompromised Host; Klebsiella Infections; Klebsiella pneumoniae; Lung Diseases, Fungal; Male; Melphalan; Neoplasm Recurrence, Local; Opportunistic Infections; Pneumonia, Bacterial; Pneumonia, Pneumocystis; Prednisone; Procarbazine; Salvage Therapy; Skin; Transplantation, Homologous; Vinblastine; Vincristine | 2001 |
Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Podophyllotoxin; Prognosis; Radiopharmaceuticals; Survival Analysis; Survival Rate; Tomography, Emission-Computed; Transplantation Conditioning; Treatment Outcome; Whole-Body Irradiation | 2002 |
Point mutations of the BCL-6 gene: clinical and prognostic correlation in B-diffuse large cell lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Chromosomes, Human, Pair 3; Cyclophosphamide; Cytarabine; Disease-Free Survival; DNA Mutational Analysis; DNA-Binding Proteins; DNA, Neoplasm; Doxorubicin; Etoposide; Female; Genes, bcl-2; Humans; Life Tables; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Methotrexate; Middle Aged; Neoplasm Proteins; Neoplasm Staging; Point Mutation; Prednisolone; Prednisone; Prognosis; Proto-Oncogene Mas; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-6; Proto-Oncogenes; Transcription Factors; Treatment Outcome; Vincristine | 2002 |
Role of early anthracycline dose-intensity according to expression of Philadelphia chromosome/BCR-ABL rearrangements in B-precursor adult acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Idarubicin; Life Tables; Male; Melphalan; Mercaptopurine; Middle Aged; Neoplasm Proteins; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Remission Induction; Retrospective Studies; Teniposide; Transplantation, Autologous; Treatment Outcome; Vincristine | 2000 |
A case of treatment-related myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemotherapy with autologous stem cell transplantation for non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bone Marrow Cells; Carmustine; Chromosome Aberrations; Chromosomes, Human, Pair 11; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Female; Gene Rearrangement; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Myelodysplastic Syndromes; Neoplasms, Second Primary; Pelvis; Pregnancy; Pregnancy Complications, Neoplastic; Transplantation, Autologous | 2002 |
Acute myocardial ischemia after high-dose therapy with BEAM regimen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease-Free Survival; Etoposide; Female; Humans; Immunoblastic Lymphadenopathy; Melphalan; Middle Aged; Myocardial Ischemia; Peripheral Blood Stem Cell Transplantation; Transplantation, Autologous | 2002 |
The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cyclosporine; Cytarabine; Data Collection; Etoposide; Female; Follow-Up Studies; Graft Enhancement, Immunologic; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Lymphocyte Transfusion; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Remission Induction; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2002 |
Factors influencing outcome and incidence of long-term complications in children who underwent autologous stem cell transplantation for acute myeloid leukemia in first complete remission.
Topics: Adolescent; Amsacrine; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Carmustine; Child; Child, Preschool; Cytarabine; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia, Myeloid, Acute; Male; Neutrophils; Peripheral Blood Stem Cell Transplantation; Recurrence; Remission Induction; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2003 |
High-dose therapy in diffuse large cell lymphoma: results and prognostic factors in 452 patients from the GEL-TAMO Spanish Cooperative Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Cytokines; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; L-Lactate Dehydrogenase; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Podophyllotoxin; Prednisone; Prognosis; Radiotherapy, Adjuvant; Remission Induction; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vincristine | 2003 |
[Foliculitis in a patient with Hodkins disease].
Topics: Adult; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Combined Modality Therapy; Cytarabine; Dacarbazine; Dermatomycoses; Dexamethasone; Doxorubicin; Etoposide; Folliculitis; Hodgkin Disease; Humans; Itraconazole; Malassezia; Male; Melphalan; Opportunistic Infections; Vinblastine | 2003 |
High-dose chemotherapy with autologous stem cell rescue in children with retinoblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carmustine; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Etoposide; Eye Enucleation; Eye Neoplasms; Female; Humans; Male; Recurrence; Retinoblastoma; Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome | 2003 |
BEAM allogeneic transplantation for patients with Hodgkin's disease who relapse after autologous transplantation is safe and effective.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cytarabine; Etoposide; Female; Graft Survival; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Remission Induction; Salvage Therapy; Survival Analysis; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome | 2003 |
Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Child, Preschool; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Drug Evaluation; Etoposide; Female; Humans; Ifosfamide; Life Tables; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Thrombocytopenia; Vincristine | 2003 |
Synergistic augmentation of antimicrotubule agent-induced cytotoxicity by a phosphoinositide 3-kinase inhibitor in human malignant glioma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chromones; Cisplatin; Drug Synergism; Enzyme Inhibitors; Etoposide; Glioma; Humans; Microtubules; Morpholines; Paclitaxel; Phosphoinositide-3 Kinase Inhibitors; Tumor Cells, Cultured; Vincristine | 2003 |
RADIO-COBALT beam therapy.
Topics: Carmustine; Cobalt; Cobalt Radioisotopes; Etoposide; Humans; Neoplasms; Radioactivity | 1953 |
Construction of a dual beam heated infrared cell.
Topics: Carmustine; Etoposide; Melphalan; Spectrophotometry | 1953 |
[Some improvements to our technic of cross beam centering by moulded apparatus].
Topics: Carmustine; Cytarabine; Etoposide; Humans; Melphalan; Radiotherapy | 1953 |
[Utilization of contiguous orthogonal beams in the treatment of semi-deep-seated tumors].
Topics: Carmustine; Etoposide; Humans; Melphalan; Neoplasms | 1953 |
Influence of beam trypsin inhibitors on thromboplastic properties of trypsin and hypochlorite-treated trypsin.
Topics: Carmustine; Etoposide; Hypochlorous Acid; Melphalan; Thromboplastin; Trypsin; Trypsin Inhibitors | 1954 |
Convergent beam roentgen tube.
Topics: Carmustine; Cytarabine; Etoposide; Humans; Melphalan; Radiotherapy | 1955 |
[Determination of the mean guide beam in pendulum radiation].
Topics: Carmustine; Etoposide; Humans; Melphalan; Radiation; Radiotherapy | 1954 |
[The effects of changed spacer tubes of the convergent beam irradiator].
Topics: Carmustine; Etoposide; Humans; Inhalation Spacers; Melphalan; Radiotherapy | 1954 |
An electronic switch for monitoring two physiologic events simultaneously on a single-beam oscilloscope.
Topics: Carmustine; Electronics; Etoposide; Monitoring, Physiologic; Oscillometry; Physiology | 1955 |
Preliminary experiences with a 50 gram converging beam radium unit.
Topics: Carmustine; Cytarabine; Etoposide; Melphalan; Radium | 1955 |
Infrared microspectroscopy. IV. A double-beam infrared microspectrometer.
Topics: Carmustine; Etoposide; Humans; Spectrophotometry | 1955 |
Some measurements of scattered radiation from roentgen diagnostic beams.
Topics: Carmustine; Etoposide; Melphalan; Radiation; X-Rays | 1956 |
[Contribution to the study of convergence beam radiotherapy].
Topics: Carmustine; Etoposide; Humans; Melphalan; Neoplasms; Radiotherapy | 1956 |
[Simple photometric double-beam recording device useful for conventional spectrophotometry].
Topics: Carmustine; Etoposide; Humans; Photometry; Spectrophotometry | 1957 |
Cobalt 60 beam therapy: some impressions after five years.
Topics: Carmustine; Cobalt; Cobalt Radioisotopes; Etoposide; Humans; Melphalan; Neoplasms; Radioactivity | 1957 |
Limitation of the primary beam in chest radiography.
Topics: Carmustine; Etoposide; Humans; Melphalan; Radiography, Thoracic | 1957 |
[Morphological findings after moving beam irradiation of esophagus carcinoma].
Topics: Carcinoma; Carmustine; Esophageal Neoplasms; Etoposide; Humans; Radiotherapy | 1957 |
[Exact focus adjustment in moving-beam irradiation].
Topics: Adaptation, Psychological; Carmustine; Etoposide; Humans; Melphalan; Radiotherapy | 1957 |
[Centering of the beam in pendulum cyclotherapy and in convergent pendulum cyclotherapy].
Topics: Carmustine; Cytarabine; Etoposide; Melphalan; Radiotherapy | 1958 |
The relative biological effectiveness of external beams of ionizing radiations.
Topics: Carmustine; Etoposide; Humans; Melphalan; Radiation Effects; Radiation, Ionizing; Relative Biological Effectiveness | 1958 |
[Stratigraphy with thick and thin layers in various changes of the beam direction].
Topics: Carmustine; Cytarabine; Etoposide; Melphalan; Radiography | 1961 |
Morphological studies on peripheral nerves exposed to a beam of high energy protons.
Topics: Carmustine; Etoposide; Humans; Peripheral Nerves; Protons; Sciatic Nerve | 1962 |
Beam flatteners for a teletherapy unit.
Topics: Carmustine; Cytarabine; Equipment and Supplies; Etoposide; Humans; Melphalan; Radiotherapy | 1961 |
The effect of solid atmospheric pollutants upon the transmission of a collimated beam of infra-red radiation.
Topics: Air Pollution; Carmustine; Etoposide; Radiation | 1961 |
[Isodoses in moving beam therapy].
Topics: Carmustine; Etoposide; Humans; Melphalan; Radiotherapy | 1962 |
Oblique variation of cross-table lateral (horizontal beam) myelography.
Topics: Carmustine; Etoposide; Intervertebral Disc Displacement; Melphalan; Myelography; Spinal Cord | 1962 |
[On pre-irradiation of the parametrium in operable cervical carcinoma with moving beam irradiation].
Topics: Carmustine; Etoposide; Female; Humans; Mesentery; Pelvic Floor; Radiotherapy; Uterine Cervical Neoplasms | 1963 |
A method of multilead D.C. registration on the one-beam oscilloscope by the chopping technique.
Topics: Carmustine; Cytarabine; Etoposide; Humans; Melphalan; Oscillometry | 1961 |
Moving beam irradiation in orthovoltage radiotherapy.
Topics: Carmustine; Cytarabine; Etoposide; Humans; Melphalan; Radiotherapy | 1962 |
Treatment of lymphoma relapses after allogeneic hematopoietic stem cell transplantation with intensive chemotherapy followed by infusion of hematopoietic stem cell from the original donor.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Melphalan; Middle Aged; Neutropenia; Recurrence; Remission Induction; Thrombocytopenia; Tomography, X-Ray Computed; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2003 |
Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neoplasms; Combined Modality Therapy; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Remission Induction; Safety; Salvage Therapy; Survival Rate; Transplantation, Autologous; Treatment Outcome | 2003 |
High-dose therapy and autologous stem cell transplantation in relapsed and refractory Hodgkin's disease: outcome based on a prognostic model.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Dose-Response Relationship, Drug; Etoposide; Female; Hodgkin Disease; Humans; Male; Middle Aged; Models, Statistical; Prognosis; Stem Cell Transplantation; Treatment Outcome | 2003 |
Comparison of BAVC to BuCy regimens in autologous stem cell transplantation for adult patients with acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Drug Combinations; Etoposide; Female; Humans; Leukemia, Erythroblastic, Acute; Leukemia, Megakaryoblastic, Acute; Leukemia, Monocytic, Acute; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Retrospective Studies; Stem Cell Transplantation; Transplantation, Autologous | 2004 |
A new roentgen-ray beam director for precision radiation therapy.
Topics: Carmustine; Etoposide; Melphalan; X-Ray Therapy | 1951 |
Directed beam therapy; a rotational therapy chair.
Topics: Carmustine; Etoposide; Humans; Patient Positioning; Radiotherapy | 1951 |
Hemopoietic recovery and infectious complications in breast cancer and multiple myeloma after autologous CD34+ cell-selected peripheral blood progenitor cell transplantation.
Topics: Adult; Aged; Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Dactinomycin; Etoposide; Female; Follow-Up Studies; Graft Survival; Hematopoiesis; Humans; Idarubicin; Ifosfamide; Infections; Male; Middle Aged; Multiple Myeloma; Neutropenia; Peripheral Blood Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vincristine; Whole-Body Irradiation | 2004 |
Infused CD34 cell dose, but not tumour cell content of peripheral blood progenitor cell grafts, predicts clinical outcome in patients with diffuse large B-cell lymphoma and follicular lymphoma grade 3 treated with high-dose therapy.
Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Etoposide; Female; Graft Survival; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Salvage Therapy; Treatment Outcome | 2004 |
High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Length of Stay; Lymphoma; Male; Melphalan; Middle Aged; Podophyllotoxin; Prognosis; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2004 |
A long-term follow-up of 33 patients with non-Hodgkin's lymphoma who received the BEAM high-dose intensification regimen with cytokine support only and no transplant.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Drug Therapy, Combination; Erythropoietin; Etoposide; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Survival Rate; Time Factors | 2004 |
Four-year survival after trans-jugular intrahepatic porto-systemic shunt for veno-occlusive disease following autologous bone marrow transplantation.
Topics: Adult; Carmustine; Combined Modality Therapy; Cyclophosphamide; Etoposide; Hemodynamics; Hepatic Veno-Occlusive Disease; Humans; Jugular Veins; Lymphoma, Large-Cell, Anaplastic; Male; Peripheral Blood Stem Cell Transplantation; Portasystemic Shunt, Surgical; Remission Induction; Thrombophilia; Transplantation Conditioning; Transplantation, Autologous | 2004 |
Venous thromboembolism after high-dose chemotherapy in a patient with Hodgkin's lymphoma receiving the new oral contraceptive ethinylestradiol and drospirenone ("Yasmine").
Topics: Adult; Androstenes; Angiography; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Contraceptives, Oral, Synthetic; Cytarabine; Etoposide; Female; Hodgkin Disease; Humans; Immunotherapy; International Normalized Ratio; Lynestrenol; Melphalan; Mineralocorticoid Receptor Antagonists; Risk; Risk Factors; Time Factors; Venous Thrombosis; Warfarin | 2005 |
Effect of pre-transplant cumulative doses of chemotherapeutic drugs on early and long-term hematological recovery after autologous bone-marrow transplantation for lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Bone Marrow; Bone Marrow Transplantation; Carmustine; Chemotherapy, Adjuvant; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Lymphoma; Male; Melphalan; Middle Aged; Multivariate Analysis; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous | 2005 |
Combined chemotherapy with carmustine, doxorubicin, etoposide, vincristine, and cyclophosphamide plus mitoxantrone, cytarabine and methotrexate with citrovorum factor for the treatment of aggressive non-Hodgkin lymphoma: a long-term follow-up study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Humans; Leucovorin; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Mitoxantrone; Survival Rate; Vincristine | 2005 |
Immune thrombocytopenia following successful treatment of cancer in children.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Cells; Carmustine; Child, Preschool; Cyclophosphamide; Daunorubicin; Etoposide; Female; Humans; Infant; Male; Neoplasms; Platelet Count; Prednisone; Purpura, Thrombocytopenic, Idiopathic; Vincristine | 2006 |
[Use of dexamethasone in treatment of high- and low-grade non-Hodgkin's lymphoma].
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dexamethasone; Etoposide; Humans; Lymphoma, Non-Hodgkin; Melphalan; Middle Aged; Treatment Outcome | 2004 |
Nephrotic syndrome in patients with peripheral blood stem cell transplant.
Topics: Acute Kidney Injury; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Busulfan; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytomegalovirus Infections; Etoposide; Glomerulonephritis, Membranous; Graft vs Host Disease; Humans; Immunosuppressive Agents; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Multiple Myeloma; Nephrotic Syndrome; Peripheral Blood Stem Cell Transplantation; Postoperative Complications; Prednisone; Rituximab; Sepsis; Staphylococcal Infections; Tacrolimus; Transplantation Conditioning | 2005 |
Mini-BEAM and autologous hematopoietic stem-cell transplant for treatment of post-transplant lymphoproliferative disorders.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppression Therapy; Lymphoproliferative Disorders; Male; Melphalan; Middle Aged; Salvage Therapy; Transplantation, Autologous; Transplants | 2005 |
Prognostic value of the age-adjusted International Prognostic Index in chemosensitive recurrent or refractory non-Hodgkin's lymphomas treated with high-dose BEAM therapy and autologous stem cell transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Medical Oncology; Melphalan; Middle Aged; Prednisolone; Prognosis; Recurrence; Remission Induction; Stem Cell Transplantation; Transplantation, Autologous; Vincristine | 2005 |
Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: a feasible and effective salvage treatment for lymphoid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Epirubicin; Etoposide; Female; Hodgkin Disease; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Mitoxantrone; Multiple Myeloma; Odds Ratio; Peripheral Blood Stem Cell Transplantation; Podophyllotoxin; Recurrence; Remission Induction; Salvage Therapy; Time Factors; Transplantation Conditioning; Treatment Outcome | 2005 |
Very acute cardiac toxicity during BEAC chemotherapy in non-Hodgkin's lymphoma patients undergoing autologous stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular System; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Female; Heart; Humans; Lymphoma, Non-Hodgkin; Magnetic Resonance Imaging; Male; Middle Aged; Natriuretic Peptides; Peptides; Prospective Studies; Stem Cell Transplantation; Time Factors; Transplantation, Autologous; Ventricular Dysfunction, Left; Ventricular Function, Left | 2005 |
Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Cytarabine; Deoxycytidine; Dexamethasone; Disease Progression; Disease-Free Survival; Etoposide; Female; Gemcitabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Prognosis; Recurrence; Retrospective Studies; Salvage Therapy; Treatment Outcome | 2006 |
Comparison of peripheral blood progenitor cell yield from standard chemotherapy used in the treatment of lymphoid malignancies and high-dose cyclophosphamide: a retrospective review of 141 patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Retrospective Studies | 2006 |
Higher incidence of chemotherapy induced oral mucositis in females: a supplement of multivariate analysis to a randomized multicentre study.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Humans; Incidence; Male; Melphalan; Middle Aged; Multicenter Studies as Topic; Multivariate Analysis; Oral Ulcer; Peripheral Blood Stem Cell Transplantation; Predictive Value of Tests; Randomized Controlled Trials as Topic; Risk Factors; Severity of Illness Index; Sex Factors; Stomatitis; Transplantation, Autologous | 2006 |
Dual agent chemoprotection by retroviral co-expression of either MDR1 or MRP1 with the P140K mutant of O6-methylguanine-DNA-methyl transferase.
Topics: 3T3 Cells; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carmustine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Gene Expression; Gene Transfer Techniques; Genes, MDR; Green Fluorescent Proteins; Hematopoietic Stem Cells; Humans; In Vitro Techniques; K562 Cells; Mice; Multidrug Resistance-Associated Proteins; Mutation; O(6)-Methylguanine-DNA Methyltransferase; Retroviridae; Transduction, Genetic | 2006 |
High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cause of Death; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2006 |
Cardiac effects within 3 months of BEAC high-dose therapy in non-Hodgkin's lymphoma patients undergoing autologous stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Atrial Natriuretic Factor; Biomarkers; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Female; Gated Blood-Pool Imaging; Heart; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Peripheral Blood Stem Cell Transplantation; Postoperative Complications; Postoperative Period; Prospective Studies; Protein Precursors; Sensitivity and Specificity; Stroke Volume; Systole; Transplantation, Autologous; Ventricular Dysfunction, Left | 2006 |
Treatment options in relapsed or refractory Hodgkin disease patients: the mini-BEAM regimen does exist too.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Drug Administration Schedule; Etoposide; Hodgkin Disease; Humans; Melphalan; Recurrence; Salvage Therapy | 2006 |
Tandem high-dose chemotherapy and autologous stem cell transplantation in refractory/relapsed Hodgkin's lymphoma: a monocenter prospective study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Deoxycytidine; Disease-Free Survival; Etoposide; Female; Gemcitabine; Hodgkin Disease; Humans; Ifosfamide; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Podophyllotoxin; Prospective Studies; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Rate; Transplantation, Autologous; Vinblastine; Vinorelbine | 2007 |
Autologous peripheral blood stem cell transplantation in multiple myeloma using oral versus I.V. melphalan.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Carmustine; Combined Modality Therapy; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Infusions, Intravenous; Male; Melphalan; Mexico; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Remission Induction; Transplantation, Autologous; Treatment Outcome | 2007 |
Successful treatment of a child with late-onset T-cell post-transplant lymphoproliferative disorder/lymphoma.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biliary Atresia; Carboplatin; Carmustine; Cyclophosphamide; Cytarabine; Disease Progression; Doxorubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Immunocompromised Host; Immunosuppressive Agents; Liver Transplantation; Lymphoma, T-Cell, Peripheral; Lymphoproliferative Disorders; Melphalan; Mesna; Postoperative Complications; Prednisone; Radiotherapy, Adjuvant; Transplantation, Autologous; Vidarabine; Vincristine | 2008 |
Dexa-BEAM as salvage therapy in patients with primary refractory aggressive non-Hodgkin lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Dexamethasone; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Salvage Therapy; Survival Rate; Transplantation, Autologous | 2007 |
Small cell carcinoma of the nasopharynx.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Carmustine; Cisplatin; Cyclophosphamide; Etoposide; Fatal Outcome; Humans; Male; Nasopharyngeal Neoplasms; Radiotherapy, Adjuvant | 2007 |
High-dose therapy and autologous stem cell transplantation for Hodgkin's lymphoma in relapse or failure after initial chemotherapy : results of the Centre National de Greffe de Moelle Osseuse de Tunis.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Cytarabine; Data Interpretation, Statistical; Disease-Free Survival; Drug Resistance, Neoplasm; Etoposide; Follow-Up Studies; Hodgkin Disease; Humans; Melphalan; Neoplasm Staging; Peripheral Blood Stem Cell Transplantation; Recurrence; Remission Induction; Time Factors; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2007 |
Spontaneous pregnancy and normal delivery after repeated autologous bone marrow transplantation and GnRH agonist treatment.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Female; Gonadotropin-Releasing Hormone; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Neoplasm Recurrence, Local; Pregnancy; Pregnancy Complications, Neoplastic | 2007 |
Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC).
Topics: Adult; Aged; Antibodies, Monoclonal; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Data Collection; Disease-Free Survival; Etoposide; Female; France; Graft vs Host Disease; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Proportional Hazards Models; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Survival Rate; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2007 |
Time-dependent effect of non-Hodgkin's lymphoma grade on disease-free survival of relapsed/refractory patients treated with high-dose chemotherapy plus autotransplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Disease-Free Survival; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Models, Statistical; Proportional Hazards Models; Stem Cell Transplantation; Time; Transplantation, Autologous; Treatment Outcome | 2008 |
[Complete remission of relapsed mixed cellularity Hodgkin's disease treated with rituximab].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cyclophosphamide; Cytarabine; Dacarbazine; Dexamethasone; Doxorubicin; Etoposide; Hodgkin Disease; Humans; Lymph Nodes; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Peripheral Blood Stem Cell Transplantation; Prednisone; Procarbazine; Remission Induction; Rituximab; Treatment Outcome; Vinblastine; Vincristine | 2007 |
High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Disease Progression; Etoposide; Female; Humans; Immunoblastic Lymphadenopathy; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Proportional Hazards Models; Remission Induction; Retrospective Studies; Stem Cell Transplantation; Survival Analysis; Transplantation Conditioning; Treatment Outcome | 2008 |
Valproic acid increases the in vitro effects of nitrosureas on human glioma cell lines.
Topics: Acetylation; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Astrocytoma; Carmustine; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Drug Synergism; Etoposide; Glioblastoma; Humans; Mitoxantrone; Valproic Acid | 2007 |
Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy--European Blood and Marrow Transplantation Mucositis Advisory Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cytarabine; Dose-Response Relationship, Drug; Etoposide; Europe; Female; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Lymphoma, Non-Hodgkin; Male; Medical Audit; Melphalan; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Prospective Studies; Research Design; Risk Assessment; Risk Factors; Stomatitis; Transplantation Conditioning; Transplantation, Autologous | 2008 |
High-dose chemotherapy with autologous stem cell transplantation in adults with recurrent embryonal tumors of the central nervous system.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neoplasms; Cisplatin; Cohort Studies; Disease Progression; Etoposide; Female; Follow-Up Studies; Humans; Lomustine; Male; Medulloblastoma; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Procarbazine; Retrospective Studies; Stem Cell Transplantation; Survival Rate; Thiotepa; Transplantation, Autologous | 2008 |
Transient global amnesia associated with the infusion of DMSO-cryopreserved autologous peripheral blood stem cells.
Topics: Adult; Alkalosis, Respiratory; Amnesia, Retrograde; Amnesia, Transient Global; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Combined Modality Therapy; Confusion; Cryoprotective Agents; Cytarabine; Dacarbazine; Dexamethasone; Dimethyl Sulfoxide; Doxorubicin; Etoposide; Hippocampus; Hodgkin Disease; Humans; Hyperventilation; Ifosfamide; Magnetic Resonance Imaging; Male; Melphalan; Paresthesia; Peripheral Blood Stem Cell Transplantation; Salvage Therapy; Vinblastine; Vision Disorders | 2008 |
Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma.
Topics: Acute Disease; Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Lymphoma, Follicular; Male; Melphalan; Middle Aged; Retrospective Studies; Transplantation Chimera; Transplantation Conditioning; Treatment Outcome | 2008 |
Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Disease Progression; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Multivariate Analysis; Myelodysplastic Syndromes; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Time Factors; Transplantation, Autologous; Treatment Outcome | 2008 |
Intracavitary chemotherapy (Gliadel) and oral low-dose etoposide for recurrent anaplastic ependymoma.
Topics: Adolescent; Antineoplastic Agents, Phytogenic; Biocompatible Materials; Brain; Brain Neoplasms; Carmustine; Child; Decanoic Acids; Ependymoma; Etoposide; Female; Humans; Magnetic Resonance Imaging; Male; Polyesters; Radiotherapy; Recurrence | 2008 |
Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carmustine; Chi-Square Distribution; Cohort Studies; Cytarabine; Drug Administration Schedule; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Length of Stay; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Mucositis; Recurrence; Risk; Statistics, Nonparametric; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2008 |
The Prospective Oral Mucositis Audit: relationship of severe oral mucositis with clinical and medical resource use outcomes in patients receiving high-dose melphalan or BEAM-conditioning chemotherapy and autologous SCT.
Topics: Adult; Aged; Analgesics, Opioid; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Humans; Length of Stay; Lymphoma, Non-Hodgkin; Male; Medical Audit; Melphalan; Middle Aged; Multiple Myeloma; Prospective Studies; Risk Factors; Stem Cell Transplantation; Stomatitis; Transplantation Conditioning | 2009 |
Increased risk for invasive aspergillosis in patients with lymphoproliferative diseases after autologous hematopoietic SCT.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Aspergillosis; Carmustine; Cyclophosphamide; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Lymphoproliferative Disorders; Male; Melphalan; Middle Aged; Neutropenia; Prospective Studies; Risk Factors; Rituximab; Vidarabine; Young Adult | 2009 |
Myeloablative chemotherapy with autologous bone marrow rescue in children and adolescents with recurrent malignant astrocytoma: outcome compared with conventional chemotherapy: a report from the Children's Oncology Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Bone Marrow Transplantation; Brain Neoplasms; Carboplatin; Carmustine; Child; Child, Preschool; Combined Modality Therapy; Cranial Irradiation; Disease Progression; Etoposide; Female; Humans; Infant; Male; Myeloablative Agonists; Neoplasm Recurrence, Local; Prognosis; Salvage Therapy; Thiotepa; Transplantation, Autologous | 2008 |
The development of a beam-walking test and its use in measuring development of balance in children.
Topics: Carmustine; Child; Cytarabine; Etoposide; Growth and Development; Melphalan; Walking | 1947 |
High-dose chemotherapy with BEAM or Busulphan/Melphalan and Thiotepa followed by hematopoietic cell transplantation in malignant lymphoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cytarabine; Drug Evaluation; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Retrospective Studies; Thiotepa; Transplantation, Autologous | 2008 |
Pseudo-bowel obstruction due to varicella zoster virus infection after autologous stem cell transplantation.
Topics: Acyclovir; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Carmustine; Cisplatin; Colitis; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Hematopoietic Stem Cell Transplantation; Herpes Zoster; Herpesvirus 3, Human; Humans; Immunocompromised Host; Immunoglobulins, Intravenous; Intestinal Pseudo-Obstruction; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Postoperative Complications; Prednisolone; Rituximab; Transplantation, Autologous; Vincristine; Virus Activation | 2009 |
delta-Aminolevulinate dehydratase activity and oxidative stress during melphalan and cyclophosphamide-BCNU-etoposide (CBV) conditioning regimens in autologous bone marrow transplantation patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Ascorbic Acid; Biomarkers; Bone Marrow Transplantation; Carmustine; Case-Control Studies; Cyclophosphamide; Etoposide; Humans; Lipid Peroxidation; Male; Melphalan; Middle Aged; Oxidative Stress; Porphobilinogen Synthase; Reactive Oxygen Species; Sulfhydryl Compounds; Transplantation Conditioning; Transplantation, Autologous | 2009 |
Self-reported experience of mucositis in cancer patients who underwent conditioning regimen and stem cell transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Mucositis; Multiple Myeloma; Neoplasms; Severity of Illness Index; Whole-Body Irradiation; Young Adult | 2009 |
Incidence and risk factors for second cancers after autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Lymphoma, Non-Hodgkin; Melphalan; Middle Aged; Neoplasms, Second Primary; Retrospective Studies; Risk Factors; Salvage Therapy; Transplantation, Autologous; Whole-Body Irradiation; Young Adult | 2009 |
Autologous stem cell transplantation for Hodgkin's lymphoma: results and prognostic factors in 51 high-risk patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Italy; Lymph Nodes; Male; Melphalan; Middle Aged; Prognosis; Remission Induction; Survival Rate; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult | 2002 |
Autologous stem cell transplant in a patient with Down syndrome and relapsed Hodgkin lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Child; Combined Modality Therapy; Cyclophosphamide; Down Syndrome; Doxorubicin; Etoposide; Granulocyte Colony-Stimulating Factor; Hodgkin Disease; Humans; Ifosfamide; Male; Mesna; Peripheral Blood Stem Cell Transplantation; Prednisone; Procarbazine; Recurrence; Remission Induction; Transplantation Conditioning; Transplantation, Autologous; Vinblastine; Vincristine; Vinorelbine | 2009 |
Palonosetron in prevention of nausea and vomiting after highly emetogenic chemotherapy before haematopoietic stem cell transplantation-single center experience.
Topics: Antineoplastic Agents; Carmustine; Emetics; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Isoquinolines; Lymphoma; Nausea; Ondansetron; Palonosetron; Quinuclidines; Serotonin Antagonists; Treatment Outcome; Vomiting | 2009 |
The combination of thalidomide, cyclophosphamide and dexamethasone is potentially useful in highly resistant Hodgkin's lymphoma.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dacarbazine; Deoxycytidine; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Hodgkin Disease; Humans; Male; Mechlorethamine; Melphalan; Organoplatinum Compounds; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Prednisolone; Prednisone; Procarbazine; Remission Induction; Rituximab; Salvage Therapy; Thalidomide; Topotecan; Transplantation, Autologous; Vidarabine; Vinblastine; Vincristine | 2010 |
Repeated spontaneous pregnancies and successful deliveries after repeated autologous stem cell transplantation and GnRH-agonist treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Female; Gonadotropin-Releasing Hormone; Humans; Lymphoma, Large B-Cell, Diffuse; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Transplantation, Autologous | 2010 |
Total body irradiation compared with BEAM: Long-term outcomes of peripheral blood autologous stem cell transplantation for non-Hodgkin's lymphoma.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Disease-Free Survival; Dose Fractionation, Radiation; Drug Resistance, Neoplasm; Etoposide; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Lymphoma, Non-Hodgkin; Male; Manitoba; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Radiation Pneumonitis; Retrospective Studies; Survival Rate; Time Factors; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Whole-Body Irradiation; Young Adult | 2010 |
Absorption measurements for broad beams of 1 and 2 megavolt roentgen rays.
Topics: Carmustine; Etoposide; Melphalan; Radiation; X-Rays | 1946 |
A double-beam, percent transmission recording infra-red spectrophotometer.
Topics: Carmustine; Etoposide; Humans; Melphalan; Spectrophotometry | 1947 |
High-dose immunoablation with autologous haematopoietic stem cell transplantation in aggressive multiple sclerosis: a single centre 10-year experience.
Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppression Therapy; Kaplan-Meier Estimate; Male; Melphalan; Multiple Sclerosis; Treatment Outcome | 2010 |
JAAD grand rounds quiz*: Dusky intertriginous plaques and acral erythema after bone marrow transplant.
Topics: Adult; Antineoplastic Agents; Bone Marrow Transplantation; Carmustine; Cyclophosphamide; Erythema; Etoposide; Female; Hodgkin Disease; Humans; Postoperative Complications | 2010 |
Simultaneous bilateral spontaneous pneumothorax following high-dose chemotherapy and bone marrow transplantation for mantle cell lymphoma without evidence of pulmonary disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Female; Humans; Lung Diseases; Lymphoma, Mantle-Cell; Melphalan; Middle Aged; Pneumothorax; Prognosis | 2010 |
Absorption measurements for broad beams of 1- and 2-million-volt X-rays.
Topics: Carmustine; Cytarabine; Etoposide; Melphalan; X-Rays | 1946 |
Pro-apoptotic role of integrin β3 in glioma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Carmustine; Cell Line, Tumor; Drug Interactions; Enzyme Inhibitors; Etoposide; Flow Cytometry; Free Radical Scavengers; Gene Expression Regulation, Neoplastic; Glioma; Humans; Integrin beta3; Nitric Oxide; Rats; RNA, Messenger; Signal Transduction; Statistics as Topic; Tetrazolium Salts; Thiazoles; Vitronectin | 2011 |
Mathematical modeling to distinguish cell cycle arrest and cell killing in chemotherapeutic concentration response curves.
Topics: Antineoplastic Agents; Apoptosis; Carmustine; Cell Cycle; Cell Line, Tumor; Drug Resistance, Neoplasm; Etoposide; Humans; Models, Biological | 2011 |
Extended retreatment with brentuximab vedotin (SGN-35) maintains complete remission in patient with recurrent systemic anaplastic large-cell lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brentuximab Vedotin; Carmustine; Clinical Trials, Phase I as Topic; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Humans; Immunoconjugates; Lymphoma, Large-Cell, Anaplastic; Maintenance Chemotherapy; Male; Melphalan; Prednisone; Remission Induction; Stem Cell Transplantation; Transplantation, Autologous; Vincristine | 2012 |
[Pulmonary Langerhans histiocytosis and Hodgkin's lymphoma].
Topics: Accidents, Traffic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bronchioles; Carmustine; Cytarabine; Dacarbazine; Doxorubicin; Etoposide; Female; Histiocytosis, Langerhans-Cell; Hodgkin Disease; Humans; Ifosfamide; Incidental Findings; Lung Diseases; Lymphatic Diseases; Marijuana Smoking; Melphalan; Methylprednisolone; Mitoguazone; Remission Induction; Smoking; Tomography, X-Ray Computed; Vinblastine; Vindesine; Vinorelbine; Young Adult | 2011 |
Acquired STAT4 deficiency as a consequence of cancer chemotherapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Boronic Acids; Bortezomib; Carmustine; Cells, Cultured; Drug Interactions; Etoposide; Flow Cytometry; Gene Expression; Humans; Interleukin-12; Interleukin-2; Leukocytes, Mononuclear; Lymphoma; Melanoma; Mice; Mice, Inbred C57BL; Protein Biosynthesis; Pyrazines; RNA Stability; Skin Neoplasms; STAT4 Transcription Factor; Ubiquitin | 2011 |
Risk factors for development of pneumonitis after high-dose chemotherapy with cyclophosphamide, BCNU and etoposide followed by autologous stem cell transplant.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Lymphoma; Male; Mediastinum; Middle Aged; Pneumonia; Radiation, Ionizing; Retrospective Studies; Risk Factors; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous; Young Adult | 2012 |
Second-line salvage chemotherapy for transplant-eligible patients with Hodgkin's lymphoma resistant to platinum-containing first-line salvage chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Prospective Studies; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Rate; Transplantation, Autologous; Young Adult | 2012 |
BCNU-associated pneumonitis: portrait of a toxicity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Etoposide; Female; Humans; Lymphoma; Male; Pneumonia; Stem Cell Transplantation | 2012 |
Improving survival in patients with transformed B cell non Hodgkin lymphoma: consolidation with ⁹⁰Yttrium ibritumomab tiuxetan-BEAM and autologous stem cell transplantation.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, B-Cell; Melphalan; Radioimmunotherapy; Treatment Outcome; Yttrium Radioisotopes | 2012 |
Mini-BEAM is effective as a bridge to transplantation in patients with refractory or relapsed Hodgkin lymphoma who have failed to respond to previous lines of salvage chemotherapy but not in patients with salvage-refractory DLBCL.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Recurrence; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Treatment Outcome; Young Adult | 2012 |
[Lenalidomide induced therapeutic response in a patient with aggressive multi-system Langerhans cell histiocytosis resistant to 2-chloro-deoxyadenosine and early relapsing after high-dose BEAM chemotherapy with autologous peripheral blood stem cell transp
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cladribine; Combined Modality Therapy; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Histiocytosis, Langerhans-Cell; Humans; Lenalidomide; Male; Melphalan; Peripheral Blood Stem Cell Transplantation; Recurrence; Remission Induction; Thalidomide; Transplantation, Autologous | 2012 |
[First case in Spain of bacteremia by Methylobacterium thiocyanatum from Hickmann catheter in an immunosuppressed patient with Hodgkin's lymphoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Biofilms; Bleomycin; Carmustine; Catheter-Related Infections; Central Venous Catheters; Cisplatin; Cross Infection; Cytarabine; Dacarbazine; Deoxycytidine; Doxorubicin; Drug Resistance, Multiple, Bacterial; Equipment Contamination; Etoposide; Female; Gemcitabine; Gram-Negative Bacterial Infections; Hodgkin Disease; Humans; Immunocompromised Host; Melphalan; Methylobacterium; Prednisone; Ribotyping; Spain; Vinblastine | 2012 |
Esophageal lesions in myeloproliferative neoplasms.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Esophageal Neoplasms; Etoposide; Humans; Male; Myeloproliferative Disorders; Prednisolone; Ulcer | 2012 |
Use of targeted therapy for refractory ALK-positive anaplastic large cell lymphoma as a bridging strategy prior to allogeneic transplantation.
Topics: Adult; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Brentuximab Vedotin; Carmustine; Cisplatin; Combined Modality Therapy; Compassionate Use Trials; Crizotinib; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Humans; Immunoconjugates; Lymphocyte Transfusion; Lymphoma, Large-Cell, Anaplastic; Male; Melphalan; Molecular Targeted Therapy; Neoplasm Proteins; Peripheral Blood Stem Cell Transplantation; Prednisone; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Receptor Protein-Tyrosine Kinases; Remission Induction; Respiration, Artificial; Respiratory Insufficiency; Transplantation, Homologous; Vincristine | 2013 |
Myeloablative chemotherapy for chemo-sensitive recurrent follicular lymphoma: potential benefit in second relapse.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; In Situ Hybridization; Kaplan-Meier Estimate; Lymphoma, Follicular; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Prognosis; Remission Induction; Time Factors; Transplantation, Autologous; Treatment Outcome | 2013 |
Acute kidney injury requiring dialysis following carmustine and etoposide during autologous stem cell transplantation.
Topics: Acute Kidney Injury; Aged; Antiemetics; Carmustine; Creatinine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Male; Renal Dialysis; Transplantation Conditioning; Transplantation, Autologous; Urinalysis | 2012 |
Primary central nervous system diffuse large B cell lymphoma transformed from orbital mucosa-associated lymphoid tissue lymphoma: complete response to combined intrathecal and systemic rituximab.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clarithromycin; Cranial Irradiation; Cyclophosphamide; Disease Progression; Etoposide; Humans; Immunophenotyping; Immunosuppressive Agents; Injections, Spinal; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Male; Meningeal Neoplasms; Methotrexate; Methylprednisolone Hemisuccinate; Orbital Neoplasms; Prednisolone; Remission Induction; Rituximab; Vincristine | 2013 |
DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: a retrospective evaluation of parallel patient cohorts of one center.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carmustine; Combined Modality Therapy; Cytarabine; Dexamethasone; Disease-Free Survival; Drug Evaluation; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Hematopoietic Stem Cell Mobilization; Humans; Ifosfamide; Kaplan-Meier Estimate; Lymphoma, T-Cell, Peripheral; Male; Melphalan; Middle Aged; Mucositis; Peripheral Blood Stem Cell Transplantation; Preoperative Care; Retrospective Studies; Salvage Therapy; Transplantation, Autologous; Treatment Outcome; Young Adult | 2013 |
Contribution of involved-field radiotherapy to survival in patients with relapsed or refractory Hodgkin lymphoma undergoing autologous stem cell transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Carmustine; Chemoradiotherapy; Cisplatin; Cohort Studies; Cytarabine; Dacarbazine; Dexamethasone; Doxorubicin; Etoposide; Female; Hodgkin Disease; Humans; Ifosfamide; Male; Mediastinal Neoplasms; Melphalan; Methylprednisolone; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Retrospective Studies; Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome; Vinblastine; Young Adult | 2015 |
Prognostic factors and long-term outcome of autologous haematopoietic stem cell transplantation following a uniform-modified BEAM-conditioning regimen for patients with refractory or relapsed Hodgkin lymphoma: a single-center experience.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Risk Factors; Transplantation, Autologous; Young Adult | 2013 |
Impact of conditioning regimen on outcome of 2-year disease-free survivors of autologous stem cell transplantation for Hodgkin lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Prognosis; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult | 2013 |
Allogeneic stem cell transplantation with BEAM and alemtuzumab conditioning immediately after remission induction has curative potential in advanced T-cell non-Hodgkin's lymphoma.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, T-Cell; Male; Melphalan; Middle Aged; Remission Induction; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous | 2013 |
Impact of palifermin on intestinal mucositis of HSCT recipients after BEAM.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; C-Reactive Protein; Carmustine; Case-Control Studies; Cytarabine; Etoposide; Febrile Neutropenia; Female; Fibroblast Growth Factor 7; Hematopoietic Stem Cell Transplantation; Humans; Inflammation; Intestinal Mucosa; Male; Melphalan; Middle Aged; Mucositis; Neutropenia; Young Adult | 2014 |
Seven-year follow-up of allogeneic transplant using BCNU, etoposide, cytarabine and melphalan chemotherapy in patients with Hodgkin lymphoma after autograft failure: importance of minimal residual disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease Progression; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Neoplasm Recurrence, Local; Neoplasm, Residual; Prognosis; Transplantation, Autologous; Transplantation, Homologous; Treatment Failure; Treatment Outcome | 2014 |
Conditioning regimen with BCNU, etoposide, cytarabine and melphalan plus amifostine for outpatient autologous stem cell transplant: feasibility and outcome in 97 patients with lymphoma.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Melphalan; Outpatients; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2014 |
Busulfan-containing conditioning regimens are optimal preparative regimens for autologous stem cell transplant in patients with diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Busulfan; Carmustine; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Remission Induction; Retrospective Studies; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult | 2014 |
Autologous stem cell transplantation for follicular lymphoma is of most benefit early in the disease course and can result in durable remissions, irrespective of prior rituximab exposure.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Follicular; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Rituximab; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2014 |
The lymphoma-like polychemotherapy regimen "Dexa-BEAM" in advanced and extramedullary multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dexamethasone; Disease-Free Survival; Drug Therapy, Combination; Etoposide; Female; Follow-Up Studies; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Registries; Retrospective Studies | 2014 |
Radium beam therapy.
Topics: Carmustine; Etoposide; Humans; Melphalan; Neoplasms; Radium | 1951 |
Radium beam therapy at the Western Infirmary of Glasgow, 1938-48.
Topics: Carmustine; Etoposide; Humans; Melphalan; Neoplasms; Radium | 1951 |
Cobalt 60 beam therapy.
Topics: Carmustine; Cobalt; Cobalt Radioisotopes; Etoposide; Melphalan; Radioactivity; Radiotherapy | 1954 |
Treatment of high-risk aggressive B-cell non-Hodgkin lymphomas with rituximab, intensive induction and high-dose consolidation: long-term analysis of the R-MegaCHOP-ESHAP-BEAM Trial.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Consolidation Chemotherapy; Cyclophosphamide; Cytarabine; Disease Progression; Doxorubicin; Etoposide; Female; Humans; Induction Chemotherapy; Lymphoma, B-Cell; Male; Melphalan; Methylprednisolone; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Podophyllotoxin; Prednisone; Prognosis; Rituximab; Treatment Outcome; Vincristine; Young Adult | 2015 |
Treatment outcome in children and adolescents with relapsed Hodgkin lymphoma--results of the UK HD3 relapse treatment strategy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Child; Chlorambucil; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dacarbazine; Dexamethasone; Disease-Free Survival; Doxorubicin; Epirubicin; Etoposide; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Ifosfamide; Kaplan-Meier Estimate; Melphalan; Multicenter Studies as Topic; Neoplasm Staging; Prednisolone; Prednisone; Procarbazine; Prognosis; Radiotherapy, Adjuvant; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Treatment Outcome; Vinblastine; Vincristine | 2014 |
ESHAP as salvage therapy for relapsed or refractory Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Cisplatin; Combined Modality Therapy; Cytarabine; Drug Evaluation; Etoposide; Febrile Neutropenia; Female; Follow-Up Studies; Hematopoietic Stem Cell Mobilization; Hodgkin Disease; Humans; Kaplan-Meier Estimate; Male; Melphalan; Methylprednisolone; Middle Aged; Radionuclide Imaging; Retrospective Studies; Salvage Therapy; Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome; Young Adult | 2014 |
BEAM-conditioned autologous SCT improves the quality of response in Waldenström's macroglobulinaemia and lymphoplasmacytic lymphoma: a single centre's 10-year experience.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Humans; Lymphoma; Male; Melphalan; Middle Aged; Stem Cell Transplantation; Survival Analysis; Transplantation, Autologous; Waldenstrom Macroglobulinemia | 2014 |
Sixteenth biannual report of the Cochrane Haematological Malignancies Group: focus on Non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Carmustine; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Etoposide; Hematologic Neoplasms; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Melphalan; Nitriles; Nitrogen Mustard Compounds; Prednisone; Primary Myelofibrosis; Pyrazines; Pyrazoles; Pyrimidines; Quality of Life; Randomized Controlled Trials as Topic; Rituximab; Vincristine | 2014 |
[Prognostic impact of anthracyclines in the treatment of aggressive lymphoma in patients over 70 years].
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Etoposide; Female; Humans; Kaplan-Meier Estimate; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Methotrexate; Prednisone; Prognosis; Proportional Hazards Models; Retrospective Studies; Rituximab; Treatment Outcome; Vincristine | 2015 |
Risk of premature menopause after treatment for Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Child; Child, Preschool; Cytarabine; Dacarbazine; Doxorubicin; England; Etoposide; Female; Follow-Up Studies; Hodgkin Disease; Humans; Infant; Melphalan; Menopause, Premature; Ovary; Poisson Distribution; Proportional Hazards Models; Radiotherapy Dosage; Risk Assessment; Surveys and Questionnaires; Vinblastine; Wales; Young Adult | 2014 |
Impressive response to pegylated liposomal doxorubicin after allogeneic transplantation in a multi-relapsed Hodgkin's lymphoma.
Topics: Allografts; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Brentuximab Vedotin; Carmustine; Combined Modality Therapy; Cytarabine; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunoconjugates; Lenalidomide; Liposomes; Male; Melphalan; Polyethylene Glycols; Recurrence; Remission Induction; Salvage Therapy; Thalidomide; Transplantation, Autologous; Young Adult | 2016 |
Improved outcomes after autologous bone marrow transplantation for children with relapsed or refractory Hodgkin lymphoma: twenty years experience at a single institution.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Carmustine; Child; Cyclophosphamide; Etoposide; Female; Gamma Rays; Graft vs Host Disease; Hodgkin Disease; Humans; Male; Myeloablative Agonists; Neoplasm Recurrence, Local; Recurrence; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2015 |
High-dose chemotherapy with carmustine, etoposide, cytarabine and melphalan followed by autologous stem cell transplant is an effective treatment for elderly patients with poor-prognosis lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease Progression; Etoposide; Female; France; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Melphalan; Prognosis; Recurrence; Retrospective Studies; Survival Analysis; Transplantation, Autologous; Treatment Outcome | 2015 |
Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Busulfan; Carmustine; Cyclophosphamide; Cytarabine; Drug Administration Schedule; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Myeloablative Agonists; Registries; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Whole-Body Irradiation | 2015 |
Autologous Stem-Cell Transplantation Without Hematopoietic Support for the Treatment of Hematologic Malignancies in Jehovah's Witnesses.
Topics: Adult; Aged; Aminocaproic Acid; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Carmustine; Combined Modality Therapy; Cyclophosphamide; Erythropoietin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Hemoglobins; Humans; Iron; Jehovah's Witnesses; Lymphoma; Male; Melphalan; Middle Aged; Multiple Myeloma; Recurrence; Stem Cell Transplantation; Transplantation, Autologous; Vitamin K 1; Young Adult | 2015 |
Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk Patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Cytarabine; Etoposide; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Recurrence; Retrospective Studies; Risk; Rituximab; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous | 2015 |
BEAM Conditioning Regimen Has Higher Toxicity Compared With High-Dose Melphalan for Salvage Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous | 2015 |
Etoposide pharmacokinetics impact the outcomes of lymphoma patients treated with BEAM regimen and ASCT: a multicenter study of the LYmphoma Study Association (LYSA).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bilirubin; Carmustine; Creatinine; Cytarabine; Disease-Free Survival; Etoposide; Female; Hodgkin Disease; Humans; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Prognosis; Proportional Hazards Models; Prospective Studies; Risk Assessment; Serum Albumin; Transplantation, Autologous; Treatment Outcome; Young Adult | 2015 |
LACE versus BEAM conditioning in relapsed and refractory lymphoma transplant: retrospective multicenter analysis of toxicity and efficacy.
Topics: Adolescent; Adult; Autografts; Carmustine; Child; Child, Preschool; Cohort Studies; Cyclophosphamide; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lomustine; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Multicenter Studies as Topic; Retrospective Studies; Survival Rate; Transplantation Conditioning; Young Adult | 2016 |
Alemtuzumab-BEAM as conditioning for allogeneic hematopoietic stem cell transplantation in relapsed/refractory Hodgkin lymphoma: a single-center analysis.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Graft vs Host Disease; Hodgkin Disease; Humans; Male; Melphalan; Recurrence; Transplantation Conditioning; Young Adult | 2016 |
Long-term follow-up of (90)Y-ibritumomab-tiuxetan ((90)YIT) in the conditioning of autologous hematopoietic transplantation for indolent and mantle cell lymphomas in a single French center.
Topics: Adult; Aged; Antibodies, Monoclonal; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Follow-Up Studies; France; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Radioimmunotherapy; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Yttrium Radioisotopes | 2016 |
A retrospective comparison of toxicity and initial efficacy of two autologous stem cell transplant conditioning regimens for relapsed lymphoma: LEAM and BEAM.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lomustine; Lymphoma; Male; Melphalan; Middle Aged; Retrospective Studies; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous | 2016 |
Cryptococcus laurentii diarrhea post hematopoietic stem cell transplant.
Topics: Administration, Intravenous; Administration, Oral; Adult; Antibiotic Prophylaxis; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; Carmustine; Cryptococcosis; Cryptococcus; Cytarabine; Diarrhea; Etoposide; Feces; Fluconazole; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Melphalan; Microbial Sensitivity Tests; Transplantation Conditioning; Transplantation, Autologous; Voriconazole | 2017 |
Radioimmunotherapy-augmented BEAM chemotherapy vs BEAM alone as the high-dose regimen for autologous stem cell transplantation (ASCT) in relapsed follicular lymphoma (FL): a retrospective study of the EBMT Lymphoma Working Party.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Case-Control Studies; Combined Modality Therapy; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Follicular; Male; Melphalan; Middle Aged; Radioimmunotherapy; Retrospective Studies; Rituximab; Survival Analysis; Transplantation, Autologous; Young Adult | 2017 |
Total Body Irradiation Is Safe and Similarly Effective as Chemotherapy-Only Conditioning in Autologous Stem Cell Transplantation for Mantle Cell Lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Whole-Body Irradiation | 2018 |
A retrospective, matched paired analysis comparing bendamustine containing BeEAM versus BEAM conditioning regimen: results from a single center experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Carmustine; Case-Control Studies; Cytarabine; Diarrhea; Disease-Free Survival; Drug Resistance, Neoplasm; Etoposide; Female; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous; Young Adult | 2018 |
Abdominal computed tomography angiography in post-transplantation sinusoidal obstruction syndrome associated with R-DHAOX/BEAM toxicity.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Computed Tomography Angiography; Cytarabine; Dexamethasone; Etoposide; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Lymphoma, Mantle-Cell; Male; Melphalan; Organoplatinum Compounds; Syndrome | 2018 |
Outcomes of DA-EPOCH-R induction plus autologous transplant consolidation for double hit lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Etoposide; Gene Rearrangement; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Large B-Cell, Diffuse; Melphalan; Middle Aged; Prednisone; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Rituximab; Transplantation, Autologous; Treatment Outcome; Vincristine | 2018 |
Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Carmustine; Cost-Benefit Analysis; Cyclophosphamide; Cytarabine; Etoposide; Female; HIV Infections; Humans; Ifosfamide; Male; Melphalan; Methotrexate; Middle Aged; Neoplasm Staging; Retrospective Studies; Rituximab; Survival Analysis | 2018 |
BEAM vs FEAM high-dose chemotherapy: retrospective study in lymphoma patients undergoing autologous stem cell transplant.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous; Young Adult | 2018 |
Survival analysis of patients with Hodgkin lymphoma who failed high dose chemotherapy and autologous stem cell transplant.
Topics: Adolescent; Adult; Allografts; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brentuximab Vedotin; Carmustine; Cisplatin; Combined Modality Therapy; Cytarabine; Dacarbazine; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunoconjugates; Kaplan-Meier Estimate; Male; Melphalan; Methylprednisolone; Middle Aged; Proportional Hazards Models; Remission Induction; Retrospective Studies; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous; Vinblastine; Young Adult | 2018 |
High-dose Bendamustine-EAM followed by autologous stem cell rescue results in long-term remission rates in lymphoma patients, without renal toxicity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Melphalan; Middle Aged; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult | 2018 |
A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cohort Studies; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Italy; Lymphoma; Male; Melphalan; Middle Aged; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous | 2018 |
High-dose Benda-EAM versus BEAM in patients with relapsed/refractory classical Hodgkin lymphoma undergoing autologous stem cell transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Recurrence; Transplantation Conditioning; Transplantation, Autologous; Young Adult | 2019 |
BEAC (carmustine, etoposide, cytarabine, and cyclophosphamide) in autologous hematopoietic cell transplantation: a safe and effective alternative conditioning regimen for Hodgkin and non-Hodgkin lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous | 2019 |
Nasoethmoidal Intestinal-Type Adenocarcinoma Treated with Cetuximab: Role of Liquid Biopsy and BEAMing in Predicting Response to Anti-Epidermal Growth Factor Receptor Therapy.
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cetuximab; Cytarabine; ErbB Receptors; Etoposide; Genotype; Humans; Intestinal Neoplasms; Liquid Biopsy; Male; Melphalan; Paranasal Sinus Neoplasms | 2019 |
BEAM versus BUCYVP16 Conditioning before Autologous Hematopoietic Stem Cell Transplant in Patients with Hodgkin Lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Podophyllotoxin; Transplantation Conditioning; Young Adult | 2019 |
A multicenter retrospective comparison of induction chemoimmunotherapy regimens on outcomes in transplant-eligible patients with previously untreated mantle cell lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease Progression; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy; Induction Chemotherapy; International Cooperation; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Remission Induction; Retrospective Studies; Transplantation Conditioning; Treatment Outcome | 2019 |
Hemophagocytic relapsed intramedullary plasmacytoma.
Topics: Adult; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Bortezomib; Carmustine; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Female; Humans; Magnetic Resonance Imaging; Melphalan; Neoplasm Recurrence, Local; Oligopeptides; Plasmacytoma; Positron Emission Tomography Computed Tomography; Pubic Bone; Rare Diseases; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2020 |
Allogenic hematopoietic stem cell transplantation for prolonged bone marrow aplasia after chimeric antigen receptor (CAR) T-cell therapy for relapsed diffuse large B-cell lymphoma.
Topics: Adrenal Cortex Hormones; Allografts; Anemia, Aplastic; Antibodies, Monoclonal, Humanized; Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Deoxycytidine; Doxorubicin; Etoposide; Gemcitabine; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy, Adoptive; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Oxaliplatin; Prednisone; Recurrence; Rituximab; Salvage Therapy; Transplantation, Autologous; Vincristine | 2020 |
Bendamustine-EAM versus BEAM regimen in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in the frontline setting: a multicenter retrospective study from Lymphoma Study Association (LYSA) centers.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Carmustine; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Melphalan; Prospective Studies; Retrospective Studies; Transplantation, Autologous | 2020 |
Outcomes of rituximab-BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cohort Studies; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Multivariate Analysis; Registries; Rituximab; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Failure; Treatment Outcome; Young Adult | 2020 |
Nitrosourea, etoposide and cyclophosphamide followed by autologous stem cell transplantation for pediatric lymphoma patients.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Etoposide; Feasibility Studies; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Lymphoma; Male; Retrospective Studies; Survival Rate; Transplantation, Autologous; Treatment Outcome | 2020 |
BEAM conditioning regimen ensures better progression-free survival compared with TEAM but not with FEAM in lymphoma patients undergoing autologous stem cell transplant.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Melphalan; Progression-Free Survival; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous | 2020 |
Substituting carmustine for lomustine is safe and effective in the treatment of relapsed or refractory Lymphoma-a retrospective study from the BSBMT (BEAM versus LEAM).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Humans; Lomustine; Lymphoma; Melphalan; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous | 2021 |
Reimagining external beam radiotherapy for glioblastoma: "old beam, new trick".
Topics: Carmustine; Cytarabine; Etoposide; Glioblastoma; Humans | 2021 |
Comparison of Mitoxantrone-Melphalan and BEAM Conditioning Regimens in Patients with Lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Melphalan; Mitoxantrone; Transplantation Conditioning; Transplantation, Autologous | 2022 |
BeEAM conditioning regimen is a safe, efficacious and economical alternative to BEAM chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Neoplasms; Outcome Assessment, Health Care; Podophyllotoxin; Transplantation Conditioning | 2021 |
BuCyE can safely replace BEAM as a conditioning regimen for autologous stem cell transplantation in the treatment of refractory and relapsed lymphomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Transplantation Conditioning; Transplantation, Autologous; Young Adult | 2021 |
Rituximab, Methotrexate, Carmustine, Etoposide, and Prednisone (RMBVP) for the treatment of relapsed/refractory primary central nervous system lymphoma: a retrospective single-center study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System; Central Nervous System Neoplasms; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Methotrexate; Neoplasm Recurrence, Local; Prednisone; Retrospective Studies; Rituximab | 2022 |
Bendamustine-EAM versus R-BEAM after high-dose cytarabine-based induction in newly diagnosed patients with mantle cell lymphoma, a LYSA retrospective study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Carmustine; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Melphalan; Retrospective Studies; Transplantation, Autologous | 2022 |
Intensive chemotherapy followed by autologous stem cell transplantation in primary central nervous system lymphomas (PCNSLs). Therapeutic outcomes in real life-experience of the French Network.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Central Nervous System; Central Nervous System Neoplasms; Cyclophosphamide; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Neoplasm Recurrence, Local; Prospective Studies; Thiotepa; Transplantation, Autologous; Treatment Outcome | 2022 |
Long Overdue "Beam-On".
Topics: Carmustine; Cytarabine; Etoposide; Humans | 2022 |
B-Cell Reconstitution After Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis.
Topics: Antilymphocyte Serum; Carmustine; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin G; Immunoglobulin Heavy Chains; Melphalan; Multiple Sclerosis | 2022 |
Bridging advanced myeloma patients to subsequent treatments and clinical trials with classical chemotherapy and stem cell support.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; Cyclophosphamide; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Middle Aged; Multiple Myeloma; Transplantation, Autologous | 2023 |
Total marrow irradiation versus total body irradiation using intensity-modulated helical tomotherapy.
Topics: Bone Marrow; Carmustine; Etoposide; Hematologic Neoplasms; Humans; Radiation Injuries; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Intensity-Modulated; Whole-Body Irradiation | 2023 |
External Beam Fast Neutron Therapy: Russian Clinical Experience and Prospects for Further Development.
Topics: Boron Neutron Capture Therapy; Brain Neoplasms; Carmustine; Etoposide; Fast Neutrons; Humans; Neutrons; Radiotherapy Dosage | 2023 |
Optimization of Fluence Map for CyberKnife Raster Scanning Intensity Modulated Radiotherapy.
Topics: Carmustine; Etoposide; Humans; Male; Prostatic Neoplasms; Radiosurgery; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Intensity-Modulated; Rectum | 2023 |
Long-Term Results with Thiotepa-Containing Conditioning Regimens for Autologous Stem Cell Transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Melphalan; Retrospective Studies; Thiotepa; Transplantation, Autologous | 2023 |
Comment on: Planned dose of intensity modulated proton beam therapy versus volumetric modulated arch therapy to tooth-bearing regions.
Topics: Carmustine; Etoposide; Humans; Proton Therapy; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Intensity-Modulated | 2023 |
Can Optical Surface Imaging Replace Non-coplanar Cone-beam Computed Tomography for Non-coplanar Set-up Verification in Single-isocentre Non-coplanar Stereotactic Radiosurgery and Hypofractionated Stereotactic Radiotherapy for Single and Multiple Brain Met
Topics: Brain Neoplasms; Carmustine; Cone-Beam Computed Tomography; Etoposide; Humans; Radiosurgery; Radiotherapy Planning, Computer-Assisted | 2023 |
Adjacent tissues modulate shear wave propagation in axially loaded tendons.
Topics: Adipose Tissue; Carmustine; Elasticity Imaging Techniques; Etoposide; Tendons; Weight-Bearing | 2023 |